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ABSTRACT 
The POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1), is a 
transcriptional regulatory factor that belongs to the POZ and Zinc Finger (POK) 
family of transcriptional factors involved in chromatin remodeling, protein-protein 
interaction, transcriptional regulation and targeting of proteins to distinct nuclear 
substructures. PATZ1 has been shown to regulate expression of different genes 
and its transcriptional activity, as for other POK proteins, depends on the POZ 
domain, which mediates oligomers formation. Therefore, it has been suggested 
that it may not be a typical transactivator but an architectural transcription factor, 
thus functioning either as activator or repressor depending on the presence of 
proteins able to interact with it, which could be different depending on the cellular 
context. The physiological role of PATZ1 is still not completely known, but it has 
been demonstrated that PATZ1 is important in testis development, in 
spermatogenesis and it plays a key role in the development of the central nervous 
system (CNS), and cardiac out-flow tract (OFT). Several studies suggest a role for 
PATZ1 in cancer but its cancer-related function is still debated between being a 
tumor suppressor or an oncogene. To better understand the role of PATZ1 in 
human cancer we focused on thyroid tumors, which represent a useful model to 
study the multi-step carcinogenesis. In this study quantitative real-time PCR (qRT-
PCR) analysis showed that PATZ1 is down-regulated in human thyroid tumors 
with respect to normal thyroid gland, with the expression levels being inversely 
correlated with the degree of de-differentiation and malignancy. 
Immunohistochemical analysis confirmed this result showing the reduction of 
PATZ1 nuclear expression and its cellular delocalization from the nucleus to the 
cytoplasm proceeding from the normal to malignant human thyroid tissues. 
Subsequently, we conducted functional studies on two cell lines derived from 
human papillary thyroid carcinomas (TPC-1 and BC-PAP) and one cell line 
derived from a human anaplastic thyroid tumor (FRO), in which PATZ1 was 
strongly down-regulated compared to normal thyroid tissue, and the same cells in 
which the presence of PATZ1 has been restored by stable transfection. The 
comparative analysis of cells expressing or not PATZ1 allowed us to identify 
noticeable differences associated with the neoplastic phenotype. Indeed, the 
restoration of PATZ1 expression impaired the proliferation capacity of BC-PAP 
and FRO cells and induced apoptosis in FRO cells. Moreover, PATZ1 expression 
inhibited cell migration and invasiveness in all the three cells lines analyzed and 
suppressed the tumorigenicity of FRO cells both in vitro and in vivo. Furthermore, 
as PATZ is essentially a transcriptional regulator, we looked for the genes 
specifically regulated by it, which could explain its role in counteracting thyroid 
cell transformation. For this purpose we focused our attention on BAX, PUMA and 
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PERP genes, that are all targets of p53 and have a role in cellular migration and/or 
apoptosis induction. We found that the expression of all three of them was up-
regulated in thyroid cell lines re-expressing PATZ1 compared to the parental 
control cells. Moreover, ChIP or EMSA assays demonstrated that PATZ1 is able 
to bind their promoters. Taken together these findings support the hypothesis that 
PATZ1 may act as a tumor-suppressor in thyroid cancer, likely inhibiting cellular 
migration and/or enhancing apoptosis through the up-regulation of  BAX, PUMA 
and PERP expression. These studies open a road to investigate the diagnostic 
value and the prognostic impact of PATZ1 in thyroid neoplasia, as well as the 
efficacy of a thyroid cancer therapy based on the re-expression of the PATZ1 gene. 
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1.BACKGROUND 
 
1.1 The POK protein family 
Transcription factors (TF) play a key role in certain mechanisms by which 
specific genes are expressed in a temporal and tissue-specific manner, and, as 
modular proteins, they can be classified mainly based on the structure of their 
DNA binding or protein-protein interacting domains. One of these domains, 
designated as a zinc finger motif on the base of its requirement for zinc, is the 
large C2H2 Krüppel-type zinc finger group, nickname due to the fact that it 
resembles the Drosophila segmentation protein Krüppel. It represents one of the 
most common types of DNA binding domains. There are approximately more than 
600 genes in the human genome encoding C2H2 motifs (Venter et al. 2001), 
suggesting that this class of TF represents a substantial portion of the genes in the 
human genome. The Broad complex, Tramtrack, and Bric a` brac (BTB), also 
known as Poxviruses and Zinc-finger (POZ) domain is an evolutionary conserved 
protein–protein interaction domain. In most cases this domain is associated with 
C2H2 zinc finger motifs in TF involved in transcriptional regulation through 
chromatin re-modeling (Kelly and Daniel 2006). Although the number of proteins 
harboring this motif is lower than the ones including C2H2 zinc fingers, more than 
100 proteins has been identified so far. In fact, it is estimated that 5–10% of the 
zinc finger proteins in humans also share this domain (Stogios et al. 2005). The 
proteins showing this combination of motifs are defined as members of the POK 
(POZ and Krüppel) family of transcriptional repressors. Therefore, the POK 
(Poxviruses and Zinc-finger (POZ) and Krüppel) family of transcription repressors 
is characterized by the presence, in their structures, of an amino-terminal 
POZ/Broad Complex, Tramtrack, and Bric a' brac (BTB) domain and several 
Krüppel-type zinc fingers at the carboxyterminal side (Costoya 2007) (Fig. 1). 
Interestingly, both in human and mouse genomes, more than 40 genes are 
associated with those domains (Stogios et al. 2005). The biological functions of 
POK proteins are defined on the base of the homo- and hetero-dimerization as well 
as protein-protein interactions properties conferred by the BTB/POZ domain, 
while the Krüppel-like C2H2 zinc fingers mediate the specific binding to DNA 
sequences located within gene-regulatory regions. Thus, the BTB/POZ domain 
promotes homo- and hetero-dimerization and exerts its transcriptional role through 
its interaction with transcriptional co-factors, including SIN3A, SMRT, NCOR1 
and other co-repressors, which in turn recruit HDACs (Histone DeACetylases). 
Transcription is highly dependent on how DNA is packaged. DNA can be tightly 
compacted, thus preventing accessibility of TF, or can be available to TF via 
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modification of the nucleosome, fundamental subunit of chromatin. This 
architecture of chromatin is strongly influenced by post-translational modifications 
of the histones. POK proteins are able to act as a molecular switch opening or 
closing the chromatin through the deacetylation of the histones, and therefore 
regulating the transcription of their target genes (Costoya 2007). Most POK 
proteins studied so far have displayed a consistent trans-repressive activity in a 
variety of cell types and on various promoters although it remains possible that the 
transcriptional activity of POK proteins may be dependent on the cellular 
environment and may include the ability to trans-activate (Kobayashi et al. 2000). 
There are many proteins belonging to the POK family, some of them involved in 
cancer, development and stem cell biology (Fig. 1). Among these proteins family 
there is the POZ/BTB and AT-hook-containing Zinc finger protein 1 (PATZ1).  
 
 
 
 
Figure 1. Structure of selected POK transcription factors. These proteins characteristically have 
an amino-terminal POZ/BTB domain and several carboxy-terminal Krüppel-type zinc fingers. 
These TF have been shown to play important roles in cancer, development and stem cell biology. 
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1.2 PATZ1 gene and protein structure 
The POZ/BTB and AT-hook-containing Zinc finger protein 1 (PATZ1), is a 
transcriptional regulatory factor also known as Zinc finger Sarcoma Gene (ZSG), 
MAZ-Related factor (MAZR) or Zinc Finger Protein 278 (ZNF278/Zfp278). The 
human PATZ1 gene is located on chromosome 22 at the position 22q12 and was 
originally cloned in the 2000 by three independent groups (Fedele et al. 2000; 
Kobayashi et al. 2000; Mastrangelo et al. 2000). Mastrangelo and coworkers 
described a submicroscopic inversion of chromosome 22q in a small round cell 
sarcoma with a t(1;22)(p36.1;q12) translocation. The resultant chimeric transcript 
contained exon 8 of the Ewing sarcoma gene fused in-frame to exon 1 of the 
PATZ1 gene, creating a protein with the transactivation domain of EWS fused to 
the zinc finger domains of PATZ1. Subsequently, the same group found that this 
paracentric inversion of chromosome 22q12 interrupted the UQCRH gene, with 
the breakpoint in intron 3, and created fusion genes with both EWS on der(22) and 
PATZ1 on der(1). Kobayashi and coworkers, as well as our group, isolated PATZ1 
by yeast 2-hybrid screenings with the POZ domain of Bach2 or the RING finger 
protein-4 (RNF4) as baits, respectively (Fedele et al. 2000; Kobayashi et al. 2000). 
PATZ1 gene consists of 6 exons and encodes four alternatively expressed isoforms 
(ranging from 537 to 687 amino acids) that share a common modular structure 
consisting of a N-terminal BTB/POZ (Bric-a-brac-Tramtrack-Broad 
complex/Poxvirus Zinc finger) domain, one AT-hook (in the central region) and 
four to seven C2H2 Zinc fingers at the C-terminus (Fedele et al. 2012) (Fig. 2). 
Although such motifs are common to factors involved in transcriptional regulation, 
the presence of all these domains in the same protein appears to be an unique 
feature of PATZ1. The AT-hook motif is a small AT-rich DNA binding domain 
that was first described in the high mobility group non-histone chromosomal 
protein HMGI(Y) and then identified in a few other proteins such as HMGI-C and 
ALL-1, and is involved in the binding to the minor groove in correspondence of 
AT-rich regions (Fedele et al. 2000). The BTB/POZ and zinc finger domains 
makes PATZ1 a member of the POK family of transcriptional repressors (Costoya 
2007). Consistent with its protein structure and with the presence of typical 
features of nuclear proteins, including two nuclear localization signals, PATZ1 
localizes in the nucleus (Fedele et al. 2000). 
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Figure 2. Schematic representation of human PATZ1 gene and its encoded protein isoforms. 
A, The human PATZ1 gene consists of 6 exons, which give rice to 4 different proteins through 
alternative splicings (depicted by exons-connecting lines). B, The two short isoforms of 537 aa and 
the two long isoforms of 641 and 687 aa are represented by their characteristic domains. 
 
 
1.3 Transcriptional activity of the PATZ1 gene 
Similarly to the other BTB/POZ proteins, the transcriptional activity of PATZ1 
requires the POZ domain (Fedele et al. 2000). However, the mechanisms by which 
transcriptional regulation by PATZ1 occurs remain to be elucidated. The POZ 
domain of the POK proteins BCL6 and PLZF, as well as other POZ domain 
containg proteins, associates with the SMRT-mSin3AHDAC-1 complex and forms 
a multimeric repressor complex involving histone deacetylation activity (Huynh  
and Bardwell 1998). PATZ1 may also be involved in the formation of such a 
complex, since we have demonstrated that its binding to gene promoters is 
influenced by HDACs inhibitors (unpublished data). Moreover, it is likely that the 
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zinc finger motifs could target the PATZ1 protein to specific DNA sequences. 
PATZ1 has been shown to regulate expression of different genes in either a 
positive or negative manner (Tab. 1). This dual behavior is in the nature of POZ-
containing TFs, because their transcriptional activity is due to the POZ-mediated 
oligomers formation, and therefore they may function either as activators or 
repressors depending on the presence of proteins able to interact with them, which 
may be different depending on the cellular context. PATZ1 also contains an AT-
hook, a motif characteristic of architectural transcriptional factors, such as the 
HMGA proteins, whose activity in gene transcription depends on the cellular 
context (Fedele and Fusco 2010). It has been reported that PATZ1 can function as 
a transcriptional repressor of basal transcription or as a co-repressor of RNF4 
RING finger protein-mediated transcription on the c-myc, CDC6, galectin-1 and 
SV40 promoters (Fedele et al. 2000). Moreover, PATZ1 acts as a transcriptional 
activator of the c-myc promoter in B cells and the c-myc transcriptional activation 
by BACH2 is enhanced by its interaction with the BTB/POZ domain of PATZ1 
(Kobayashi et al. 2000). PATZ1 is also able to activate mast cell protease 6 (Morii 
et al. 2002) and FGF4 (Kobayashi et al. 2000), and to repress androgen receptor 
(Pero et al. 2002), CD8 (Bilic et al. 2006) and BCL-6 genes (Pero et al. 2012). 
Consistent with the CD8 regulation, it has been shown that PATZ1 is an important 
part of the transcription factor network that controls the CD4 versus CD8 lineage 
fate of double-positive thymocytes (Sakaguchi et al. 2010) (Tab. 1).  
 
Table 1. Genes regulated by PATZ1  
Positive regulation Negative regulation 
c-myc (Kobayashi et al. 2000) c-myc (Fedele et al. 2000) 
BACH2 (Fedele et al. 2000) Galectin-1 (Fedele et al. 2000) 
Mast cell protease 6 (Morii et al. 2002) SV 40 (Fedele et al. 2000) 
FGF4 (Kobayashi et al. 2000) Androgen receptor (Pero et al. 
2002) 
 CD-8 (Bilic et al. 2006) 
 BCL-6 (Pero et al. 2012) 
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1.4 PATZ1 expression and role in development 
The physiological role of PATZ1 is still not completely known, but our group 
described an important role in testis development and spermatogenesis. Indeed, 
PATZ1 is expressed in spermatogonia and its lack led to increased apoptosis of the 
spermatocytes and total absence of spermatids and spermatozoa with subsequent 
male infertility (Fedele et al. 2008).  
PATZ1 is strongly and widely expressed during the early steps of the 
embryogenesis especially in the central nervous system (CNS), where it is clearly 
restricted to the actively proliferating neuroblasts in the periventricular neocortical 
neuroepithelium, in the telencephalic cortical plate, in the hippocampus, and in the 
striatal neuroepithelium and subventricular zone; then, even though it keeps to be 
ubiquitously expressed, it is still abundant in restricted organs during the medium 
and late developmental stages (Valentino et al. 2012). Its ubiquitous expression is 
also kept in the adult life, but it is generally lower than in embryonic tissues and is 
still abundant in selected tissues, including skeletal muscle, spinal cord and thyroid 
(Fedele unpublished data). In order to understand the role of PATZ1 in 
development, adult life and cancer, a PATZ1 knock-out mouse model has been 
generated in our laboratory. The analysis of Patz1 -/- mouse embryos suggests that 
this gene plays an important role in the development of the CNS, and the cardiac 
out-flow tract (OFT). In fact, they showed defects in the CNS with a clear 
reduction of periventricular cells, and altered positioning of the cardiac OFT. 
Moreover, most Patz1 -/- embryos dye in utero: homozygous mutant pups totaled 
only 4% of the newborn offspring from heterozygous intercrosses, instead of the 
expected 25%, indicating that most PATZ1-null mice died during embryogenesis, 
probably because of the defects accumulated during CNS and cardiac OFT 
development. The few Patz1 -/- mice that survived showed defects in 
spermatogenesis (i.e. increased apoptosis of the spermatocytes and total absence of 
spermatids and spermatozoa) and a general growth retardation (Fedele et al. 2008; 
Valentino et al. 2012). The growth defects may be due, at least in part, to 
alterations in cell cycle progression and premature senescence. In fact, Patz1 -/- 
mouse embryonic fibroblasts (MEFs) showed arrest at or beyond the restriction 
point in either G1 or G2 phase and enter into premature cellular senescence 
(Fedele et al. 2008; Valentino et al. 2012). The results obtained on the Patz1-null 
MEFs are consistent with recent data showing growth inhibition and accelerated 
senescence in human umbilical vascular endothelial cells (HUVECs) interfered for 
PATZ1 expression (Cho et al. 2011).  
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1.5 PATZ1 and cancer 
Several studies suggest a role for PATZ1 in cancer but its cancer-related 
function is still debated between a tumor suppressor or an oncogenic one. The 
PATZ1 gene maps on the FRA22B fragile site (on chromosome 22) which suffers 
loss of heterozygosity in several solid tumors and it has been found rearranged 
with Ewing sarcoma (EWS) gene in a small round cell sarcoma, with the loss of 
heterozygosis of the wild-type PATZ1 allele, suggesting a potential tumor 
suppressor role (Mastrangelo et al. 2000; Burrow et al. 2009). In addition, our 
research group showed that in some cell lines PATZ1 is able to reduce the 
promoter activity of the proto-oncogene c-myc and may cooperate with the 
oncoprotein BCL6 in the inhibition of its own promoter. In particular we 
demonstrated that PATZ1 can bind BCL6 exon 1 and negatively modulate BCL6 
promoter activity in GC-derived lymphoma B cells, thus acting as a tumor 
suppressor in lymphomagenesis (Fedele et al. 2000, Pero et al. 2012). 
 On the other hand, an oncogenic role for PATZ1 has also been suggested. 
Other groups showed that PATZ1 is capable to activate c-myc in other cellular 
contexts (Kobayashi et al. 2000), is overexpressed in some human malignant 
neoplasias, including colon and breast tumors (Tian et al. 2008; Yang et al. 2010) 
and its down-regulation by siRNA either blocks the growth or induces apoptosis of 
cell lines derived from colorectal cancer or gliomas, respectively (Tian et al. 2008; 
Tritz et al. 2008). Moreover, we demonstrated that in testicular seminomas, 
teratomas and embryonal carcinomas there is a significant overexpression of 
PATZ1 (Fedele et al. 2008). However, the PATZ1 protein localized in cytoplasm 
rather than nucleus, suggesting that this altered localization could lead to a 
reduction in the putative anti-oncogenic activity of PATZ1, but the molecular 
mechanisms that, because of the mis-localization of PATZ1, can lead to tumor 
development, have not been clarified yet. Similarly, our group recently 
demostrated mislocalization of PATZ protein to the cytoplasm in a group of 
human Diffuse large B-cell lymphoma (DLBCL) (unpublished data). Interestingly, 
it has been also shown that the delocalization of PATZ1 in testicular seminomas 
depends on estrogen receptor-β levels and the translocation from cytoplasm to the 
nucleus is mediated by cAMP (Esposito et al. 2011), as it was previously 
demonstrated in other cell systems, such as PC3M prostate carcinoma cells and 
normal fibroblasts (Yang et al. 2010). Yang and co-workers demonstrated that 
PATZ1 binds the RIα subunit of the cAMP-dependent protein kinase in the 
cytoplasm, and it is known that alteration of RIα expression, and then of the cAMP 
signaling, may confer cell growth advantage. Therefore, the sequestration of 
PATZ1 in the cytoplasm through its interaction with RIα would enable PATZ1 to 
translocate into nucleus and transactivate/repress its target genes upon activation 
of the cAMP pathway (Yang et al. 2009).  
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The analysis of PATZ1 knock-out mice carried out in our laboratory provided a 
strong effort to the tumor-suppressor hypothesis, since both heterozygous and 
homozygous Patz1 knock-out mice spontaneously develop tumors, including 
BCL6-expressing Non-Hodgkin lymphomas, sarcomas, hepatocellular carcinomas 
and rare lung adenocarcinomas (Pero et al. 2012). In particular, at the age of 4-24 
months (average of 19 months), pathological analysis demonstrated that 9 out 63 
Patz1 +/+ mice, 50 out of 75 Patz1 +/- mice, and 9 out of 11 Patz1 -/- mice 
developed multiple neoplastic lesions, including both malignant tumors and benign 
lymphoproliferative diseases. All the tumors raised in heterozygous animals do not 
lose or mutate the second wild-type allele, and express the wild-type PATZ1 
protein, thus excluding loss of heterozygosity as an explanation for the increased 
occurrence of tumors in Patz1 +/- mice compared to Patz1 +/+ mice and 
suggesting an haploinsufficient tumor suppressor role for PATZ1. Consistent with 
the role of PATZ in BCL6 autoregulation, Patz1-knock-out mice developed 
thymus hyperplasias or lymphomas and showed increased levels of BCL6, thus 
suggesting that PATZ causes up-regulation of BCL6 expression, which in turn 
could be responsible for the thymus pathological phenotype. This hypothesis was 
validated crossing Patz1 +/- mice with Bcl6 +/- mice to generate double mutants 
that had shown a normal phenotype rescue, indicating a key role for Bcl6 
expression in its pathologic development (Pero et al. 2012). The controversial role 
of PATZ1 in tumorigenesis could be easily explained considering that its 
transcriptional modulation is highly dependent on specific molecular partners of a 
particular cellular context. Moreover, as for other well known architectural factors, 
it is possible an involvement in the development of neoplastic disease either if 
hyper- or hypo-expressed, stressing the great importance of the correct gene 
dosage for these factors. It is noteworthy in this regard that PATZ1 interacts with 
the HMGA proteins, which are architectural transcriptional factors that act as both 
oncogenes or tumor suppressors depending on the cellular context (Fedele et al. 
2012). 
 
 
 
 
1.6 Thyroid cancer 
 Carcinoma of the thyroid gland is an uncommon cancer, but one of the most 
frequent malignancies of the endocrine system and its incidence has been steadily 
increasing in many regions of the world. The thyroid carcinoma is a good multi-
step carcinogenesis model because it differs in malignant potential as a result of 
different genetic alterations (Fig. 3). The vast majority of thyroid tumors (over 
95%) arises from thyroid follicular epithelial cells, while a minority (3-5%), 
named medullary thyroid carcinomas, originates from para-follicular or C-cells 
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(Carcangiu et al. 1984; DeLellis et al. 2004; Kondo et al. 2006). Thyroid tumors 
are divided into benign and malignant tumors. Benign tumors are represented by 
goiters and follicular adenomas (FTA). Malignant tumors are, in the great majority 
of cases, carcinomas. Carcinomas derived from follicular cells are commonly 
divided into several subtypes characterized by different morphology, etiology and 
clinical behavior and they are sub-divided into well-differentiated thyroid 
carcinomas (WDTCs), poorly differentiated thyroid carcinomas (PDTCs) and 
anaplastic or undifferentiated thyroid carcinomas (ATC) (De Lellis et al. 2004; 
Nikiforov et al. 2009). WDTCs include two types: papillary thyroid carcinomas 
(PTCs) and follicular thyroid carcinomas (FTCs). The PTC is the most common 
thyroid carcinoma (about 80% of cases). It is characterized by the classic papillary 
architecture and cells with typical nuclear alterations (ground-glass nuclei). It is 
often multifocal and tends to metastasize to regional lymph nodes (DeLellis et al. 
2004). The FTC is a relatively rare cancer (about 10% of thyroid cancers) that may 
develop from a pre-existing benign adenoma (FTA) or directly from the normal 
tissue "bypassing" the stage of adenoma. It is well differentiated, usually unifocal, 
encapsulated, and may be of conventional type or oncocityc type (Hurthle cells). 
Less-differentiated thyroid cancers, namely PDTCs and ATCs, can develop de 
novo although many of them arise through the process of stepwise 
dedifferentiation of PTCs and FTCs (Nikiforov et al. 2011). In particular, the ATC 
is a very rare (2-5% of thyroid cancers), highly aggressive and lethal tumor 
characterized by very undifferentiated cells, mostly  insensitive to radiotherapy 
and conventional chemotherapy (Ain, 1999; Yau et al. 2008). The PDTC (also 
known as insular carcinoma) has  an intermediate behavior between WDTC and 
ATC (Tallini 2011). The theory of sequential progression of well-differentiated 
thyroid carcinoma trough the spectrum of poorly differentiated to undifferentiated 
thyroid carcinomas is supported by the presence of pre- or co- existing well-
differentiated thyroid carcinoma with less differentiated types and the common 
core of genetic loci with identical allelic imbalances in co-existing well-
differentiated components (van der Laan et al. 1993). Similar to other cancer 
types, thyroid cancer initiation and progression occurs through gradual 
accumulation of various genetic (rearrangements that activate proto-oncogenes, 
point mutations and loss of tumor suppressor function) and epigenetic alterations, 
including activating and inactivating somatic mutations, alteration in gene 
expression patterns, micro-RNA dysregulation and aberrant gene methylation. A 
substantial fraction of PTCs (30%) shows a typical large alteration involving a 
rearrangement of the RET proto-oncogene. The rearrangement consists in the 
fusion of the tyrosine kinase domain (TK) of RET with other genes that provide 
the chimeric gene of promoter and 5' coding region. In about 10% of PTC cases 
rearrangements of the gene coding for TRK, another tyrosine kinase protein, 
which determines its fusion to partner genes similarly to RET/PTC 
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rearrangements, were identified. At least ten different types of RET/PTC 
rearrangements have been reported (Nikiforov 2002). RET/PTC1 and RET/PTC3 
are the most frequent rearrangement found in PTCs. RET/PTC1 was generated by 
the fusion of RET TK domain with the 5’ terminal region of the gene CCD6 
(Grieco et al. 1990), whereas in RET/PTC3 the TK domain of RET is fused to the 
RFG gene (Santoro et al. 2004). In most cases of PTCs (40%) a point mutation of 
the BRAF gene was recovered, while in 10-20% of cases mutations of RAS genes 
(RAS K-RAS, H-ras and N-RAS) are observed. BRAF mutations are found in 29-
69% of papillary carcinomas but not in thyroid follicular carcinomas and in up to 
13% of poorly differentiated thyroid carcinomas and 35% of undifferentiated 
thyroid carcinomas (Kondo et al. 2006). In PTCs, BRAF mutation and RET/PTC 
rearrangements are mutually exclusive and cannot be found simultaneously in the 
same patients, yet they are not completely equivalent, since it has been shown that 
PTCs positive for BRAF are more aggressive than those positive for RET/PTC 
(Kimura e al. 2003; Soares et al. 2003). BRAF point mutation are not a significant 
event in post Chernobyl thyroid carcinomas; instead a chromosomal 
rearrangement (AKAP9-BRAF), that represents a paracentric inversion, has been 
identified in radiation-associated thyroid cancer (Ciampi et al. 2005). Mutation of 
RAS genes (K-RAS, H-RAS, and N-RAS), present in codons 12, 13 and 61, are 
observed in 10-20% of PTCs (Namba et al. 1990; Vasko et al. 2004). RAS gene 
mutations represent early molecular lesions since they are also frequently found in 
FTAs, which are considered FTC precursors. Mutations of RAS genes are also 
observed in 40-50% of conventional FTCs and in 20-40% of FTAs, while another 
group of FTCs (35%) presents a rearrangement PAX8/PPAR (Pallante et al. 2010). 
The PAX8/PPARγ rearrangement leads to the fusion between a portion of the 
PAX8 gene, which encodes a paired domain transcription factor, and PPARγ gene 
(Kroll et al. 2000); this fusion results in strong overexpression of the chimeric 
PAX8/PPARγ protein (Kroll et al. 2000; Powell et al. 2004) although the 
mechanism of its transforming activity remains to be fully understood. The PDTCs 
and ATCs can come from the WDTC. Therefore, the mutations that occur in the 
early stages of WDTCs are also reported in PDTCs and ATCs: in PDTCs 
RET/PTC rearrangements (13%) and mutations in the RAS (46-55%) and BRAF 
(12-17% ) genes were identified, while in the ATC only mutations of RAS (6-
52%) and BRAF (25-29%) genes were reported. In more advanced stages of 
thyroid carcinogenesis, alterations of PI3K and PTEN were also found (Paes & 
Ringel  2008 ). The molecular alteration that characterizes the ATC compared with 
differentiated thyroid carcinomas is the mutation of the p53 tumor suppressor 
gene. Almost all ATCs show inactivation of p53 and is therefore highly probable 
that it is the deficiency of p53, combined with mutations of oncogenes such as 
RAS and BRAF, to determine the high proliferative index and high aggressiveness 
of this tumor. Indeed, p53 mutations are common in both PDTCs (17-38%) and 
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ATCs (67-88%), but rare or absent (0-9%) in WDTCs (Ito et al. 1992; Donghi et 
al. 1993; Fagin et al. 1993). Other genes have been implicated in thyroid 
neoplasias. Even though critical molecular mechanisms of thyroid carcinogenesis 
have been clarified, other molecular steps of neoplastic progression still need to be 
investigated. 
 
 
 
 
 
Figure 3. Model of multi-step carcinogenesis of thyroid tumors. Three distinct pathways have 
been proposed for the initiation of thyroid tumors including hyper-functioning follicular thyroid 
adenoma, FTC and PTC. Genetic defects that result in activation of RET or BRAF represent 
frequent early initiating events associated with radiation exposure that leads to PTC development. 
RAS mutations represent frequent early initiating events, associated with iodine deficiency, that 
lead to FTC development. By contrast, most PDTCs and ATCs are considered to derive from pre-
existing well-differentiated thyroid carcinoma through the accumulation of additional genetic 
events that include nuclear accumulation of β-catenin (encoded by CTNNB1) and p53 inactivation.  
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1.7 p53 in thyroid cancer 
 
Dubbed as the “guardian of the genome” and the “cellular gatekeeper”, the p53 
protein is a transcription factor that acts to transmit a variety of stress-inducing 
signals to different anti-proliferative cellular responses. Following various 
intracellular and extracellular stimuli such as DNA damage, heat shock, hypoxia, 
and oncogene overexpression, p53 is activated and emerged as a pivotal regulatory 
protein which triggers diverse biological responses (Levine 1997; Vousden and Lu 
2002). Most of the biological effects elicited by p53 can be attributed to its ability 
to act as a sequence-specific transcription factor, which regulates expression of 
different cellular genes to modulate various cellular processes  (Farmer et al. 
1992), although protein-protein interactions may also play a role. In response to 
various types of stress, p53 is accumulated in the nucleus and binds specific 
promoters that, in turn, activate the transcription of specific genes. p53 
downstream target genes are differentially regulated depending on the cell type, 
extent of the damage which has influenced p53 activation, and various other 
factors (Oren 2003). The product of the downstream target genes of p53 regulate 
cell cycle arrest, DNA repair, epithelial-mesemchymal transition (Zilfou et al. 
2009). Among them there are p21Waf/Cip1 (which mediates G1 cell growth arrest), 
Gadd45 (which mediates DNA repair), BAX and PUMA (which mediate apoptosis) 
and PERP (which mediates apoptosis and cell-cell adhesion). Another p53 major 
target gene is MDM2, coding for an ubiquitin ligase that binds to the N-terminus 
of the p53 protein and causes p53 inactivation by its nuclear export and 
degradation. p53 is also a major regulator of cell senescence (Hofseth et al. 2004). 
Indeed, telomere shortening caused by cell replication triggers p53 activation, 
thereby blocking cell cycle and favoring cell entry into senescence. As a 
consequence, p53 inactivation may contribute to the increased number of cell 
replications and, eventually, to the accumulation of further genetic abnormalities 
and the acquisition of the immortalized phenotype in cultured cells. Finally, the 
p53 gene can use different internal promoters and\or internal translation start sites 
to produce a variety of N-terminally truncated isoforms with a variable degree of 
dominant negative activity (Malaguarnera et al. 2007). The p53 protein has three 
major functional domains, the N-terminal transactivation domain (TAD), the C-
terminal oligomerization domain (OD), and a core domain (DBD), which has 
DNA-binding activity. The vast majority of p53 mutations occurs within the DBD 
domain (Murray-Zmijewski et al. 2006). Approximately half of all human tumors 
have a mutation or loss in the p53 gene leading to inactivation of its function 
(Soussi and Beroud 2001). At variance with other human malignancies, p53 
mutations are not frequent in thyroid cancer and are believed to be responsible 
mainly for cancer progression to poorly differentiated and aggressive phenotype 
(Olivier et al. 2002). Studies on p53 protein expression in a large series of thyroid 
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tumor specimens suggest that, although not mutated, p53 activity may be inhibited 
in thyroid cancer by other mechanisms (Pollina et al. 1996). Indeed, increased p53 
protein levels were observed by immunohistochemistry not only in anaplastic and 
poorly differentiated thyroid cancer, where p53 mutations are frequent, but also in 
well-differentiated cancers, in the absence of any p53 mutations (Soares et al. 
1994). Non functioning p53 cannot induce Mdm2, its major degrading protein, and 
consequently accumulates in the cell nucleus. A strong p53 staining in paraffin-
embedded specimens, therefore, is considered indirect evidence of nonfunctioning 
p53 (Dobashy et al. 1993).  Thyroid cancers are also characterized by the loss of 
function of  p63 and p73, two members of the p53 protein family (Malaguarnera et 
al. 2007). In general, the tumor suppressor activity of these proteins is kept latent 
by several mechanisms, including interaction with p53 mutants, dominant negative 
isoform overexpression, and impaired activation mechanisms. The overexpression 
of the High Mobility Group A (HMGA) oncogenes in thyroid cancers is one of the 
causes of the p53 family members loss of function. HMGA proteins are non-
histone proteins, with several different functions, including gene transcription, 
malignant transformation promotion, and metastatic progression. The expression 
level of HMGA genes is maximal during the embryonic development, while it is 
very low in well-differentiated and adult cells (Reeves et al. 2001). In thyroid 
cancer, as in several human cancers, the HMGA1 protein level is high and 
correlates with the increasing degree of malignancy and metastatic potential. 
HMGA1 protein has an inhibitory effect on both ectopic and endogenous p53 
family member activity. In particular, HMGA1 interacts with p53, p63 and p73 
and it is able to inhibit p53 activity on G1 cell cycle arrest and apoptosis (Frasca et 
al. 2006). Moreover, HMGA1 overexpression promotes cytoplasmic relocalization 
of the p53 activator homeodomain-interacting protein kinase 2 (HIPK2), thus 
disabling the p53 phosphorylation at S46, which is required for its apoptotic 
function (Pierantoni et al. 2007). Interestingly, p53 may be used as a diagnostic 
and/or prognostic marker in thyroid cancer and as a predictive factor of 
chemioresistance. Indeed, since a consistent series of thyroid malignant tissues 
displays a positive immunostaining for at least one of the p53 family members 
(p53, p63 and p73), it is reasonable to hypothesize a possible use of these proteins 
in thyroid nodules differential diagnosis (Nishida et al. 1996). Moreover, several 
reports indicate that wild-type p53 gene delivery into anaplastic thyroid cancer 
cells induces a partial differentiation, with re-expression of thyroid specific-genes, 
and makes cells more vulnerable to the effect of chemotherapy (Moretti et al. 
1997). 
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1.8 BAX 
The Bax (Bcl-2 Associated protein X) protein is one of the principal targets of 
p53 which activates an apoptotic program after DNA damage, irradiation, or in 
response to the activity of oncogenes and other stress factors. Apoptosis, the main 
and more studied form of programmed cell death, plays a central role in tissue 
homeostasis during development and all along the life of multicellular organisms. 
Alterations of apoptosis are involved in tumorigenesis, as well as in the cellular 
response to anti-tumor treatments (Hickman et al. 2002). Bax is a central regulator 
of the mitochondria-dependent apoptotic pathway. It is a member of the Bcl-2 
protein family that includes proteins involved in apoptosis regulation characterized 
by the presence of one or more of the so-called “Bcl-2 Homology” domains (BH1 
to BH4). The BH domains are involved in protein-protein interactions and their 
presence is fundamental for the function of the Bcl-2 family proteins. The main 
function of these proteins is to regulate the permeability of the outer mitochondrial 
membrane to different apoptogenic factors, namely cytochrome c, Smac/Diablo, 
Omi/HtrA2, endonuclease G, and apoptosis-inducing factor (AIF). Among the 
Bcl-2 family members there are both pro-apoptotic factors (like Bax, Bak and 
PUMA) and antiapoptotic factors (like Bcl-2 and Bcl-Xl) (Renault et al. 2011). In 
non-apoptotic cells, Bax remains under a closed conformation, making it poorly 
able to interact with other partners. It has been suggested that several proteins are 
able to retain Bax under this conformation (for example Ku70, humanin and 14-3-
3) (Amsel et al. 2008; Nomura et al. 2003). Following a death signal, cytosolic 
BAX translocates to the mitochondria where it becomes an integral membrane 
protein. BAX overexpression induces mitochondrial permeability transition, which 
leads to the release of cytochrome c. Released cytochrome c binds to and activates 
APAF-1, which in turn recruits procaspase-9. This leads to the activation of the 
downstream caspase cascade and execution of the cell death (Lindsten et al. 2000). 
This p53-dependent apoptotic program is based both on the transcriptional 
activation of pro-apoptotic factors (Bax, PIG3, CD95, Perp, Noxa and PUMA) and 
on some transcription-independent p53 activities. Indeed, p53 is able to induce the 
mitochondrial outer membrane permeabilization and to activate some BH 
containing proteins interacting with them (Zilfou et al. 2009). Finally, it is 
important to underline that BAX gene plays an important role in human 
tumorigenesis: it is often mutated or downregulated in tumor tissues and it may be 
considered a tumor-suppressor. In thyroid tumorigenesis and tumor biology, the 
role of the pro-apoptotic BAX is controversially discussed. Hermann and co-
workers showed elevated BAX expression in patients with thyroid carcinoma 
associated with p53 wild-type overexpression, suggesting that the increased BAX 
expression might be the consequence of dysregulation of wild-type p53 in these 
tumors (Hermann et al. 2001). 
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1.9 PUMA 
PUMA (p53 upregulated modulator of apoptosis) belongs to the BH3-only 
subgroup of Bcl-2 family proteins, which share sequence similarity only within the 
BH3 domain. PUMA is a critical mediator of p53-dependent and -independent 
apoptosis induced by a wide variety of stimuli, including genotoxic stress, 
deregulated oncogene expression, toxins, altered redox status, growth 
factor/cytokine withdrawal and infection. In response to genotoxic stress, such as 
DNA damage, PUMA is transactivated by p53 (Vogelstein and Kinzler,  2004 ; J 
Yu and L Zhang 2008). Along with another BH3-only protein, Noxa, which in 
most cases has a minor function, PUMA accounts for virtually all of the 
proapoptotic activity of p53. PUMA is also activated by other transcription factors 
to initiate p53-independent apoptotic responses to nongenotoxic stimuli, including 
growth factor/cytokine deprivation, endoplasmic reticulum (ER) stress and 
ischemia/reperfusion. Similar to other BH3-only proteins, PUMA serves as a 
proximal signaling molecule that transduces death signals to the mitochondria 
where it acts through multidomain Bcl-2 family members to induce mitochondrial 
dysfunction and caspase activation. The BH3 domain of PUMA is required for its 
interactions with Bcl-2- like proteins, such as Bcl-2 and Bcl-XL (Nakano and 
Vousden 2001). PUMA primarily acts to indirectly activate Bax and/or Bak by 
relieving the inhibition of these proteins by antiapoptotic Bcl-2 family members, 
including Bcl-2, Bcl-XL, Mcl-1, Bcl-w and A1. It has also been suggested that 
PUMA can trigger apoptosis by directly activating Bax, or through cytoplasmic 
p53 in some cells. In contrast to its prominent function in p53-dependent 
apoptosis, the function of PUMA in p53-independent apoptosis remains to be fully 
appreciated. In addition to p53, a number of other transcription factors are 
implicated in PUMA induction. The oncoproteins E2F1 and c-myc can induce 
PUMA through their respective binding sites in the PUMA promoter (Fernandez et 
al. 2003; Hershko and Ginsberg, 2004). Moreover, general transcription factors, 
including C/EBPβ, CREB, c-Jun and Sp1 have been implicated in PUMA 
induction, some of which may do so by cooperating with p53 or p73 (Qiao et al. 
2003; Hayakawa et al. 2004). On the other hand, PUMA transcription is subject to 
negative regulation by transcriptional repressors, including Slug (Wu et al. 2005), 
some alternative splice products of p73 (∆Np73 and p73α) (Melino et al. 2004) or 
p63 (∆Np63) (Rocco et al. 2006) and microRNA (Choy et al. 2008). Until now the 
activity of PUMA seems to be exclusively controlled by transcription, whereas 
other BH3-only proteins are often activated through multiple mechanisms 
including post-translational modifications. With such versatile functions, it is 
perhaps not surprising that PUMA has been implicated in many pathological and 
physiological processes including cancer, tissue injury, neurodegenerative 
diseases, immune response and bacterial or viral infection. Several lines of 
evidence suggest that the function of PUMA is compromised in cancer cells. First, 
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more than half of human tumors contain p53 mutations (Vogelstein and Kinzler, 
2004), which abrogate the induction of PUMA by irradiation and many 
chemotherapeutic drugs (Yu and Zhang, 2005). Second, frequent overexpression 
of antiapoptotic Bcl-2 family proteins and other antiapoptotic oncoproteins in 
tumors antagonizes PUMA-induced apoptosis. Third, PUMA expression was 
found to be reduced in malignant cutaneous melanoma, and PUMA expression 
appears to be an independent predictor of poor prognosis in patients. In addition, 
approximately 40% of primary human Burkitt’s lymphomas do not express 
detectable levels of PUMA, which is attributable, in part, to DNA methylation. 
However, PUMA does not appear to be a direct target of genetic inactivation in 
human cancer (Yu and Zhang 2008). Finally, PUMA may be an excellent 
therapeutic target, as activating PUMA inhibits tumor growth by restoring 
apoptosis in cancer cells, whereas inhibiting PUMA curbs excessive apoptosis 
associated with tissue injury and neurodegeneration (Yu and Zhang 2008). 
 
 
 
 
1.10 PERP 
 
PERP (p53 apoptosis effector related to PMP-22) gene was discovered as a p53 
target gene, involved in DNA damage-induced apoptosis, whose expression was 
high in apoptotic cells. However, in addition to this apoptotic function downstream 
of p53, PERP plays a role in development (Beaudry et al. 2010). PERP is a 
member of the claudin/PMP-22/EMP family of fourpass membrane proteins which 
participate in a variety of cellular processes including ion channel function, 
receptor trafficking, tight junction formation, and myelination. In particular, PERP 
is a component of the desmosomes which are cell-cell junctions important for 
tissue integrity. The dynamic regulation of cell-cell adhesion junctions, including 
desmosomes, is thought to be an important facet of wound healing. Desmosomes 
are multiprotein cell-cell adhesion complexes essential for maintaining the 
structural integrity of tissues through connection to the intermediate filament 
network. Desmosomal adhesion junctions are initially destabilized at the wound 
front, presumably to facilitate proliferation and migration, and are reassembled 
later during the sealing of the epithelium. Desmosome complexes form when the 
desmosomal cadherins, desmogleins and desmocollins, participate in heterotypic 
interactions that bring the plasma membranes of adjacent cells in close apposition. 
The cytoplasmatic tails of these cadherins interact with plakoglobin and 
plakophilins, which connect to the intermediate filament cytoskeleton via 
desmoplakin (Attardi et al. 2000). Several studies have shown that PERP has an 
important  role in promoting cell adhesion and is essential for wound healing. 
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PERP’s critical role in desmosomal adhesion was evidenced by the presence of 
dramatic blisters observed in the epidermis and oral mucosa of mice lacking Perp 
as well as by the ultrastructural abnormalities observed in desmosomes of these 
mice. Moreover, the analysis of conditional Perp knock-out mice (in which Perp 
expression is selectively ablated in stratified epithelia) suggests that this gene has a 
tumor-suppressor function. In particular, it has been demonstrated that PERP 
ablation predisposes mice to UVB induced squamous cell carcinoma (SCC) 
development by enhancing tumor initiation and progression. These effects are 
elicited at multiple levels, leading both to compromised apoptosis in response to 
ultraviolet light and loss of desmosomal adhesion. The defective apoptosis could 
allow the inappropriate survival of damaged cells, which could help initiate 
tumors. Interestingly, the loss of cell-cell and cell-matrix adhesion is a common 
feature of tumor progression and in particular of the epithelial-mesenchymal 
transition (EMT) (Beaudry et al. 2010). The EMT is a process characterized by 
loss of cell adhesion, repression of E-cadherin expression and increased cell 
motility. EMT is essential for numerous developmental processes and it is a 
typical step of the transformation process of epithelial cells (Muller et al. 2011). 
The absence of PERP in mice induces the expression of some genes involved in 
promoting inflammation, which is a well-established causative factor in 
tumorigenesis. The hypothesis that PERP has a tumor-suppressor function is 
confirmed also by the fact that its locus (in human chromosome 6q24) is mutated 
in a variety of cancers, including melanoma, cervical cancer, ovarian cancer, and 
breast cancer. Moreover, it has been recently discovered that PERP loss affects 
mammary epithelial homeostasis by causing the accumulation of inflammatory 
cells around mature mammary epithelium (Millikin et al. 1991; Foulkes et al. 
1993; Noviello et al. 1996). Finally, PERP expression is reduced in many breast 
cancer cell lines compared with untransformed cells and PERP deficiency also 
promotes the development of mouse mammary cancer (Dusek et al. 2012). 
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2. AIM OF THE STUDY 
The POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1) is a 
transcription factor whose expression is frequently de-regulated in human cancer. 
It is still debated if PATZ1 is a tumor suppressor or an oncogene. To better 
understand the role of PATZ1 in human cancer we focused on thyroid tumors, 
which include a wide spectrum of lesions with different phenotypic characteristics 
and biological behaviors, thus representing a useful model to study the multi-step 
carcinogenesis. Furthermore, thyroid cancer is one of the most frequent 
malignancies of the endocrine system, whose mechanisms of pathogenesis are still 
far from being completely elucidated. Therefore, the aim of my study has been to 
elucidate PATZ1 function in thyroid cell transformation. 
 
Beside the study of PATZ1 role in thyroid cancer, projects developed during my 
PhD program regarded: 
 
1. Pero R, Palmieri D, Angrisano T, Valentino T, Federico A, Franco R, 
Lembo F, Klein-Szanto AJ, Del Vecchio L, Montanaro D, Keller S, Arra 
C, Papadopoulou V, Wagner SD, Croce CM, Fusco A, Chiaretti L, Fedele 
M. POZ-, AT-HOOK-, and zinc finger containing protein (PATZ) 
interacts with human oncogene B cell lymphoma 6 (BCL6) and is 
required for its negative autoregulation. J Biol Chem 2012; 
287(22):18308-17. (Attached at the end) 
 
 
2. Valentino T, Palmieri D, Vitiello M, Simeone A, Palma G, Arra C, Chieffi 
P, Chiariotti L, Fusco A, Fedele M. Embryonic defects and growth 
alteration in mice with homozygous disruption of the Patz1 gene. J Cell 
Physiol 2013;228(3):646-53. (Attached at the end) 
 
3. Fedele M, Palmieri D, Chiappetta G, Pasquinelli R, De Martino I, Arra C, 
Palma G, Valentino T, Pierantoni GM, Viglietto G, Rothstein JL, Santoro 
M, Fusco A. Impairment of the p27kip1 function enhances thyroid 
carcinogenesis in TRK-T1 transgenic mice. Endocr Relat Cancer. 2009 
Jun;16(2):483-90. (Attached at the end) 
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4. Fedele M, Visone R, De Martino I, Palmieri D, Valentino T, Esposito F, 
Klein-Szanto A, Arra C, Ciarmiello A, Croce CM, Fusco A. Expression of 
a truncated Hmga1b gene induces gigantism, lipomatosis and B-cell 
lymphomas in mice. Eur J Cancer. 2011 Feb;47(3):470-8. (Attached at the 
end) 
 
 
5. Palmieri D, Valentino T, D'Angelo D, De Martino I, Postiglione I, Pacelli 
R, Croce CM, Fedele M, Fusco A. HMGA proteins promote ATM 
expression and enhance cancer cell resistance to genotoxic agents. 
Oncogene. 2011 Jul 7;30(27):3024-35. (Attached at the end) 
 
 
6. Palmieri D, D'Angelo D, Valentino T, De Martino I, Ferraro A, Wierinckx 
A, Fedele M, Trouillas J, Fusco A. Downregulation of HMGA-targeting 
microRNAs has a critical role in human pituitary tumorigenesis. 
Oncogene. 2012 Aug 23;31(34):3857-65. (Attached at the end) 
 
 
7. Palmieri D, Valentino T, De Martino I, Esposito F, Cappabianca P, 
Wierinckx A, Vitiello M, Lombardi G, Colao A, Trouillas J, Pierantoni 
GM, Fusco A, Fedele M. PIT1 upregulation by HMGA proteins has a 
role in pituitary tumorigenesis. Endocr Relat Cancer. 2012 Apr 
10;19(2):123-35. (Attached at the end) 
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3. MATERIALS AND METHODS 
 
 
3.1 Cell cultures, transfections and plasmids 
Continuos human carcinoma thyroid cell lines TPC-1 and BC-PAP, derived 
from papillary thyroid cancer, FRO and FB1 derived from anaplastic thyroid 
cancer, and human embryonic kidney HEK293 cells were cultured in DMEM 
supplemented with 10% FBS, L-glutamine, and penicillin/streptomycin (GIBCO-
BRL) in a 5% CO2 atmosphere. For transient transfection TPC-1 and FRO cells 
were transfected using Neon Electroporation System (Invitrogen), according to 
manufacturer’s instruction. FB1 and BC-PAP cells  were transfected using Arrest-
in reagent (Open Biosystems, Huntsville USA). HEK293 transfection were 
performed by Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
instruction. All the cell lines were transfected with HA-PATZ1 plasmid encoding 
for PATZ1 variant 4 or the empty vector pCEFL-HA. For the stable transfection of 
TPC-1, BC-PAP, FRO and FB1 cell lines the same transfecting agent and the same 
protocol as the transient transfection were used. The cells were transfected with 
PATZ1-eGFP-C2 plasmid encoding for the human of PATZ1 variant 4 or with the 
empty vector eGFP-C2, both expressing the gene for the resistance to neomycin. 
Stable transfectants were clonally selected in medium with 1µg/ml neomycin 
(G418) (Life Technologies) for 10 days, and cell clones were screened for PATZ1 
expression by qRT-PCR and Western blot analysis. The selected cell clones of 
TPC-1/PATZ1, BC-PAP/PATZ1, FRO/PATZ1, FB1/PATZ1 and the control cells 
were cultured in DMEM supplemented by 10% FBS, L-glutamine, 
penicillin/streptomycin (GIBCO-BRL) and neomycin (G418) 0,5 µg/ml  in a 5% 
CO2 atmosphere. 
 
 
3.2 Human thyroid tissue samples and immunohistochemistry  
Neoplastic and normal human thyroid tissues and RNA samples were collected 
by the research group of Doctor G. Chiappetta at the Istituto dei Tumori di Napoli 
or by the research group of Professor A. Fusco at the Istituto di Endocrinologia ed 
Oncologia Sperimentale of Naples and derived from the Service d’Anatomo-
Pathologie, Centre Hospitalier Lyon Sud, Pierre Benite, France. For 
immunohistochemistry, 6 µm paraffin sections were deparaffinised and then 
placed in a solution of absolute methanol and 0.3% hydrogen peroxide for 30 min 
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and then washed in PBS before immunoperoxidase staining. The slides were then 
incubated overnight at 4 °C in a humidified chamber with the antibodies diluted 
1 : 100 in PBS. The slides were subsequently incubated with biotinylated goat anti-
rabbit IgG for 20 min (Vectostain ABC kits, Vector Laboratories, Burlingame, 
CA, USA) and then with premixed reagent ABC (Vector) for 20 min. The 
immunostaining was performed by incubating the slides in diaminobenzidine 
(DAB-DAKO) solution containing 0.06 mM DAB and 2 mM hydrogen peroxide 
in 0.05% PBS, pH 7.6, for 5 min, and, after chromogen development, the slides 
were washed, dehydrated with alcohol and xylene and mounted with cover slips 
using a permanent mounting medium (Permount). The antibodies used are an 
home-made rabbit polyclonal anti-PATZ1 which reacts against the amino-terminal 
portion of the protein and anti-PERP (ab48032, Abcam). Tissue samples were 
scored as positive for immunohistochemistry when tissue immunoreactivity was 
detected in at least 10% of the cells. Negative controls were performed by omitting 
the first antibody. No staining was observed when normal thyroid gland was 
stained with antibodies pre-incubated with the peptide against which the antibodies 
were raised or without the primary antibodies (data not shown).  
 
 
3.3 Protein extraction, Western blotting and antibodies 
Cells were lysed in buffer containing 1% Nonidet P-40, 1 mmol/liter EDTA, 50 
mmol/liter Tris-HCl (pH 7.5), and 150 mmol/liter NaCl supplemented with 
Complete protease inhibitors (Roche Applied Science). Total proteins were 
resolved in a 8% polyacrylamide gel under denaturing conditions and transferred 
to nitrocellulose filters for Western blot analyses. Membranes were blocked with 
5% BSA in TBS and incubated with the primary antibodies. Membranes were then 
incubated with the horseradish peroxidase–conjugated secondary antibody 
(1:3.000) and the reaction was detected with a Western blotting detection system 
(enhanced chemiluminescence; GE Healthcare). The primary antibodies used are 
anti-PATZ1 antibody (polyclonal antibody raised against a conserved peptide 
recognizing all PATZ1 isoforms of mouse and human origin) and anti-E-cadherin 
(610181) (BD Transduction Laboratories). To ascertain that equal amounts of 
protein were loaded, the membranes were incubated with antibodies against the 
anti-vinculin protein (sc-7649) (Santa Cruz Biotechnology, Santa Cruz, CA). 
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3.4 Co-immunoprecipitation assay 
For co-immunoprecipitation experiments, antigens and antibodies were 
incubated for 3 hours and then supplemented with protein A-sepharose or G 
sepharose beads. After 1 h, the beads were collected and washed five times with 
lysis buffer and boiled in Laemmli sample buffer for western blotting analysis. 
The antibodies used are antip53 (sc-126) (Santa Cruz Biotechnology, Santa Cruz, 
CA), anti-PATZ1 (polyclonal antibody raised against a conserved peptide 
recognizing all PATZ1 isoforms of mouse and human origin), and non-specific 
IgG (Santa Cruz Biotechnology, Santa Cruz, CA). 
 
 
3.5 RNA extraction and qRT-PCR analysis 
Total RNA was isolated using TRI-reagent solution (Sigma, St Louis, MO, 
USA) and treated with DNase (Invitrogen). Reverse transcription was performed 
according to standard procedures (Qiagen, Valencia, CA). qRT-PCR analysis was 
performed using the Power SYBR Green PCR Master Mix (Applied Biosystems) 
according to manufacters’s instructions with the following primer sequences to 
amplify the indicated genes: 
hPATZ1all-variants-Fw: 5’-TACATCTGCCAGAGCTGTGG-3’ 
hPATZ1all-variants-Rev: 5’-TGCACCTGCTTGATATGTCC-3’ 
hPATZ1short-variant-Fw: 5’-CTGAGCGGCCTCACAAGT-3’ 
hPATZ1short-variant-Rev: 5’-GTCGCTAGGAAGAGGTTCCA-3’ 
mPATZ-Fw: 5’-GAGCTTCCCCGAGCTCAT- 3’ 
mPATZ –Rv:e 5’ -CAGATCTCGATGACCGACCT- 3’ 
hBAX-Fw: 5’-ATGTTTTCTGACGGCAACTTC-3’ 
hBAX-Rev: 5’-ATCAGTTCCGGCACCTTG-3’ 
hPERP-Fw: 5’-GACCCCAGATGCTTGTCTTC-3’ 
hPERP-Rev: 5’-ACCAGGGAGATGATCTGGAA-3’ 
hPUMA-Fw: 5’-TTCTCCGGAGTGTTCATGC-3’ 
hPUMA-Rev: 5’-TACAGCGGAGGGCATCAG-3’  
mBAX-Fw: 5’-GTGAGCGGCTGCTTGTCT-3’ 
mBAX-Rev: 5’-GGTCCCGAAGTAGGAGAGGA-3’ 
mPERP-Fw: 5’-GACCCCAGATGCTTGTTTTC-3’ 
mPERP-Rev: 5’-ACCAGGGAGATGATCTGGAA-3’ 
mPUMA-Fw: 5’-GACCTCAACGCACAGTACGA-3’ 
mPUMA-Rev: 5’-GAGATTGTACAGGACCCTCCA-3’ 
hG6PD-Fw: 5’-GATCTACCGCATCGACCACT-3’ 
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hG6PD-Rev: 5’-AGATCCTGTTGGCAAATCTCA-3’ 
mG6PD-Fw: 5’-GAAAGCAGAGTGAGCCCTTC-3’ 
mG6PD-Rev: 5’-CATAGGAATTACGGGCAAAGA-3’ 
To calculate the relative expression levels we used the 2-∆∆CT method (Livak and 
Schmittgen, 2001). Primers specific for the glucose-6-phosphate dehydrogenase 
(G6PD) were used for normalization of Real-Time quantitative PCR data. 
 
 
3.6 Proliferation assay 
For colony assay the cells were plated at a density of 90% in 100-mm dishes, 
transfected with 5 µg of HA-PATZ1 plasmid encoding for the short isoform of 
PATZ1 or the empty vector pCEFL-HA, and supplemented with neomycin (G418) 
24 h later. Two weeks after the onset of drug selection, the cells were fixed and 
stained with crystal violet (0.1% crystal violet in 20% methanol, SIGMA). After 
an incubation of 30 min, crystal violet has been removed, the plates were washed 
with PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM NaH2PO4), photographed and 
the cells were counted. For the growth curves the cells (4 × 104 cells/dish) were 
plated in a series of 6-cm culture dishes and counted daily for 10 consecutive days 
through the Bürker chamber. The count was performed in the presence of  trypan 
blue, a dye that penetrate in cells that have lost membrane integrity and which 
shows, therefore, dying cells. 
 
 
3.7 DNA ladder assay 
Cells were plated (2,5× 105 cells) in 100-mm dishes and 7 days later the assay 
was performed. The cells were harvested, washed with PBS 1X (137 mM NaCl, 
2.7 mM KCl, 4.3 mM NaH2PO4) and lysed in buffer containing 0,5% TRITON, 
5mM Tris pH 7.4, 20 mM EDTA) for 20 min in ice. Then cells were centrifugated 
at 13.200 rpm for 30 min and the supernatant containing DNA fragments was 
obtained. DNA was precipitated and the pellet was resospended and incubated for 
30 min at 37 ℃ with 20  µL of buffer TE (10 mmol/L Tris-HCl, 1 mmol/L EDTA) 
and RNase 0,4 mg/ml. 12 µL of each samples was loaded on minigel for 
electrophoresis. Doxorubicin treatment (10 µg/ml) was used as a positive control. 
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3.8 SA–β-gal assay 
 Cells, plated (1 × 105 cells/dish) in a series of 6-cm culture dishes 24 hours 
before the assay, were washed twice with PBS and immersed in fixation buffer 
(2% [w/v] formaldehyde, 0.2% [w/v] glutaraldehyde in PBS) for 7 min. After 3 
additional PBS washes, the cells were allowed to stain overnight in staining 
solution (40 mM citric acid/sodium phosphate, pH 6.0; 150 mM NaCl; 2.0 mM 
MgCl2; 1 mg/ml X-gal) at 37°C without CO2 to avoid changes in pH. The next 
day, the staining solution was replaced with PBS, and the stained and unstained 
cells were counted under light microscopy (at least 24 fields). 
 
 
3.9 Migration and invasion assay 
The migration assay was conducted in triplicate using plates transwell cell 
culture chambers according to described procedures (Corning Costar Corp., 
Cambridge, MA). Briefly, confluent cell monolayers were harvested with 
trypsin/EDTA , centrifuged at 1.200 rpm for 5 min, resuspended in medium 
without serum and plated (5 × 104 cells) to the upper chamber of a polycarbonate 
membrane filter of 8 µM pore size. The lower chamber was filled with complete 
medium. The cells were then incubated at 37°C in a humidified incubator in 5% 
CO2 for 24h and 48h. Non migrating cells on the upper side of the filter were 
wiped off and migrating cells on the reverse side of the filter were stained with 
0.1% crystal violet in 20% methanol for 30 min, washed in PBS 7.4 (137 mM 
NaCl; 2.7 mM KCl, 4.3 mM NaH2PO4), photographed and counted. The rate of 
invasion was carried out, again by using plates transwell cell culture chambers in 
the presence of a Matrigel (BD Biosciences). The plate has been appropriately 
pretreated with a cold solution containing serum-free medium and Matrigel 
(diluted 1:4) and was left 45 min in the incubator at a temperature of 37 ° C, 
temperature at which the Matrigel polymerizes to produce a matrix biologically 
active that resembles the basement membrane of mammalian cells. Then the assay 
was performed as the migratory assay.  
 
 
3.10 Soft agar colony forming assay 
For soft agar assays 7 ml of mixture of serum supplemented medium and 0.5% 
agar  were added in a 60-mm culture dish and allowed to solidify (base agar). 
Next, on top of the base layer was added a mixture of serum supplemented 
medium and 0.35% agar (total of 2 mL) containing 2x104 of FRO cells expressing 
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PATZ1 or control cells (obtained as described before) and allowed to solidify (top 
agar). Subsequently, the dishes were kept in culture incubator maintained at 370C 
and 5% CO2 for 14 days to allow for colony growth. After 14 days the colonies 
were counted. 
 
 
3.11 Tumorigenesis in vivo 
The tumorigenicity of the FRO cells expressing PATZ1 or control cells was 
tested by subcutaneous injections of 2x106 cells into athymic mice. Severe 
combined immunodeficient mice (7 weeks old) Foxn1 nu/nu female mice (Harlan 
Laboratories) were s.c. injected in the right flank with 2 × 106 of FRO cells 
expressing PATZ1 and in the left flank with 2 × 106 of control cells suspended in 
0.1 mL PBS. Tumor growth was assessed every day by measuring with calipers. 
Tumor volume was calculated using the following formula: (length × width)/2. 
Excised tumor sections were weighed, snapfrozen for protein analysis and fixed in 
formalin for immunohistochemical analysis. Staining with hematoxylin and eosin 
was performed for histologic confirmation of tumor cell growth. The humane care 
and use of the mice were in accordance with institutional guidelines.  
 
 
3.12 Chromatin immunoprecipitation (ChIP) assays 
For ChIP analysis 5x106 HEK293 cells after transfection were cross-linked 
using formaldehyde 1% for 10 min at room temperature. The reaction was stopped 
with Glycine 0,125 M for 5 min. The cells were washed twice with cold PBS, 
harvested and lysed sequentially by 10 min in ice and 5 minute centrifugation at 
3000 X g at 4°C with 1 mL buffer A (10 mM HEPES pH 8, 10 mM EDTA pH 8, 
0,5 mM EGTA pH 8, 0,25% Triton X-100 and protease inhibitors), and then with 
1 mL buffer B (10 mM HEPES pH 8, 200 mM NaCl, 1 mM EDTA pH 8, 0,5 mM 
EGTA pH 8, 0,01% Triton X-100 and protease inhibitors). The pellets were then 
resuspended in 200 µl of lysis buffer (10mM EDTA, 50 mM Tris-HCl pH 8, 1% 
SDS and protease inhibitors), and sonicated 5 times for 30 s at maximum settings 
obtaining fragments between 0,3 and 1,0 kbp. The samples were cleared by 
centrifugation at 14000 rpm for 15 min. After centrifugation 20 µl of the 
surnatants were used as imputs, and the other parts of the samples diluted 2,5-fold 
in Ip buffer (100 mM NaCl, 2 mM EDTA pH 8, 20 mM Tris-HCl ph 8, 0,5% 
Triton X-100 and protease inhibitors). The samples were subjected to 
immunoprecipitation with specific antibody anti-HA or non-specific IgG, after 2 
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hours preclearing at 4°C with Protein A Sepharose SA/Salmon Sperm (Upstate). 
Precipitates were washed sequentially with 1 mL Ip buffer (150 mM NaCl, 2 mM 
EDTA pH 8, 25 mM Tris-HCl ph 8, 1% Triton X-100 and SDS 0,1%), 1 ml Wash 
buffer 1 (500 mM NaCl, 2 mM EDTA pH 8, 20 mM Tris-HCl ph 8, 0,5% Triton 
X-100 and SDS 0,1%), 1 ml Wash Buffer 2 (0,25 M LiCl, 1% NP40, 1% Na 
deoxycholate, 1 mM EDTA and 10 mM Tris-HCl ph 8), and then twice with 1 mM 
EDTA, 10 mM Tris-HCl pH 8. Precipitated chromatin complexes were removed 
from the beads through 15 min incubation with 250 µl of 1% SDS, 0,1 M 
NaHCO3. This step was repeated twice. For qRT-PCR analysis, 1µl out of 30µl 
immunoprecipitated DNA was used with primers described below. 
Primers used were: 
BAX-prom -250/-530-Fw 5’-TAATCCCAGCGCTTTGGAA -3’ 
BAX-prom-250/-530 -Re 5’-GTCCAATCGCAGCTCTAATG -3’ 
PERP-prom -950/-700 -Fw 5’-CCACCCTTCCTGTCACATCT-3’ 
PERP-prom -950/-700 -Re 5’-GCAGTCCACTTCCTATCACGA-3’ 
 
 
3.13 Electrophoretic mobility shift assay (EMSA) 
DNA binding assay with the recombinant proteins were performed as 
previously described (Thanos and Maniatis 1995). Briefly, 5 ng of human PATZ1 
recombinant protein spanning from aa 259 to aa 367 (H00023598-Q01) (Abnova) 
were incubated with radio-labelled double-strand oligonucleotide, corresponding 
to region spanning bases -50 to -24 of the human PUMA promoter region. PATZ1 
recombinant protein was incubated in a solution made of 20 mM HEPES pH 7.9, 
40 mM KCl, 0,1 mM EDTA, 0,5 mM MgCl2, 0,5 mM DTT, 0,1 mM PMSF, 0,5 
mg poly (dC-dG), 2 mg BSA and 10% glycerol, to a final volume of 20 ml, for 10 
min at room temperature. The samples were incubated for 15 min after addition of 
2,5 fmol of a 32P-end-labelled oligonucleotide. A 200-fold molar excess of 
unlabelled oligonucleotide was addes as specific competitor. The DNA-protein 
complexes were resolved on 6% nondenaturing acrylamide gels and visualized by 
exposure to autoradiographic films. 
 
 
3.14 Statistical analysis. 
 Student’s t-test was used to determine the significance for all the quantitative 
experiments. Error bars represent the standard deviation (s.d.) of the average. 
Statistical significance for all the tests, assessed by calculating the p-value, was 
<0.05. 
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4. RESULTS 
 
4.1 PATZ1 gene expression is down-regulated in thyroid cancer 
In order to evaluate a possible involvement of PATZ1 in neoplastic 
transformation of the thyroid gland, the expression of PATZ1 gene has been 
analyzed, by quantitative RT-PCR (qRT-PCR), in two panels of human thyroid 
tumors representative of different histological types and different degrees of 
differentiation compared to normal thyroids. The first qRT-PCR was carried out 
on RNAs of 9 normal thyroids, 9 papillary carcinomas (PTC), 4 follicular 
carcinomas (FTC) and 8 anaplastic carcinomas (ATC) collected by the research 
group of Dr. Gennaro Chiappetta at the Istituto dei Tumori di Napoli. The 
experiment showed down-regulation of PATZ1 in all tumor samples compared 
with normal thyroids with an inverse correlation with both malignancy and degree 
of de-differentiation. Indeed, as reported in Fig. 4 (Panel A), there was a negative 
fold change in PATZ1 expression in PTC (up to -3,85) compared to the normal 
tissue; this down-regulation was stronger in FTC (up to -20) and is even more 
pronounced in ATC (up to -33,3). The second qRT-PCR was performed on RNAs 
of 3 normal thyroids, 19 PTC and 4 ATC collected by the research group of 
Professor Alfredo Fusco at the Istituto di Endocrinologia ed Oncologia 
Sperimentale of Naples and derived from the Service d’Anatomo-Pathologie, 
Centre Hospitalier Lyon Sud, Pierre Benite, France. This experiment confirmed 
that in all thyroid tumors the expression of PATZ1 is reduced compared to normal 
thyroid. Indeed, as shown in Fig. 4 (Panel B),  there was a negative fold change in 
PATZ1 expression from -1,5 to -12,6 in the PTC samples and from -5,4 to -20 in 
ATC samples. These results suggest that PATZ1 can play a tumor suppressor role 
in thyroid cancer, mainly involved in the late stages of carcinogenesis.  
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Figure 4. PATZ1 expression in Thyroid Cancer. A, qRT-PCR analysis of PATZ1 in a panel of 9 
PTC, 4 FTC and 8 ATC in comparison with a pool of 9 wild-type normal thyroid samples. B, qRT-
PCR analysis of PATZ1 in a panel of 19 PTC and 4 ATC in comparison with a pool of 3 wild-type 
normal thyroid samples. The fold change indicates the relative change in expression levels between 
tumor samples and normal samples, assuming that the value of each normal sample is equal to 1. 
The results shown are the mean + SE of three analyses for each sample. 
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4.2 PATZ1 protein is delocalized in thyroid cancer 
Subsequently, we analyzed PATZ1 protein expression and localization by 
immunohistochemistry (IHC). The experiment was performed in collaboration 
with the research group of Doctor G. Chiappetta at the Istituto dei Tumori di 
Napoli on a panel of human paraffin embedded normal and neoplastic thyroid 
samples, including 27 normal thyroids, 2 goiters, 11 adenomas, 26 PTC, 9 FTC, 16 
ATC and 5 poorly differentiated thyroid carcinoma (PDTC). The analysis was 
performed using an anti-PATZ1 polyclonal antibody, which reacts against the 
amino-terminal portion of the protein and that recognizes all the isoforms of 
PATZ1. All samples of normal thyroid parenchyma and goiters expressed PATZ1 
at a high level in the nucleus, which coincides with the strong PATZ1 staining in 
all follicles (Fig. 5). Conversely, compared to normal samples, PATZ1 expression 
in the nucleus was found to be weaker in adenoma (55%, 6/11 samples), in PTC 
(42%, 11/26 samples) and FTC (45%, 4/9 samples), and completely negative in 
most of poorly differentiated (80%, 4/5 samples) and anaplastic (75%, 12/16 
samples) carcinomas (Table 2). Interestingly, PATZ1 protein showed a 
progressive displacement from the nucleus to the cytoplasm with a direct 
correlation with the undifferentiated and malignant phenotype. Indeed, in all 
normal thyroid tissues (100%, 27/27) and goiters (100%, 2/2) analyzed, PATZ1 is 
expressed and is present only in the nucleus, while in most adenoma samples (54% 
, 6/11), PTCs (73%, 19/26) and FTCs (89%, 8/9), PATZ1 protein was localized 
also in the cytoplasm. In 60% (3/5) of PDTCs PATZ1 protein was localized only 
in the cytoplasm as in 12,5% (2/16) of ATCs. Moreover, in 20% (1/5) of PDTCs 
and in 62% (10/16) of ATCs, PATZ1 expression was completely absent (Table 3). 
These results confirmed the inverse correlation between PATZ1 expression and 
the thyroid malignant phenotype. 
 
Figure 5. Normal and neoplastic thyroid tissues analyzed for PATZ1 protein expression by 
immunohistochemistry. PATZ1 staining was intense in the nucleus of normal thyroid tissue (1) 
and its localization moves to the cytoplasm proceeding from the normal to malignant samples such 
as in the PTC sample shown here (2), whereas it was absent in ATC (3). 
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Table 2 and 3. Summary of IHC results showing the expression and the sub-cellular 
localization of PATZ1. The subcellular localization of PATZ1 moves from the nucleus to the 
cytoplasm as they proceed from the normal to malignant samples, with an inverse correlation to the 
degree of de-differentiation, up to be completely absent in ATC. 
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4.3 Characterization of PATZ1 gene expression in human cell lines of thyroid 
carcinoma and restoration of PATZ1 expression in TPC-1, BC-PAP and FRO 
cells. 
In order to investigate a causal role of PATZ1 in thyroid carcinogenesis and 
choose a suitable cellular system to work, we evaluated the expression of PATZ1 
gene in a series of human cell lines derived from thyroid carcinomas. This series 
includes cells derived from papillary (TPC-1, FB2, BC-PAP), follicular (WRO) 
and anaplastic (FRO, FB1, ACT1, 8505c) thyroid carcinomas compared to 3 
normal thyroids. The analysis was carried out by qRT-PCR using primers able to 
amplify all transcript variants of PATZ1. As shown in Fig. 6, in all tumor cell lines 
the expression of PATZ1 is reduced compared to normal control, represented by 
normal thyroid tissue. 
 
Figure 6. PATZ1 expression in human thyroid cancer cell lines. qRT-PCR analysis of PATZ1 
in 3 PTC-derived cell lines (TPC-1, BC-PAP and FB2), 1 FTC-derived cell line (WRO) and 4 
ATC-derived cell lines (FRO, FB1, ACT1, 8505C) in comparison with a pool of 3 normal thyroid 
glands. The fold change indicates the relative change in expression levels between thyroid cancer 
cell lines and the pool of normal thyroid glands, assuming that the value of each normal sample is 
equal to 1. The results shown are the mean + SE of three analyses for each sample. 
 
Subsequently, two cell lines representative of papillary thyroid carcinoma 
(TPC-1 and BC-PAP) and two representative of anaplastic thyroid carcinoma (FB1 
and FRO) were selected to restore PATZ1 expression by stable transfecting a 
vector encoding for PATZ1 variant 4. Cells transfected with the correspondent 
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empty vector have been used as negative controls. Following the transfection, 
PATZ1 expressing clones, called TPC1/PATZ1, BC-PAP/PATZ1, FB1/PATZ1 
and FRO/PATZ1, were selected and the restoration of PATZ1 expression has been 
confirmed by qRT-PCR and Western-Blot analysis compared to clones transfected 
with the empty vector (CTRL). For qRT-PCR analysis we used primers able to 
amplify the short transcript variant of PATZ1 and for Western Blot analysis we 
used an anti-PATZ1 polyclonal antibody that recognizes all the isoforms of 
PATZ1. We also carefully observed the morphology of the clones at the optical 
microscope, and found some differences compared to control clones; indeed, some 
clones of TPC-1 re-expressing PATZ1 showed a shift toward an epithelial-like 
phenotype retaining a packed cuboidal and organized morphology compared to 
control cells that, instead, exhibited a spindle-shaped morphology (Fig. 7, panel 
A). Moreover, most FB1/PATZ1 clones showed features of a suffering phenotype 
with condensed nuclei and vacuolated cytoplasm (Fig. 7, panel B). Based on the 
data of Western-Blot, qRT-PCR analysis and morphological changes, we selected 
specific clones of TPC-1/PATZ1 (PA 1, PA 5, PA6) (Fig. 8, panel A-B), BC-
PAP/PATZ1 (PA 3, PA7, PA10) (Fig. 8, panel  C-D) and FRO/PATZ1 (PA11, 
PA16, PA17) (Fig. 8 panel E-F) in order to characterize growth and malignant 
properties in terms of proliferation, death, aging, migration, invasion and 
tumorigenicity. The TPC-1, BC-PAP and FRO cells transfected with the empty 
vector, were used as controls (CTRL). We were not able to keep FB1/PATZ1 
clones in culture, because they stop to grow and die after few passages, thus 
suggesting a toxic role for PATZ1 expression in this cancer cell line.  
 
Figure 7. Effect of restoration of PATZ1 expression in TPC-1 and FB1 cells. Representative 
optical microscope images showing morphological changes of 2 cell clones of TPC-1 re-expressing 
PATZ1 and 2 cell clones of FB1 re-expressing PATZ1 compared to their CTRL. 
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Figure 8. Restoration of PATZ1 expression in TPC-1, BC-PAP and FRO cells. qRT-PCR and 
Western Blot analysis of PATZ1 in 3 selected cell clones of TPC-1 (PA1, PA5, PA6) (A-B), BC-
PAP (PA3, PA7, PA10) (C-D) and FRO (PA11, PA16, PA17) (E-F) transfected with a vector 
encoding for the short isoform of the PATZ1 gene compared to a clone transfected with the empty 
vector (CTRL).   
 
 
4.4 PATZ1 inhibits growth rate in BC-PAP and FRO cells and induces 
apoptotic cell death in FRO cells 
To determine whether the loss of PATZ1 gene expression affects thyroid 
carcinogenesis, we first analyzed the properties of proliferation and survival 
carrying out a colony-forming assays in TPC-1, BC-PAP and FRO cells 
transfected with the empty vector (pCEFL-HA) or with the vector encoding for 
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PATZ1 (HA-PATZ). The colonies were scored after 10 days. All the assays 
carried out on TPC-1 showed no difference in the number of colonies expressing 
or not PATZ1, while BC-PAP and FRO cells transfected with PATZ1 showed a 
reduced number of colonies compared to controls: the inhibition was about the 
40% for the BC-PAP cells and about 80% for the FRO cells (Fig. 9). 
 
 
Figure 9. Colony-forming assay with PATZ1 transfection in TPC-1, BC-PAP and FRO cells. 
TPC-1, BC-PAP and FRO cells were transfected with a vector expressing PATZ1 cDNA and its 
corresponding empty vector. Cells were cultured for 10 days, selected for resistance to G418 and 
stained with crystal violet. The assays were quantified by counting the number of colonies formed. 
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To confirm these results and deeper investigate the cause of growth inhibition, 
we performed growth curves and cell viability assays on selected clones of TPC-
1/PATZ1, BC-PAP/PATZ1 and FRO/PATZ1 compared to their respective 
controls (Fig. 10, panel A-C). In agreement with results from the colony assays, 
the growth rate of TPC-1/PATZ1 clones did not show any difference compared to 
control. Indeed, both the slope of the straight lines and the saturation density were 
similar in the different clones and controls. Furthermore, the absence of 
differences in the incorporation of trypan blue by the cells, showed a similar cell 
viability in all TPC-1/PATZ1 clones compared to controls (data not shown). 
Conversely, BC-PAP/PATZ1 clones, and especially FRO/PATZ1 clones, showed 
a significant decreased proliferation capacity that in FRO/PATZ1 clones is 
accompanied by a significant increase in cell death compared to their respective 
controls (Fig. 10, panel D). To analyze the mechanism of death in these cells, 
DNA-laddering analysis have been performed. This assay showed a strong DNA-
laddering in FRO/PATZ1 cells compared to their control, whereas no differences 
of a DNA ladder-like pattern were observed in TPC1/PATZ1 and BC-PAP/PATZ1 
clones compared to controls. These results suggest that a mechanism of apoptosis 
is responsible of the low survival of PATZ-expressing FRO cells (Fig. 10, panel 
E). 
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Figure 10. PATZ1 effects on the growth rate and apoptosis. A, B, C Growth curves performed 
on different stably expressing PATZ1 cell clones of TPC1 (PA 1, PA 5, PA 6), BC-PAP (PA 3, PA 
7, PA 10) and FRO (PA 11, PA 16, PA 17) compared to control cells expressing the empty vector 
(CTRL). Representative curves of 3 independent experiments are reported. D, Tripan Blue staining 
assay in FRO/PATZ1 cells at different time points in culture. Mean values + SD of 3 different cell 
clones expressing PATZ1 (PA 11, PA 16, PA17) are reported. E, DNA ladder assay in 
FRO/PATZ1 (PA 11, PA 16, PA 17) cells performed after 5 days in culture, when the percentage 
of dead cells was highest, to investigate whether death observed was due to apoptosis. Doxorubicin 
(Doxo) treatment was used as a positive control. 
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4.5 PATZ1 inhibits cellular senescence in TPC-1 and FRO cells 
Cellular senescence is an irreversible state of cell proliferation arrest, which can 
be caused by diverse factors, such as telomere shortening or dysfunction, 
oncogenic activation, chromatin perturbation, DNA damage, oxidative or 
inflammatory stresses, irradiation and so on (Collado et al. 2006). A large body of 
evidence suggests that cellular senescence may be an underlying mechanism for 
protection against cancer development due to uncontrolled proliferation (Campisi 
et al. 2007). To analyze weather induced cellular senescence in thyroid cancer is 
impaired by PATZ1 expression, we conducted senescence-associated β-
galactosidase (β-SA) staining assays on the selected clones of TPC1/PATZ1, BC-
PAP/PATZ1 and FRO/PATZ1 compared to their controls. The cells were plated 
with only one medium change to induce a mild culture stress. Seven days later the 
assay was performed. As shown in Fig. 11, β-galactosidase activity was positive in 
controls cells, as evidenced by the presence of green cells. Conversely, a 
significant reduction in the number of senescent cells in the clones TPC1/PATZ1 
and FRO/PATZ1 compared to their controls was found. This result was even more 
striking in the FRO/PATZ1 clones, where we could easily appreciate a drastic 
reduction of senescent cells in clone FRO/PA11 and a total absence of positivity in 
clones FRO/PA16 and FRO/PA17. We could not evaluate the cellular senescence 
in BC-PAP cells because control cells not showed positive β-galactosidase 
staining (data not shown). The anti-senescence effect of PATZ expression in TPC1 
and FRO cells is consistent with our recent data, showing that PATZ1 (-/-) 
embryonic fibroblasts (MEFs) enter into premature cellular senescence (Valentino 
et al. 2012), and with other recent data showing growth inhibition and accelerated 
senescence in human umbilical vascular endothelial cells (HUVECs) interfered for 
PATZ1 expression (Cho et al. 2011). These data suggest a role for PATZ1 in 
protecting these tumor cells from going to stress-induced senescence. This role is 
apparently in contrast with its tumor suppressor function, since senescence is one 
of the main barriers to tumor progression. However, previous data showed that a 
tumor suppressor gene can inhibit senescence and simultaneously block other 
functions related to the development and/or progression of the tumor (Pan et al. 
2011). 
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Figure 11. PATZ1 inhibits cellular senescence in TPC-1 and FRO cells. A, senescence-
associated β-galactosidase (SA-beta-gal)-staining performed on different stably expressing PATZ1 
cell clones of TPC1 (PA 1, PA 5, PA 6) and FRO (PA 11, PA 16, PA 17) compared to control cells 
expressing the empty vector (CTRL). Representative images are reported. B, Quantification of SA-
β-gal positive cells. Values are the mean +/- S.D. of three independent experiments. At least 20 
different fields were analyzed for each experimental point.  
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4.6 PATZ1 inhibits cell migration and invasion in papillary and anaplastic 
thyroid cancer cells  
Cell migration and invasiveness are key features of cancer cells responsible for 
tumor progression and metastasis (Bravo-Cordero et al. 2012). To analyze whether 
PATZ1 re-expression affects the migratory and invasive capabilities in PTC- and 
ATC-derived cell lines, a transwell migration and invasion assays have been 
performed. Specifically, the migration has been analyzed by a Transwell assay 
using the Boyden chamber composed of a polycarbonate membrane with pores of 
8µm in size. The cells, plated in serum-free medium, were analyzed 24 hours later 
for their ability to have crossed the membrane attracted by the serum placed 
below, on the bottom of the plate. For each 200X field the migrated cells were 
counted. 
The results of this migration assay were concordant for all the three cellular 
systems: indeed TPC-1/PATZ1, BC-PAP/PATZ1 and FRO/PATZ1 clones showed 
a drastic reduction in their migration capability compared to controls (Fig. 12). 
Then, to analyze whether the presence of PATZ1 could interfere also with the cell 
invasiveness, we conducted a similar assay through the Boyden chamber in the 
presence of Matrigel, a mixture of gelatin protein that mimics the extracellular. 
Also in the presence of Matrigel, TPC-1/PATZ1 and FRO/PATZ1 cells showed a 
lower invasive capacity than control cells. BC-PAP cells were not able to invade at 
the experimental conditions used.  
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Figure 12. PATZ1 inhibits cell migration and invasion in TPC-1, BC-PAP and FRO cells. A, 
transwell assays performed on different stably expressing PATZ1 cell clones of TPC1 (PA 1, PA 5, 
PA 6), BC-PAP (PA 3, PA 7, PA 10) and FRO ( PA 11, PA 16, PA 17) compared to control cells 
expressing the empty vector (CTRL). Representative images are reported. B, C, D, the graphs show 
the mean values of three independent transwell or invasive assays by counting the number of cells 
that have migrated underneath the Boyden chamber in absence (purple bars) or in presence (blue 
bars) of matrigel. 
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4.7 PATZ1 expression in anaplastic thyroid cancer cells inhibits 
tumorigenicity in vitro and in vivo 
In order to confirm the hypothesis that PATZ1 may have a tumor-suppressor 
function in thyroid cells, the transformed phenotype of the tumorigenic ATC-
derived FRO cells was analyzed both in vitro and in vivo. In vitro, the 
tumorigenicity has been tested with a soft agar assay, a common method to 
monitor anchorage-independent growth, by measuring cell proliferation in a 
semisolid culture medium. As shown in Fig. 13 (Panels A-B),  FRO/PATZ1 clones 
were not able to grow in soft agar differently from the parental cell line expressing 
the backbone vector. To confirm in vivo the loss of the tumorigenic potential in 
FRO cells mediated by PATZ1 re-expression, FRO/PATZ1 and control cells were 
subcutaneously inoculated in athymic mice (on the right and left side, respectively, 
of the same mouse), and tumor dimensions were measured every day to analyze 
their growth rate. When a tumor reached a diameter of 1500 mm, the mouse was 
sacrificed, and the tumors of both sides removed, weighted and frozen or 
embedded into paraffin. Consistent with the in vitro results, the growth rate of 
tumors developed from FRO/PATZ1 cells was significantly inhibited compared to 
those originated from control cells (Fig. 13, panel C-D).   
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Figure 13. PATZ1 expression blocks tumorigenesis of FRO cells in vitro and in vivo. A, 
representative images of growth in soft agar of FRO clones expressing PATZ1 or the empty vector 
(CTRL). B, colonies with a diameter greater than 20 µm were counted after 2 weeks. C, D In vivo 
tumorigenic assay: inoculation of FRO cells expressing the empty vector (CTRL) or PATZ1 in 
athymic nude mice. C, A representative mouse and its derived xenografts. D, Tumor growth curves 
in cohorts of 10 mice. Mean values + SD. 
 
 
Subsequently, the tumors removed and embedded into paraffin were processed 
and examined for morphologic characterization by hematoxylin and eosin (H&E) 
staining in collaboration with the research group of Doctor G. Chiappetta at the 
Istituto dei Tumori di Napoli. Interestingly, as shown in Fig. 14, some tissues 
derived from tumors developed in athymic mice injected with FRO/PATZ1 cells, 
displayed features of epithelial differentiation. Conversely, tumors generated in 
athymic mice injected with FRO control cells, showed a disorganized and solid 
growth pattern.  
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Figure 14. H&E staining of tumors developed in athymic mice. Representative images of 
tumors tissue derived from athymic mice injected with FRO/PATZ1(PATZ1) or control cells 
(CTRL). The tumors developed from FRO/PATZ1 cells showed features of a more differentiated 
morphology respect to those originated from control cells. In the same FRO/PATZ1 xenograft is 
possible to see the coexistence of both a disorganized solid pattern, similar to xenografts from 
CRTL cells (left side of the dotted line), and features of epithelial differentiation represented by 
follicular-like structures (indicated by the arrow in the outset). 
 
 
 
Consistently, while FRO/CTRL cells expressed E-cadherin at low levels, 
suggesting a mesenchymal phenotype, FRO/PATZ1 cells strongly expressed E-
cadherin as detected by Western blot, pointing to an epithelial differentiation 
through PATZ1 re-expression (Fig. 15). These data support the hypothesis that 
PATZ1 may have a tumor-suppressor function in thyroid cells.  
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Figure 15. Expression of E-cadherin in FRO/PATZ1clones. Western Blot analysis of E-cadherin 
in 4 FRO/PATZ1 cell clones (PA10, PA13, PA16, PA17) compared to FRO cell line not 
transfected (FRO) or a clone transfected with the empty vector (CTRL). 
 
 
4.8 BAX, PUMA and PERP are up-regulated in PATZ1-transfected FRO cells 
To investigate the molecular mechanisms by which PATZ1 exerts its tumor 
suppressor role in thyroid carcinogenesis, since it is a transcriptional regulator, we 
looked for the genes specifically regulated by it. By in silico analysis through the 
TraFaC homology Server (Jegga et al., 2002), we found a number of genes with 
putative binding sites for PATZ1. Among them we focused on some p53-regulated 
genes, including PUMA and PERP, which could explain the role of PATZ1 in the 
thyroid cell transformation and in particular in the mechanisms of apoptosis and 
migration. Moreover, we decided to focus our attention also on another p53-
regulated and proapoptotic gene, BAX, because our recent unpublished data 
showed the regulation of BAX promoter activity by PATZ1 in HEK293 and 
SAOS-2 cells. Therefore, we evaluated whether PATZ1 regulates the expression 
of these genes in FRO cells, in which, as I showed before, we observed that the 
restoration of PATZ1 expression is able to induce apoptosis. To this aim RNA was 
extracted from FRO/PATZ1 clones and their controls, and qRT-PCR was 
performed. As shown in Fig. 15, PATZ1 re-expression up-regulates BAX, PUMA 
and PERP mRNA levels in these cells, thus suggesting a positive role for PATZ1 
in the transcriptional expression of these genes (Fig. 16).  
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Figure 16. Up-regulation of BAX, PERP and PUMA gene expression in FRO/PATZ1clones. 
qRT-PCR results showing the significant increase of BAX, PERP and PUMA expression in FRO 
clones expressing PATZ1 compared to controls (CTRL). 
 
 
4.9 BAX, PUMA and PERP gene expression depends upon the presence of 
PATZ1 
To support the hypothesis of a role for PATZ1 in BAX, PUMA and PERP gene 
expression regulation, we analyzed BAX, PUMA and PERP expression in PATZ1-
knockout mice, previously generated in our laboratory. In particular we compared 
BAX, PUMA and PERP mRNA levels in PATZ1 (+/+), (+/-) and (-/-) MEFs. As 
shown in Fig. 17, the expression of these genes is significantly changed in both 
Patz1 (+/-) and Patz1 (-/-) MEFs compared to wild-type controls. In particular, 
BAX  and PUMA are down-regulated, confirming PATZ1 as an activator of their 
expression. Conversely, PERP is up-regulated, suggesting PATZ1 as an inhibitor 
of PERP expression, which is in contrast with what we observed in thyroid cells. 
This difference may be due to the different cellular context as PATZ1 may act as 
an architectural transcription factor and its action may mainly depend on its 
interactors, which may differ from cell to cell. It is noteworthy that in Patz1 +/- 
and Patz1 -/- cells the expression levels of BAX, PERP and PUMA were 
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undistinguishable, indicating that down-regulation of PATZ1 expression has the 
same effect as loss of PATZ1 expression on their transcriptional regulation.   
 
Figure 17. Down-regulation of BAX and PUMA expression, and up-regulation of PERP 
expression in Patz1-knockout MEFs. qRT-PCR results showing decrease of BAX and PUMA, 
and the increase of PERP expression in MEFs heterozygous (+/-) and homozygous (-/-) for a 
Patz1-null mutation. 
 
 
4.10 PATZ1 binds to the promoters of BAX, PUMA and PERP  
To evaluate whether the role played by PATZ1 in the regulation of BAX, 
PUMA and PERP gene expression depends on a direct binding of PATZ1 to their 
promoter regions, we performed ChIP assays. HEK293 cells were transiently 
transfected with HA-tagged-PATZ1, crosslinked and immunoprecipitated with 
anti-HA or non specific IgG antibodies as control. Immunoprecipitation of 
chromatin was then analyzed by quantitative PCR, using primers spanning the -
250/-530 region of BAX and the -950/-700 region of PERP. Occupancy of these 
promoter regions by PATZ1 was clearly detectable in anti-HA precipitated 
chromatin. No precipitation was observed with IgG precipitates (Fig. 18, Panel A). 
The binding of PATZ1 to PUMA promoter was evaluated by electrophoresis 
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mobility shift assay (EMSA), analyzing a region spanning nucleotides from -50/-
24 which contains two putative PATZ1 binding sites and one p53 consensus 
sequence. As shown in Fig. 18, panel B, a PATZ1-recombinant peptide (spanning 
from aa 259 to aa 367) was able to bind the 32P-end-labelled double strand PUMA 
promoter oligonucleotide. Binding specificity was demostrated by competition 
experiments showing loss of binding with the addition of a 200-fold molar excess 
of unlabelled PUMA promoter oligonucleotide.  
 
 
Figure 18. Binding of PATZ1 on BAX, PERP and PUMA promoters. A, ChIP assay on 
HEK293 transfected with HA-tagged-PATZ1. After transfection cells were crosslinked and 
immunoprecipitated using anti-HA antibody. As an immunoprecipitation control non specific IgG 
was used. B, EMSA performed with a radiolabelled oligonucleotide spanning from -50 to -24 of 
the human PUMA promoter incubated with 5 ng of a recombinant PATZ1 peptide. The arrows 
indicate the PATZ1/DNA complexes. To assess the specificity of the binding, the reaction mixture 
was preincubated with a 200X-fold excess of unlabelled oligonucleotide used as competitor. 
 
 
 
4.11 PATZ1 correlates with PERP expression in human thyroid tumors 
In order to verify whether PATZ1 down-regulation inversely correlates with 
BAX, PERP and PUMA expression in human thyroid cancer, we started to analyze 
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PATZ1 and PERP protein expression, by immunohistochemistry, in a few human 
paraffin embedded thyroid tumors representing different histological types 
compared to the normal thyroid gland. We found a positive correlation between 
PATZ1 and PERP expression,  especially in ATC samples. Indeed, as shown in 
Fig.19, both PATZ1 and PERP are expressed in the normal thyroid, while in ATC 
PATZ1 and PERP expression was completely absent. These preliminary data need 
to be validated by further experiments increasing the number of samples in order 
to get a statistical significance. 
 
Figure 19. PATZ1 correlates with PERP expression. Representative IHC images showing the 
PATZ1 and PERP expression in normal thyroid and Anaplastic carcinoma (40X). 
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5. DISCUSSION AND CONCLUSIONS 
 
The expression of POZ/BTB and AT-hook-containing zinc finger protein 1 
(PATZ1) is frequently de-regulated in human cancer but the molecular basis of 
PATZ1 role in cancer still remains to be elucidated, and it is still debated if 
PATZ1 is a tumor suppressor or an oncogene.  In a previous work we 
demonstrated that PATZ1 acts as a tumor suppressor in lymphomagenesis by 
inhibiting BCL6 expression. Moreover, the analysis of PATZ1 knock-out mice, 
carried out in our laboratory, provided a strong effort to the tumor-suppressor 
hypothesis, since PATZ1 knock-out mice spontaneously develop tumors, including 
BCL6-expressing Non-Hodgkin lymphomas, sarcomas, hepatocellular carcinomas 
and rare lung adenocarcinomas (Pero et al. 2012). To further investigate the role of 
PATZ1 in neoplastic transformation we decided to focus on thyroid tumors. 
Thyroid cancer is one of the most frequent malignancies of the endocrine system. 
It is a good model of multi-step carcinogenesis since it includes a wide spectrum 
of lesions with different phenotypic characteristics, biological behaviors and 
grades of malignity, but the mechanisms of pathogenesis are still far from being 
completely elucidated. So far, several oncogenes have been demonstrated to be 
involved in human thyroid carcinomas, particularly in the papillary histotype, but 
little is known with regard to tumor suppressor genes. In addition, about 20-25% 
of thyroid carcinomas seem not to present mutations or expression changes of well 
known oncogenes. Therefore, other mechanisms such as up- or down-regulation of 
some genes may have an important role in thyroid carcinogenesis. The results 
reported in the present study seem to support a role for PATZ1 gene as a tumor 
suppressor in human thyroid carcinogenesis. Indeed, the analysis of PATZ1 gene 
performed by qRT-PCR in a large number of thyroid carcinoma samples and 
thyroid carcinoma–derived cell lines, demonstrated  that PATZ1 is strongly down-
regulated in most thyroid tumors compared with normal thyroids, and that its 
expression is inversely correlated with both malignancy and degree of de-
differentiation. A severe reduction of PATZ1 mRNA was observed in follicular 
carcinomas (FTC), in which the average down-regulation value was -20 fold 
changes, and anaplastic carcinomas (ATC), with a negative fold change up to 33,3, 
with respect to normal thyroid gland. Interesting results were obtained when 
PATZ1 protein expression was analyzed by immunohistochemistry. We found that 
in human thyroid carcinomas PATZ1 protein not only is downregulated but also 
presents a different localization. Indeed, in all normal thyroid tissues PATZ1 was 
strongly expressed only in the nucleus; in all differentiated carcinomas (both 
papillary and follicular) PATZ1 was present both in the nucleus and in the 
cytoplasm, while in undifferentiated carcinomas (poorly differentiated and 
anaplastic) more than 50% of the PATZ1 protein was localized in the cytoplasm. 
Moreover, in 62,5% of anaplastic carcinomas PATZ1 expression was completely 
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absent. Presently, we have no data that allow us to understand whether this new 
cellular localization PATZ1 can play an active role or whether it just stucks there 
in a state of inactivity. However, it has been recently demonstrated an interaction 
between PATZ1 and the RIα subunit of PKA under the proliferative stimulus 
induced by the cAMP (Yang et al, 2009); as a result of this interaction, PATZ1 is 
sequestered in the cytoplasm, losing the ability to regulate target genes, therefore 
supporting its role as a tumor suppressor.  
To determine whether PATZ1 may contribute to thyroid carcinogenesis, we 
restored PATZ1 expression, by stable transfection, in two representative cell lines 
of papillary thyroid carcinoma (TPC-1 and BC-PAP) and two representative of 
anaplastic thyroid carcinoma (FB1 and FRO), selected specific clones of each cell 
lines re-expressing PATZ1, and characterized their growth and transformed 
properties. The first step has been the analysis of proliferation and survival of 
clones expressing PATZ1 compared to control cells. The cell division 
(proliferation) is a physiological process that occurs in almost all tissues. 
Normally, the balance between proliferation and programmed cell death, usually 
apoptosis, is strictly maintained by adjusting both processes to ensure tissues 
homeostasis. Mutations that lead to cancer, lead to impairment of these orderly 
processes, destroying their regulatory programs (Fearon et al. 1990). Therefore, 
the analysis of these cellular processes (proliferation and survival) was crucial to 
understand whether PATZ1 is involved in mechanisms underlying the 
pathogenesis of neoplasia. To this aim, we performed colony assays, growth 
curves and cell viability assays. On selected clones of TPC-1/ PATZ1 and control 
cells we showed no differences in growth and survival, suggesting that in this cell 
line PATZ1 does not have a role in these processes, generally associated with the 
early stages of tumor development. Conversely, colony assays and growth curves 
performed in BC-PAP/PATZ1 and FRO/PATZ1 clones showed a significant 
decreased proliferation capacity that, only in the case of FRO/PATZ1 
transfectants, was accompanied by a significant increase in cell death compared to 
controls. To understand whether a mechanism of apoptosis was responsible of the 
low survival of these cells, we performed  DNA-ladder assay. Apoptosis is an 
ordered and orchestrated cellular process that occurs in physiological and 
pathological conditions. The down-regulation of a tumor suppressor gene can 
result in reduced apoptosis and enhanced tumor growth and development (Wong 
SY 2011). The assay showed no differences in TPC1/PATZ1 and BC-PAP/PATZ1 
clones compared to their control, whereas strong DNA-laddering was observed in 
FRO/PATZ1 cells compared to controls, indicating that a mechanism of apoptosis 
is responsible for the low survival of these cells. Further studies are necessary to 
understand the decreased growth rate of BC-PAP cells re-expressing PATZ1 
looking at the different phases of the cell cycle by fluorocitometric assays. These 
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assays will also be performed in FRO/PATZ1 cells, to analyze if the decreased cell 
growth may be due to a proliferative defect, other than the induction of apoptosis.  
Very striking results were obtained from senescence assays. Cellular 
senescence is an irreversible state of cell proliferation arrest, which can be caused 
by diverse factors, such as telomere shortening or dysfunction, oncogenic 
activation, chromatin perturbation, DNA damage, oxidative or inflammatory 
stresses, irradiation and so on (Collado et al. 2006). A large body of evidence 
suggests that the activation of various oncogenes induces an increase of 
senescence in cell lines, accompanied by a reduction in the expression and activity 
of tumor suppressor genes such as p53 and p16. This phenomenon may be a 
mechanism of protection of cells against neoplastic transformation (Campisi et al. 
2007; Serrano et al. 1997). TPC-1 and FRO cells re-expressing PATZ1 showed a 
reduction in the β-galactosidase activity compared to controls, while both BC-
PAP/PATZ1 transfectants and controls not showed positive staining for β-
galactosidase. However, it has already demostrated that the parental BC-PAP cells 
displayed a very minimal β-galactosidase activity (Nowicki et al. 2011). The result 
obtained with TPC1/PATZ1 and FRO/PATZ1 clones is consistent with our recent 
data, showing that PATZ1 (-/-) embryonic fibroblasts (MEFs) enter into premature 
cellular senescence (Valentino et al. 2012), and with previous data showing 
growth inhibition and accelerated senescence in human umbilical vascular 
endothelial cells (HUVECs) interfered for PATZ1 expression (Cho et al. 2011), 
thus confirming an anti-senescent role for PATZ1. This role of PATZ1 is 
apparently in contrast with its tumor suppressor function, since senescence is one 
of the main barriers to tumor progression. However, previous data showed that a 
tumor suppressor gene can inhibit senescence and simultaneously block other 
functions related to the development and/or progression of the tumor (Pan et al. 
2011).  
In this work we also demonstrated an inhibitory effect of PATZ1 re-expression 
on cell migration and invasiveness. Cell migration and invasiveness are key 
features of cancer cells responsible for tumor progression and metastasis (Bravo-
Cordero et al. 2012). The process that leads cancer cells to migrate from the tumor 
site of origin to other sites begins with an epithelial-mesenchymal transition 
(EMT), a process during which cells undergo drastic changes, such as the 
alteration of the cell-cell and cell-extracellular matrix adhesion, the remodeling of 
the cytoskeleton and various molecular processes (Ylmaz and Christofori 2010). 
All the thyroid cell lines re-expressing PATZ1, TPC-1, BC-PAP and FRO showed 
a drastic reduction in their migration and invasiveness capability compared to 
controls. Moreover, PATZ1 expression in tumorigenic FRO cells inhibits both 
tumorigenicity in vitro and in vivo. Indeed, FRO re-expressing PATZ1 are not able 
to grow in soft agar, and inhibits tumors growth when injected into athymic mice, 
thus supporting a tumour suppressor role for PATZ1 in thyroid carcinogenesis. 
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Interestingly, some tumor tissues derived from FRO/PATZ1 cells injected in 
athymic mice, displayed features of epithelial differentiation, while tumors arisen 
starting from FRO control cells injected in athymic mice, showed a disorganized 
and solid growth pattern, suggesting a role of PATZ1 in negatively regulating the 
EMT and the tumor progression. Consistently, while FRO and FRO/CTRL cells 
expressed E-cadherin at low levels, suggesting a mesenchymal phenotype, 
PATZ1-transfected cells strongly expressed E-cadherin as detected by Western 
blot, pointing to an epithelial differentiation through PATZ1. 
Thus, PATZ expression in vitro affected several hallmarks of malignancy, 
including anchorage-independent proliferation, survival, EMT and invasion. 
Therefore, we suggest that the loss of PATZ1 expression exerts a functional role in 
the pathogenesis of thyroid cancer, and they are consistent with a specific role of 
PATZ1 in the signaling pathways involved in cell survival and metastatic 
progression. In particular, we hypothesize that down-regulation of PATZ 
expression could be an expedient of the cancer cells to escape apoptosis and go 
towards the epithelial-mesenchimal transition (EMT), which allows the cells to 
acquire the ability to migrate. 
To dissect the molecular pathways that involves PATZ in both cell survival and 
metastatic progression, since PATZ is a transcriptional regulator, we looked for 
the genes directly regulated by it, which could explain the role of PATZ in the 
thyroid cell transformation. Among the genes with putative binding sites for 
PATZ1, we focused on some p53-regulated genes. After its activation, p53 is able 
to regulate various processes, such as cell cycle arrest, DNA repair, apoptosis, 
senescence, EMT, migration, invasiveness and metastasis (Zilfou et al. 2009). 
Under physiological conditions, p53 inhibits, directly or indirectly, repressors of 
the E-Cadherin protein, such as SLUG, TWIST and Snail. Otherwise, a loss of 
expression or function of p53, or the presence of a p53 mutant, determines the 
activation of such repressors; thereby is observed a decrease in the expression of 
E-Cadherin and a consequent loss of cell-cell junctions (Muller et al. 2011).  
In this work we demonstrated that PATZ1 binds to the promoter regions of the 
p53-regulated genes BAX, PUMA and PERP. In FRO/PATZ1 cells all these genes 
were up-regulated, suggesting a positive role of PATZ1 on their expression. In 
another cell systems, such as MEFs, wild-type or knockout for the PATZ1 gene, 
we found again a positive role of PATZ1 on BAX and PUMA expression, being 
them down-regulated in PATZ1-KO cells, whereas PERP was down-regulated, 
suggesting a negative role of PATZ in its transcription. This difference may be due 
to the different cellular context, since PATZ1 likely acts as an architectural 
transcription factor and its activity mainly may depend on its interactors.  
BAX, PUMA and PERP are down-stream effectors of p53 involved in 
apoptosis and, as far as PERP is concerned, also in cell motility and migration. 
There are already some evidences suggesting that PATZ1 and p53 are functionally 
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related. Indeed, other members of the POZ/BTB domain-containing protein family 
(HIC1, PLZF, BACH1, NAC-1 and BCL6) have been linked directly or indirectly 
to the p53 regulation (Kelly et al. 2006). Moreover, it has been recently shown that 
PATZ1 inhibits endothelial cell senescence through a p53 dependent pathway. In 
particular, Cho et al. have demonstrated that in HUVEC cells PATZ1 knockdown 
decreased cell proliferation and accelerates senescence unlike p53 knockdown 
cells; further, PATZ1 increased p53 protein levels in p16 knockdown cells (Cho et 
al. 2011). Therefore, we speculate that PATZ1 is present in the same complex with 
p53 on the promoter regions of BAX, PUMA and PERP and may exert its tumor-
suppressor role cooperating with p53. This hypotesis is supported by our findings 
showing that PATZ1 and p53 interacts each other and that PATZ1 is able to 
cooperate with p53 in the transcriptional activation of BAX promoter. (Palmieri et 
al., manuscript in preparation). To verify our hypothesis, next experiments will 
investigate whether PATZ1 occupies BAX, PERP and PUMA promoter regions 
together with p53 and whether PATZ1 acts on PERP and PUMA promoters 
exactly as it does on BAX promoter. Moreover, we will confirm the ChIP data in 
FRO cells, and eventually in other thyroid cancer cells, expressing PATZ1, to 
ensure that the proposed mechanism of PATZ is active in the thyroid system. 
Furthemore, we will perform Elettroforetic Mobility Shift Assays (EMSA) in 
order to confirm the binding of PATZ1 to BAX and PERP promoters and, using 
mutated probes, identify the nucleotides important for this binding. Interestingly, 
we also planned to verify whether PATZ1 down-regulation inversely correlates 
with BAX, PERP and PUMA expression in human thyroid cancer samples at both 
mRNA and protein levels by qRT-PCR and immunohistochemistry analysis. 
Preliminary immunohistochemical data showed a positive correlation between 
PATZ1 and PERP expression in some anaplastic thyroid samples compared to 
normal thyroid samples, but further analysis, increasing the number of samples, 
are needed to validate these data.  
In conclusion, in this study we demonstrated a role for PATZ1 as a tumor 
suppressor in human thyroid carcinogenesis. Our data indicated that the reduced 
PATZ1 gene expression is associated with a malignant phenotype of thyroid 
neoplasias and its delocalizzation into the cytoplasm may be an expedient of the 
neoplastic cell to inactivate its function. On the contrary, if re-expressed, PATZ1 
is able to induce apoptosis, to inhibit cell migration and invasiveness and block 
tumorigenesis in vitro and in vivo, thus allowing a regression in neoplastic 
transformation. Moreover, we propose that the apoptosis induction, observed in 
FRO cells following PATZ1 expression, could be due to the induction of BAX, 
PUMA and/or PERP expression. Likewise, the inhibition of FRO cells migration 
may be due to induction of PERP expression.  
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From this study we envisage for the future a role for PATZ1 as a new diagnostic 
and/or prognostic factor of thyroid cancer, and figure out the up-regulation of 
PATZ1 expression as a therapeutic approach for advanced stages of cancer. 
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Interacts with Human Oncogene B Cell Lymphoma 6 (BCL6)
and Is Required for Its Negative Autoregulation*
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Background: PATZ is a transcription factor, whose role in cancer is still under debate.
Results: PATZ interacts with BCL6 and negatively modulates its expression. Consistently, Patz1 knockdown mice showed
up-regulation of BCL6 expression and BCL6-dependent B cell neoplasias.
Conclusion: PATZ is a tumor suppressor that acts by cooperating with BCL6 in its negative autoregulation.
Significance: This work helps in understanding the pathology of BCL6-expressing lymphomas in which BCL6 is not mutated.
ThePATZ1 gene encoding a POZ/AT-hook/Kruppel zinc fin-
ger (PATZ) transcription factor, is considered a cancer-related
gene because of its loss or misexpression in human neoplasias.
As for other POZ/domain andKruppel zinc finger (POK) family
members, the transcriptional activity of PATZ is due to the
POZ-mediated oligomer formation, suggesting that it might be
not a typical transactivator but an architectural transcription
factor, thus functioning either as activator or as repressor
depending on the presence of proteins able to interact with it.
Therefore, to better elucidate PATZ function, we searched for
its molecular partners. By yeast two-hybrid screenings, we
found a specific interaction between PATZ and BCL6, a human
oncogene that plays a key role in germinal center (GC) derived
neoplasias. We demonstrate that PATZ and BCL6 interact in
germinal center-derived B lymphoma cells, through the POZ
domain of PATZ. Moreover, we show that PATZ is able to bind
the BCL6 regulatory region, where BCL6 itself acts as a negative
regulator, and to contribute to negatively modulate its activity.
Consistently, disruption of one or both Patz1 alleles in mice
causes focal expansion of thymus B cells, in which BCL6 is up-
regulated. This phenotype was almost completely rescued by
crossing Patz11/2 with Bcl61/2 mice, indicating a key role for
Bcl6 expression in its development. Finally, a significant num-
ber of Patz1 knock-out mice (both heterozygous and homozy-
gous) also develop BCL6-expressing lymphomas. Therefore, the
disruption of one or bothPatz1 allelesmay favor lymphomagen-
esis by activating the BCL6 pathway.
The PATZ1 gene encodes four main alternative proteins
ranging from 537 to 687 amino acids that contain an N-termi-
nal POZ domain, one or two AT-hooks in the central region,
and four to six C2H2 zinc fingermotifs at the C terminus (1–3).
Both the AT-hooks and the POZ domain are characteristic of
protein factors involved in gene transcription by interacting
with a number of other protein factors. Indeed, PATZ protein,
also known as MAZR, ZNF278, or ZSG, is a transcriptional
regulatory factor that may function either as activator or as
repressor depending upon the cellular context; it has been
reported to either activate or repress c-Myc (1, 2), to activate
mast cell protease 6 (4), and to repress androgen receptor (5)
and CD8 (6) genes.
Different functional and genetic evidences suggest that
PATZ might be directly involved in human tumors. Indeed,
PATZ1 is rearranged and deleted in small round cell sarcoma
(3), and the chromosomal region where it is located (22q12) is
in the human fragile site FRA22B, which suffers loss of
heterozygosity in tumors (7). Increased expression of PATZ1
mRNA has been observed in human malignant neoplasias,
including colorectal (8), breast (9), and testicular (10) tumors.
Moreover, PATZ knockdown by siRNA either blocks the
growth or induces apoptosis of cell lines derived from colorec-
tal cancer or gliomas, respectively (8, 11). However, in testicular
tumors alone, PATZ protein expression has been analyzed,
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demonstrating that it was mislocalized to cytoplasm (10, 12).
Therefore, although PATZ1 is strongly suggested to be a can-
cer-related gene, its role as tumor suppressor or oncogene is
still controversial.
In the present study, starting from a yeast two-hybrid screen-
ing usingPATZ1 full-length cDNAas bait, we demonstrate that
PATZ associates with BCL6,3 a protein that shares with PATZ
the N-terminal POZ domain, responsible for such association,
and is involved in B andT cell development and lymphomagen-
esis (13–15, 38). We show that PATZ participates in BCL6
function by enhancing its activity of transcriptional repressor
on BCL6 promoter in GC-derived lymphoma B cells. We also
show that the knock-down of PATZ in mice causes BCL6-ex-
pressing thymus B cell hyperplasias (that eventually lead to B
cell lymphomas), in which BCL6 is critical for their onset. The
development of BCL6-expressing lymphomas in Patz1 knock-
down mice indicates a potential haploinsufficient tumor sup-
pressor role for the PATZ1 gene, whose disruption may lead to
the lymphomas by activating the BCL6 pathway.
EXPERIMENTAL PROCEDURES
Two-hybrid Analysis—Two-hybrid screens were performed
in yeast using full-length PATZ1 (isoform 4) cDNA as a bait.
Human heart and placenta cDNA libraries (Clontech) were
simultaneously analyzed. A total of about 2 3 106 clones were
tested for each library, and the specificity of interaction was
assessed as described previously (16).
Plasmids—Full-length and truncated (devoid of the BTB/
POZdomain) cDNAs for the human PATZprotein (isoform 4),
Myc-tagged at their 39-end, were subcloned into the XbaI-
HindIII sites of the pcDNA3.1 plasmid (Invitrogen). The cDNA
for the human BCL6 protein was subcloned into the EcoRI site
of the pCEFL-HA vector (17), in-frame with the upstream HA
tag. The BCL6i-luc reporter construct was obtained by cloning
the 24.9 to 12.0-kb fragment of the BCL6 promoter into the
pGL3Basic vector as described previously (18).
Protein Extraction, Immunoprecipitation, and Immunoblot
Analysis—Tissues and cells were lysed in buffer containing 1%
Nonidet P-40, 1mmol/liter EDTA, 50mmol/liter Tris-HCl (pH
7.5), and 150 mmol/liter NaCl supplemented with Complete
protease inhibitors (Roche Applied Science). Total proteins
were immunoprecipitated, in the presence or absence of 100
ng/ml ethidium bromide, as described previously (19), or they
were directly resolved in a 10% polyacrylamide gel under dena-
turing conditions and transferred to nitrocellulose filters for
Western blot analyses. Membranes were blocked with 5% BSA
in TBS and incubated with the primary antibodies. The anti-
bodies used were: anti-HA (sc-805), anti-Myc (sc-40), anti-
BCL6 (sc-858), anti-tubulin (sc-5546), anti-vinculin (sc-7649)
(Santa Cruz Biotechnology, Santa Cruz, CA), and anti-PATZ
(polyclonal antibody raised against a conserved peptide recog-
nizing all PATZ isoforms of mouse and human origin).
Cell Cultures and Transcriptional Activity Assays—Raji cells,
originally derived from a Burkitt lymphoma, were cultured in
RPMI 1640 medium adjusted to contain 1.5 g/liter sodium
bicarbonate, 4.5 g/liter glucose, 10 mM HEPES, 1.0 mM sodium
pyruvate, penicillin/streptomycin (Invitrogen/Life Technolo-
gies Italia, Monza, Italy), and 10% FBS (JRH Biosciences,
Lenexa, KS). They were transfected by using the Amaxa
Nucleofector kit V (Lonza, Cologne, Germany) following the
manufacturer’s instructions. COS-1 cells were cultured in
DMEMwith 10%FBS (JRHBiosciences). Theywere transfected
using Lipofectamine Plus reagents (Invitrogen/Life Technolo-
gies Italia) according to the manufacturer’s instructions and
harvested 42 h after transfection. Cell lysates were extracted as
described below and analyzed for luciferase activity. For tran-
scriptional activity assays, a total of 2 3 106 cells (Raji) were
seeded into each well of a 12-well plate and transiently trans-
fected with 4 mg of BCL6i-luc, 5 mg of HA-BCL6, and 0.25–0.5
mg of PATZ-Myc, together with 1 mg of Renilla and various
amounts of the backbone vectors to keep the total DNA con-
centration constant. Transfection efficiency, normalized for
Renilla expression, was assayed with the Dual-Luciferase sys-
tem (Promega Corp., Madison, WI). All transfection experi-
ments were repeated at least three times. Aliquots of the same
lysates were resolved by SDS-PAGE, transferred to nitrocellu-
lose, and immunoblottedwith anti-BCL6, anti-PATZ, and anti-
vinculin antibodies, as above described.
Chromatin Immunoprecipitation—Chromatin immunopre-
cipitation (ChIP) of Raji cells (;3 3 107) or chopped spleens
(;1 mg) from Patz11/1, Patz11/2, and Patz12/2 mice was
carried out with an acetyl-histone H3 immunoprecipitation
assay kit (Upstate Biotech Millipore, Lake Placid, NY) accord-
ing to themanufacturer’s instructions (19). The antibodies used
are described above. Input DNA and immunoprecipitated
DNA were analyzed by standard PCR for the presence of BCL6
exon 1 and lipoprotein lipase (LPL) promoter sequences using
the following primers: BCL6 exon 1, forward, 59-CTCTTACT-
CGCCTCTCTAAC-39; BCL6 exon 1, reverse, 59-CGGCGGC-
AGCAACAGCAATAATCAC-39; LPL pr, forward, 59-ACC-
AAAGTGTCAAGGGCAAC-39; and LPL pr, reverse,
59-ATTCCCTAAACCCAGCATCC-39.
We also used real-time quantitative PCR to amplify the BCL6
exon 1, as described below. Primers specific for the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene were used for
normalization of real-time quantitative PCR data. The following
primers were used: qBcl6 exon 1, forward, 59-TAACACCACAA-
ACTTGCAAAAGG-39; qBcl6 exon 1, reverse, 59-CTCCTCGA-
GCTAAATACACAAAAG-39; qGapdh pr, forward, 59-TGA-
GTCCTATCCTGGGAACCATCA-39; qGapdh pr, reverse,
59-TTTGAAATGTGCACGCACCAAGCG-39.
Generation of Patz1-Knock-out Mice—The Patz1 gene tar-
geting vector was derived from a lFXII phage library of a
129SvJ mouse strain (Stratagene, La Jolla, CA). It was designed
to delete a 2317-bp PstI-XhoI fragment, including the start
codon, the coding regions for the POZ domain, the AT-hook,
and the first four zinc fingers. It was constructed by subcloning
the 59-flanking region (the SpeI-PstI 3-kb fragment), the neo
cassette, and the 39-flanking region (the XhoI-XbaI 3.2-kb frag-
ment) into the Bluescript plasmid (Stratagene) that contained a
PacI digestion site inserted at a distance from the multicloning
site. The targeting vector was linearized with PacI before elec-
troporation into embryonic stem (ES) cells (Incyte Genomics,
3 The abbreviations used are: BCL6, B cell lymphoma 6 protein; BCL, B type
lymphoma; GC, germinal center; ES, embryonic stem.
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PaloAlto, CA).Among 700G418-resistant ES clones examined,
10 (1.4%) underwent homologous recombination. Two cor-
rectly targeted ES cell lines were injected into C57Bl/6J blasto-
cysts. Both ES cell lines gave rise to germ line chimeras that
were backcrossed to C57Bl/6J females to obtain Patz1
heterozygous offspring. For Southern blot analysis, tail DNA
samples were digested with StuI and probed with an external 59
genomic fragment that would detect 9.3- or 8-kb fragments,
corresponding to thewild-type andmutant alleles, respectively.
Themice weremaintained under specific pathogen-free condi-
tions, and all studies were conducted in accordance with Italian
regulations for experimentations on animals.
Isolation of mRNA and Quantitative RT-PCR—Total RNA
was extracted using TRI-reagent solution (Sigma) according to
the manufacturer’s protocol, treated with DNase I (Invitrogen/
Life Technologies Italia), and reverse-transcribed using ran-
dom hexanucleotides as primers and MuLV reverse transcrip-
tase (PerkinElmer Life Sciences) following the manufacturer’s
instructions. For quantitative RT-PCR, each reaction was per-
formed three times in triplicate using the SYBR Green PCR
master mix (Applied Biosystems, Foster City, CA) under the
following conditions: 10 min at 95 °C followed by 40 cycles (15
s at 95 °C and1min at 60 °C). Subsequently, a dissociation curve
was run to verify amplification specificity. The 22DDCTmethod
was used to calculate relative expression levels (20). Primers
specific for the glucose-6-phosphate dehydrogenase (G6PD)
genewere used for normalization of real-time quantitative PCR
data. The following primers were used: Patz, forward, 59-GAG-
CTTCCCCGAGCTCAT-39; Patz, reverse, 59-CAGATCTCG-
ATGACCGACCT-39; G6pd, forward, 59-CAGCGGCAACTA-
AACTCAGA-39; G6pd, reverse, 59-TTCCCTCAGGA-
TCCCACAC-39.
Histology and Immunohistochemistry—Dissected tissues
were fixed in 10% formalin and embedded in paraffin by stan-
dard procedures. Mounted sections (5 mm thick) were stained
with hematoxylin and eosin or incubated in a 750-watt micro-
wave oven for 15 min in EDTA (10 mM, ph 8.0) and processed
for immunohistochemistry using the avidin-biotin-peroxidase
LSAB1 kit (Dako, Glostrup, Denmark). Endogenous peroxi-
dase was quenched by incubation in 0.1% sodium azide with
0.3% hydrogen peroxide for 30min at room temperature. Non-
specific binding was blocked by incubation with nonimmune
serum. The antisera were directed toward B220 (RA3-6B2;
SouthernBiotech, Birmingham, AL), CD3 (ab5690; Abcam,
Cambridge,UK), CD79a (ab3121; Abcam), BCL6 (sc-858; Santa
Cruz Biotechnology), and PATZ (described above).
IgH Gene Rearrangement Analysis—Genomic DNA was iso-
lated from tumor masses or normal tissues from control mice,
and Southern blotting was performed with the 32P-labeled
DNA probe PJ3 representing the JH4 region of the IgH locus
(21). A 1.3-kb Pst-1 fragment from theGapdh genewas used for
loading control.
Analysis of Lymphocyte Cell Surface Antigens—Spleens and
thymi removed frommice were dissociated into single cells and
stained for FACS analysis on a FACSCalibur flow cytometer
(BD Biosciences, Buccinasco, Italy) as described previously
(22). All the antibodies used were obtained from Pharmingen.
Statistical Analyses—Kaplan-Meyer survival curves were
used to analyze the percentage of tumor-free mice. Differences
were analyzed by the log rank test. The one-way analysis of
variance followed by Tukey’s multiple comparison test was
used to compare groups of experiments. The statistical signifi-
cant difference was considered when the p value was ,0.05.
RESULTS
PATZ Interacts with BCL6—To identify PATZ interacting
proteins, two-hybrid screenings of human heart and placenta
pretransformed libraries were performed. A total of 87 positive
clones (61 and 26 from heart and placenta, respectively) were
isolated. Fourteen clones from heart and two from placenta
libraries contained most of the coding sequence of the BCL6
gene (data not shown). To confirm the interaction between
PATZ and BCL6 in mammalian cells, co-immunoprecipitation
experiments were performed. To this aim, total cell extracts
from COS-1 cells transiently transfected with constructs
encoding Myc-tagged PATZ, Myc-tagged PATZ-DPOZ
(devoid of the BTB/POZ domain), and HA-tagged BCL6 (Fig.
1A) were subjected to immunoprecipitation using anti-Myc
antibody. As shown in Fig. 1B, co-precipitation of the BCL6
protein was observedwhen constructs for BCL6 and full-length
PATZwere co-transfected, andnotwhenBCL6was transfected
together with PATZ-DPOZ or with the backbone vector.
Therefore, PATZ and BCL6 form a complex in mammalian
cells, and the POZ domain of PATZ is necessary for such
interaction.
FIGURE1. InteractionbetweenPATZandBCL6.A, schematic representationof portions of PATZandBCL6encodedby the transfected expression vectors.AT,
AT-hook domain; black ovals, zinc finger motifs. B, co-immunoprecipitation (IP) of transfected PATZ-Myc, PATZ-DPOZ-Myc, and HA-BCL6 proteins in COS-1
cells. C, reciprocal co-immunoprecipitation of endogenous PATZ and BCL6 in Raji cells. Immunoprecipitation in the presence of EtBr was performed to control
that it was not mediated by contaminating DNA. Immunoprecipitation with nonspecific IgG was carried out as a control for the specificity of the interaction.
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Next, to ensure that the interaction between PATZ and
BCL6 takes place in a physiological context, endogenous PATZ
and BCL6 were co-immunoprecipitated in Raji cells, deriving
from a Burkitt lymphoma, which is a GC-derived lymphoma
expressing both proteins. The result, shown in Fig. 1C, further
demonstrates that PATZ and BCL6 interact in vivo.
PATZ Is Involved in BCL6 Negative Autoregulation—To
study the functional consequences of the interaction between
PATZ and BCL6, we investigated whether PATZ and BCL6
associate on a BCL6 endogenous target promoter. Previous
experiments demonstrated that the BCL6 gene contains two
non-STAT6 functional BCL6 binding sites located within exon
1 (23). Thus, we examined whether PATZ could bind exon 1 of
the BCL6 gene in vivo. Endogenous PATZ and BCL6 bind to
exon 1 ofBCL6, as determined byChIP experiments inRaji cells
(Fig. 2A). This result was further confirmed in vivo usingmouse
spleens, a tissue that harbors GC cells, where both PATZ and
BCL6 proteins were immunoprecipitated on BCL6 exon 1 (Fig.
2B). Interestingly, BCL6 binding to its own promoter was
enhanced (Fig. 2B) in spleens lacking PATZ (obtained from
Patz1 knock-outmice described below). The absence of immu-
noprecipitated PATZ in Patz1-null tissues confirmed the bind-
ing of PATZ to BCL6 exon 1 observed in the wild-type mice.
It is known that BCL6, by binding to its exon 1 and recruiting
the distal cis-acting factor ZEB1, represses its own transcrip-
tion, thus establishing a circuit of negative autoregulation (23,
24). To further investigate the role of PATZ in such a function
of BCL6, we used a reporter construct driving luciferase gene
expression under control of a BCL6 genomic sequence of 6.9
kb, including the ZEB1-responsive element, exon 1, and 1.5 kb
of intron 1 (BCL6i-luc) (18). Raji cells were co-transfected with
BCL6i-luc and plasmids expressing PATZ, BCL6, or both pro-
teins (Fig. 2C). As expected, BCL6 expression resulted in down-
regulation of the BCL6 promoter activity. A similar, but less
strong, activity was also achieved by PATZ, leading to a dose-
dependent repression of this BCL6 promoter region. Interest-
ingly, PATZ and BCL6 co-transfection resulted in the enhance-
ment of the BCL6-dependent repression (Fig. 2C). Western
blot analysis of Raji cells transfected or not with increasing
amounts of PATZ expression plasmid, as in Fig. 2C, confirmed
the negative dose-dependent effect of PATZ on BCL6 expres-
sion (Fig. 2D). To finally assess the dependence of BCL6 expres-
sion from PATZ, we analyzed, by Western blot, the BCL6 pro-
tein levels in mouse embryonic fibroblasts from Patz11/1 and
Patz12/2 mice (described below). As shown in Fig. 2E, Patz1-
null mouse embryonic fibroblasts showed a significant increase
in BCL6 expression, which confirms the negative regulatory
role of PATZ on it.
Disruption of Mouse Patz1 Gene Causes Thymus B Cell
Expansion, Which Eventually Leads to B Cell Lymphomas—To
gain insights into the physiological role of PATZ in vivo, a tar-
geting vector was designed to knock out the mouse Patz1 gene
FIGURE 2.Role of PATZonBCL6promoter.A, ChIP analysis performedon Raji cells using specific anti-PATZ and anti-BCL6 polyclonal antibodies to detect the
endogenous in vivobinding of PATZ andBCL6 to exon 1of BCL6. The recoveredDNAwas used as a template for PCRwith primers that specifically amplify exon
1 of BCL6 or the promoter region of the LPL gene (negative control). input indicates PCR products with chromosomal DNA without immunoprecipitation.
Nonspecific IgGwas used as a negative control. B, ChIP assay, revealed by quantitative PCR, on spleens from Patz11/1 and Patz12/2mice to detect the binding
of PATZ and BCL6 proteins to exon 1 of Bcl6DNA. The percentage of immunoprecipitatedDNAwith respect to the input is reported. C, luciferase activity of the
BCL6 promoter (24.9 to 12.0 kb) in Raji cells. Where indicated, 0.25 and 0.5 mg of PATZ and/or 5 mg of BCL6 expression vectors were co-transfected with the
BCL6i-luc plasmid. Where required, backbone vectors were also transfected to reach the same total amount of DNA for each experimental point. Data express
mean6 S.D. of three independent experiments.Asterisks indicate the statistical results of amultiple comparison test versuspromoter basic activity. *, p, 0.05;
**, p , 0.01, ***, p , 0.001. D, representative Western blot analysis to detect BCL6 expression in Raji cells transfected or not with increasing amounts of PATZ
expression plasmid, as in C. As a control for equal loading, the same blot was incubated with antibodies against vinculin. E, Western blot analysis of BCL6
expression in mouse embryonic fibroblasts from Patz11/1 and Patz12/2 mice. Vinculin has been analyzed as a loading control.
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by homologous recombination in ES cells (Fig. 3A). Inactivation
of the Patz1 allele was verified by analyzing Patz1 expression in
adult tissues using quantitative RT-PCR andWestern blot (Fig.
3, B and C). As expected, Patz1mRNA and protein were unde-
tectable in homozygous mutants, whereas they were present at
about half-levels in heterozygous as compared with wild-type
controls. Heterozygous mice were viable and fertile, but
heterozygous intercrosses produced viable homozygous
mutants at non-Mendelian frequencies. Indeed, the large
majority of homozygous mutants (about 75% on average) died
prenatally due to developmental defects in the cardiac outflow
tract.4Here we focused on some phenotypes, observed in adult
mice (both heterozygous and homozygous for the Patz1-null
mutation), which can be due to an impaired regulation of the
BCL6 gene.
By 2–3 months of age, with a similar frequency (75%),
Patz11/2 and Patz12/2 mice develop thymus hyperplasias
characterized by focal expansion of an intramedullary B cell
population (Fig. 4A). B cells are the minority cell type (0.82 6
0.50%) in the thymus of wild-type animals, as confirmed by
FACS analysis in a cohort of 20 animals, but significantly
increase to an average of 5.94 6 4.42 (p , 0.05) in an equal
number of Patz11/2 mice (Fig. 4B). A similar increase of B cells
was also observed in Patz12/2, where, for the limited number of
available animals, we could only do a qualitative analysis (data
not shown). To exclude that this B cell expansion could be due
to formation of intrathymic reactive B cell follicles possibly
induced by an altered CD4 helper versus cytotoxic subset ratio
(25), we analyzedCD41 andCD81 lymphocyte populations by
FACS in Patz11/2 thymi showing B cell hyperplasia, without
finding any differences in comparison with wild-type controls
(data not shown). Interestingly, in 4 out of 75 Patz11/2 mice
sacrificed at an advanced age (17–22 months old), we also
found thymus B cell lymphomas, characterized by large cells
with marked cell-to-cell variation in size and shape and abun-
dant pale cytoplasm, which were diagnosed as diffuse large B
cell lymphomas by our pathologists (Fig. 4C and data not
shown).
Thymus B Cell Lesions in Patz1 Knock-out Mice Are Depen-
dent on Bcl6 Expression—Pathological thymus B cells are con-
sidered to originate from the GC (26). Accordingly, focal
expression of BCL6 was detected in Patz1-knock-out thymus
lesions (either hyperplasia or lymphomas) but was absent in the
wild-type controls (Fig. 5A). Western blot analyses on thymus
tissues from Patz11/2 mice confirmed the expression of BCL6,
which was absent in Patz11/1 controls (Fig. 5B). Up-regulation
of BCL6 in these cells is consistent with the role of PATZ in
BCL6 autoregulation (see above), which leads us to suggest that
decreased or null levels of PATZ causes up-regulation of BCL6
expression, which in turn could be responsible for the thymus
pathological phenotype. To validate our hypothesis of a role for
increased BCL6 expression in the development of certain phe-
notypes in Patz1 knock-out mice, we crossed Patz11/2 with
Bcl61/2 mice (27) to generate double mutants. Patz12/2;
Bcl61/1, Patz11/1;Bcl62/2, and Patz12/2;Bcl62/2 mice died
during embryogenesis. However, because we observed the thy-
mus phenotype in Patz1 heterozygous mice, we analyzed the
alterations present in Patz11/2;Bcl61/1 mice and compared
them with the double heterozygous Patz1/Bcl6mutants.
Cohorts of 10 Patz11/2;Bcl61/1 and 10 Patz11/2;Bcl61/2
mice were equally distributed by gender and sacrificed at 12
months of age. Their thymus was analyzed by histological,
immunohistochemical, and FACS assays. As shown in Fig. 5C,
where representative FACS analyses are shown, 100% of the
Patz11/2;Bcl61/2 mice analyzed did not show any significant
thymus B cell expansion as compared with the Patz11/2;
Bcl61/1 controls. Immunohistochemical analyses confirmed
this result in 80% of the cases, whereas in the remaining 20% of
double heterozygousmice, an aberrant thymus B cell hyperpla-
sia was observed, but it was strongly reduced as compared with
that observed in Patz11/2;Bcl61/1 mice (Fig. 5D). These
results confirm a key role for the up-regulation of BCL6 in the
pathological thymus phenotype of Patz1 knock-out mice.
Increased Tumorigenesis in Patz1 Knock-out Mice—Al-
though initially healthy, many adult Patz11/2 and most of the
few available Patz12/2 mice developed signs of morbidity and
displayed visible tumors as they aged. As evident in the survival
curves in Fig. 6A, Patz12/2 and Patz11/2 mice showed an
increased incidence of neoplastic lesions at ;17 or 21 months
of age, respectively. Only 12% of the Patz12/2 and 67% of the
Patz11/2 animals were tumor-free at 20 months, in contrast to
the 95% of wild-typemice that were tumor-free at the same age.
The histological analyses revealed that 43 of 75 (57%)
Patz11/2 and 9 of 11 (82%) Patz12/2 mice developed malig-
nant tumors, versus only 7 of 63 (11%) wild-type mice. Patz1
knock-out tumors were mainly lymphomas, but hepatocellular
carcinomas and rare sarcomas and lung adenocarcinomas were
also detected. Wild-type animals developed lymphomas and
4 T. Valentino,D. Palmieri,M. Vitiello, A. Simeone, G. Palma, C. Arra, P. Chieffi, L.
Chiariotti, A. Fusco, and M. Fedele, manuscript submitted.
FIGURE3.GenerationofPatz1knock-outmice.A, schematic representation
of thewild-type andmutant alleles and the targeting vector. St, StuI; Sp, SpeI;
P, PstI; Ex., exon; Xb, XbaI. B and C, quantitative RT-PCR (B) and Western blot
analysis (C) in tissues from Patz11/1, Patz11/2, and Patz12/2 mice, to detect
PATZ expression and confirm its knock-out at both RNA and protein levels.
Data express mean 6 S.D. of three independent experiments.
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one hepatocellular carcinoma (Fig. 6B and data not shown).
Lymphomas from wild-type mice were all of the B cell lineage
but did not show BCL6 expression nor PATZ down-regulation
as compared with normal controls (data not shown).
To determine whether the tumors in Patz11/2 mice
occurred via loss of heterozygosity or haploinsufficiency, PATZ
protein expression and Patz1 gene sequence were analyzed in
the tumor tissues from Patz11/2 mice. Western blot (Fig. 6C)
and immunohistochemical analysis (data not shown) revealed
that PATZ was present in all of the tumors examined. Further-
more, sequence analysis of Patz1 cDNA isolated from eight
Patz11/2 tumors showed no mutation or rearrangement (data
FIGURE 4. Thymus neoplasias in Patz1 knock-outmice. A, immunohistochemical analysis in representative thymus sections of Patz11/1 and Patz11/2 mice.
B220 staining shows thepresenceof a focal B cell hyperplasia in themedulla of themutant sample,whereas only scatteredB cellswere present in thewild-type
control. Scale bars, 100 mm. B, flow cytometry dot blots of the thymi showed in B stained with CD19 and CD5 antibodies. A distinct population of cells that
positively stains with CD19-PE antibody in the Patz11/2 (lower panel) is evident. No appreciable CD191 cell population was found in the wild-type control
(upper panel). For each analysis, 10,000 events were counted. The relative percentage of CD191 cells (B lymphocytes) was indicated in the right-bottom corner
of each dot plot. PE, Phycoerythrin. C, representative sample of a thymus B cell lymphoma developed by a Patz11/2 mouse. Left panels, hematoxylin and eosin
staining; right panels, immunostaining for B220. Scale bars, 100 mm.
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FIGURE5.KeyroleofBCL6 in thymusBcell expansionofPatz1knock-outmice.A, immunohistochemical stainingofBCL6 in representative thymus samples
from Patz11/1 (left panel) and Patz11/2 (right panel) mice. Scale bar, 100mm. B, Western blot analysis for BCL6 expression in a pool of three Patz11/1 and three
Patz11/2 thymi. C, flow cytometry of representative thymi from Patz11/1;Bcl61/1, Patz11/2;Bcl61/1, and Patz11/2;Bcl61/2 mice. The thymocytes were double-
stained for specific B (CD19) andT cell (CD5) surface antigens. For each analysis, 10,000 eventswere counted. The relative percentageof CD191 cells (B lymphocytes)
was indicated in the right-bottom corner of eachdot plot. CD19-PE, CD19-Phycoerythrin staining.D, immunohistochemical analysis of the thymi shown in C to detect
B cells (stainedwith anti-B220). Only scatteredpositive cellswere detected in Patz11/1;Bcl61/1 (a,b) andmost Patz11/2;Bcl61/2 thymi (h,u). Large focal hyperplasias
of B cells were detected in Patz11/2;Bcl61/1 (g, d) thymi, and small focal positivity was detected in some Patz11/2;Bcl61/2 thymi (e, z). Scale bars, 100mm.
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not shown). These results indicate that haploinsufficiency,
rather than loss of heterozygosity, accounts for the tumor
occurrence in Patz11/2 mice, thus suggesting Patz1 as a hap-
loinsufficient tumor suppressor gene.
Spleen lymphomas were the most representative malignant
diseases in Patz1 knock-out mice, and they were further char-
acterized to determine themechanism by which reduced Patz1
expression induces such neoplasias. Tumor sections from
Patz11/2 mice were stained with antibodies raised against T
cell- and B cell-specific markers to determine the cell type of
origin of the lymphoma. Interestingly, we found both B type
and T type lymphomas with a prevalence of B (28%) versus T
lymphomas (17%). The B type lymphoma (BCL) subtypes, as
defined by Morse et al. (28), were as follows: (a) diffuse large B
cell (16.8%), (b) follicular B cell (5.6%), (c) pre-B cell (2.8%), and
(d) small B cell lymphomas (2.8%) (Fig. 6D). Flow cytometry
analysis confirmed the immunohistochemical data (data not
shown). To further characterize lymphoid neoplasias, IgH gene
configuration was analyzed by Southern blot of EcoRI-digested
spleen DNA from Patz11/1 and Patz11/2 mice using a probe
representing the JH4 region of the IgH locus (Fig. 6E). The
6.5-kb fragment represents the germ line configuration of the
gene. All BCLs showed oligoclonal rearrangements of the germ
line IgH joining region (Fig. 6E, asterisks). Interestingly, benign
lymphoproliferative diseases often showaberrantV(D)J recom-
bination at the IgH locus, suggesting that theymay represent an
FIGURE 6. Increased lymphomagenesis in Patz1 knock-out mice. A, Kaplan-Meyer tumor incidence analysis of Patz11/1, Patz11/2, and Patz12/2 mice.
Cohorts of 63 wild-type, 75 heterozygous, and 11 homozygous Patz1 knock-out mice were monitored and harvested when they exhibited symptoms of
disease. The curveswere significantly different (p,0.0001) as determinedby log rank test.B, the lymphoidphenotype, as a functionof the relativepercentage,
in mice homozygous and heterozygous for the Patz1-null mutation versuswild-type controls was plotted as pie charts. The number of mice analyzed for each
genotype is the same as in A. C, Western blot analysis showing expression of BCL6 and PATZ in spleen samples from Patz11/1 and Patz11/2 mice. a-Tubulin
expressionwas evaluated as a loading control.N, normal;Hy, hyperplasia; Ly, lymphoma.D, immunohistochemical staining for thephenotypic characterization
of lymphomas in Patz1 knock-out mice. Representative Patz11/2 spleen samples of all types of lymphomas observed are shown (for the percentage of each
type, see under “Results”). Antibodies used for the staining are indicated on the top. H&E, hematoxylin and eosin staining; DLBCL, diffuse large cell B cell
lymphoma; TCL, T cell lymphoma; pre-BCL, pre-B cell lymphoma; FBL, follicular B cell lymphoma; SBL, small B cell lymphoma. Scale bars, 100 mm. E, IgH gene
rearrangements were analyzed by Southern blot on EcoRI-digested spleen DNA. Control (1/1) is the wild-type mouse with the genomic 6.5-kb fragment
representing thegene in its germ line configuration.All hyperplastic (Hy) andBcell lymphomasamples fromPatz11/2mice, andnormal spleen fromaPatz12/2
mouse, show rearranged extra bands (asterisks). The histological diagnoses of the spleens are indicated above.
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early stage in the development of BCLs. The same Southern
blotwas also probed for gapdh, which gave rise to a unique band
for all loaded samples (data not shown). Both BCLs and lym-
phoproliferative diseases expressed BCL6, whereas it was not
detectable in wild-type controls or normal spleens from Patz1
knock-out mice (Fig. 6C), suggesting a key role for this onco-
protein in development of such neoplasias.
DISCUSSION
Previous studies suggest a cancer-related role for PATZ (3,
8–11), but the mechanisms by which PATZ is involved in the
process of carcinogenesis are still controversial. Our data indi-
cate that PATZ acts as a tumor suppressor in lymphomagenesis
by inhibiting BCL6 expression.We first showed that PATZ and
BCL6 bind to each other. This finding is consistent with the
notion that POK proteins, such as PATZ and BCL6, commonly
aggregate in large nuclear complexes by self-interaction, as het-
erodimers with other POK proteins and in association with
unrelated partners, such as transcriptional corepressors, as a
way to extend the repertoire of their target genes and/or the
ways they act on their expression (29). BCL6 is the most com-
monly altered proto-oncogene in non-Hodgkin lymphomas,
the majority of which derive from normal GC B cells (30). In
fact, its sustained expression causes malignant transformation
of GC B cells (31). Nearly half of human diffuse large B cell
lymphomas, the most common form of non-Hodgkin lympho-
mas, express BCL6 constitutively, mainly as a consequence of
BCL6 gene rearrangements and activating pointmutations that
target the 59 regulatory region of this gene (23, 24, 32, 33). How-
ever, different studies showed that BCL6 expression in lym-
phoma is largely independent from the corresponding chromo-
somal alterations, suggesting that mechanisms other than gene
rearrangements or mutations can deregulate its expression in
lymphomas (34, 35). BCL6 expression is tightly regulated in a
lineage- and developmental-stage-specificmanner, and disrup-
tion of normal controls can contribute to lymphomagenesis
(13, 14, 36). Transcription of the BCL6 gene is negatively self-
regulated bymeans of the interaction of two BCL6 binding sites
within exon 1 of the gene and the BCL6 protein itself, which is
a potent transcription repressor, and both chromosomal trans-
locations and activating mutations allow lymphoma cells to
bypass this negative autoregulation mechanism (23, 24). To
date, a variety of corepressors have been described. Among
them, the CtBP1 and ZEB1 transcriptional repressors are
required for BCL6 autoregulation (18, 37). In a recent model, a
repressive complex at the BCL6 locus that involves binding of
transcription factors to both exon 1 and a distant cis-acting
element (HSS-4.4) has been suggested to regulate BCL6 tran-
scription. In this complex, ZEB1 and BCL6, which bind to dis-
tant sites, are linked through binding of the common corepres-
sor CtBP1 (18). In the present study, we show that PATZ can
bind BCL6 exon 1 and negatively modulate BCL6 promoter
activity. Therefore, we speculate that PATZ can be one of the
transcription factors involved in the complex and that, because
of its ability to bind theminor groove ofDNAvia theAT-hooks,
could be crucial for the bending of DNA required to put
together distant cis-acting transcription factors. Because PATZ
can interact and cooperate with BCL6, we can suggest that it
acts together with BCL6 in its autoregulation. However, we
cannot exclude that PATZ can also act without BCL6, thus
contributing to keep BCL6 expression off when BCL6 is not
expressed at all. Consistent with a role of PATZ in BCL6 nega-
tive regulation, we also show thatmice carrying a null mutation
of the Patz1 gene develop an aberrant expansion of thymus B
cells, inwhichBCL6 expression is up-regulated.Webelieve that
this phenotype, which we demonstrated to be dependent on
BCL6 expression, is also responsible for the development of
BCLs thatwe observe in both thymi and spleens of Patz1 knock-
out mice at a later age.
In conclusion, our data indicate a haploinsufficient tumor
suppressor role for PATZ that would act in lymphomagenesis
by down-regulating BCL6 expression.
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Embryonic Defects and
Growth Alteration in Mice
With Homozygous Disruption
of the Patz1 Gene
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PATZ1 is an emerging cancer-related gene coding for a POZ/AT-hook/kruppel Zinc finger transcription factor, which is lost or
misexpressed in human neoplasias. Here, we investigated its role in development exploring wild-type and Patz1-knockout mice during
embryogenesis. We report that the Patz1 gene is ubiquitously expressed at early stages of development and becomes more restricted at
later stages, with high levels of expression in actively proliferating neuroblasts belonging to the ventricular zones of the central nervous
system (CNS). The analysis of embryos inwhich Patz1was disrupted revealed the presence of severe defects in theCNS and in the cardiac
outflow tract, which eventually lead to a pre-mature in utero death during late gestation or soon after birth.Moreover, the Patz1-null mice
showed a general growth retardation, which was consistent with the slower growth rate and the increased susceptibility to senescence of
Patz1ÿ/ÿmouse embryonic fibroblasts (MEFs) compared to wild-type controls. Therefore, these results indicate a critical role of PATZ1
in the control of cell growth and embryonic development.
J. Cell. Physiol. 228: 646–653, 2013.  2012 Wiley Periodicals, Inc.
The PATZ1 gene encodes four alternatively expressed proteins,
ranging from 537 to 687 amino acids, that share a common
modular structure consisting of a POZ domain, two AT-hooks
and four to seven C2H2 Zinc fingers (Fedele et al., 2000;
Kobayashi et al., 2000; Mastrangelo et al., 2000). According to
these domains, PATZ is a member of the POK (POZ and
Kruppel) family of transcriptional repressors (Costoya, 2007),
but it may function either as activator or repressor depending
upon the cellular context. Indeed, it has been reported to either
activate or repress c-myc (Fedele et al., 2000; Kobayashi et al.,
2000), to activate mast cell protease 6 (Morii et al., 2002) and
FGF4 (Kobayashi et al., 2000), and to repress androgen
receptor (Pero et al., 2002) and CD8 (Bilic et al., 2006) genes.
Consistentwith theCD8 regulation, it has been recently shown
that PATZ is an important part of the transcription factor
network that controls the CD4 versus CD8 lineage fate of
double-positive thymocytes (Sakaguchi et al., 2010). Moreover,
we have previously reported that PATZ has a critical role in the
spermatogenesis, by regulating the apoptotic pathways in germ
cells (Fedele et al., 2008).
Several studies suggest a role of PATZ in carcinogenesis. In
fact, the PATZ1 gene maps on the FRA22B fragile site, which
suffers loss of heterozygosity in several solid tumors (Burrow
et al., 2009), and it has been found rearranged with the EWS
gene in a small round cell sarcoma, with the loss of
heterozygosity of thewild-type PATZ1 allele (Mastrangelo et al.,
2000), suggesting a potential tumor suppressor role. However,
an oncogenic role for PATZ1 has also been suggested since it is
overexpressed in some human malignant neoplasia, including
colon (Tian et al., 2008), testicular (Fedele et al., 2008), and
breast (Tritz et al., 2008) tumors. Consistently, PATZ
down-regulation by siRNA either blocks the growth or induces
apoptosis of cell lines derived from colorectal cancers or
gliomas, respectively (Tian et al., 2008; Yang et al., 2010). PATZ
was found mislocalized in testicular seminomas, teratomas, and
embryonal carcinomas from the nucleus to the cytoplasm,
suggesting that its function could be impaired in these tumors
or, alternatively, that it may acquire some new cytoplasmic
function that could contribute to neoplastic transformation
(Fedele et al., 2008). Interestingly, it has been recently shown
that such delocalization of PATZ in testicular seminomas
depends on oestrogen receptor-b levels and the translocation
from cytoplasm to the nucleus is mediated by cAMP (Esposito
et al., 2011), as it was previously demonstrated in other cell
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systems, such as PC3M prostate carcinoma cells and normal
fibroblasts (Tritz et al., 2008).
Since it is known that a large number of genes involved in
embryonic development are either tumor suppressor or
oncogenes (Dean, 1998), we focused on studying the role of
PATZ during development. To this aim we first analyzed Patz1
expression during normal mouse development. Then, we
analyzed the phenotype of mouse embryos null for Patz1 in
comparison with wild-type (WT) controls. Finally, we
examined the growth characteristics of Patz1ÿ/ÿmice and their
embryo-derived fibroblasts.
Materials and Methods
In situ hybridization
The probe used for this study was a 489 bp fragment carrying a
portion of the mouse Patz1 cDNA. The same fragment, cloned in
the opposite orientation in pGem3Z, was used to obtain a sense
probewhich we used as a control of the specificity of hybridization.
Probe synthesis and labeling was carried out as previously
described (Chiappetta et al., 1996). Embryos of 8.5, 10.5, 12.5, 14.5,
and 17.5 days post coitum (dpc), obtained from C57/Bl6 mice
mated between 9 pm and 10 pm, were collected and classified
according to the Theiler staging (Theiler, 1989). Three
independent embryos for each stage have been analyzed. Tissue
preparation, hybridization, and washes were carried out as
previously described (Chiappetta et al., 1996). Ethical Committee
approval was given in all instances.
Generation and genotyping of mutant mice
The Patz1 gene targeting vector was derived from a lFXII phage
library of a 129SvJ mouse strain (Stratagene, La Jolla, CA). It was
designed to delete a 2,317-bp PstI–XhoI fragment, including the
start codon, the coding regions for the POZ domain, the AT-hook
and the first four zinc fingers (Supplementary Fig. 1). It was
constructed by subcloning the 50-flanking region (the SpeI–PstI 3 kb
fragment), the neo cassette and the 30-flanking region
(the XhoI–XbaI 3.2 kb fragment) into the Bluescript plasmid
(Stratagene) that contained a PacI digestion site inserted at a
distance from the multi-cloning site (Pero et al., 2012). The
targeting vector was linearized with PacI before electroporation
into embryonic stem (ES) cells (Incyte Genomics, Palo Alto, CA).
Two correctly targeted ES cell lines were injected into C57Bl/6J
blastocysts. Both ES cell lines gave rise to germ line chimeras that
were backcrossed to C57Bl/6J females in order to obtain Patz1
heterozygous offspring. For Southern blot analysis, tail DNA
samples were digested with StuI and probed with an external 50
genomic fragment that detects 9.3 or 8-kb fragments,
corresponding to theWT andmutant alleles, respectively. All mice
were maintained under standardized nonbarrier conditions in the
Laboratory Animal Facility of Istituto dei Tumori di Napoli (Naples,
Italy), and all studies were conducted in accordance with Italian
regulations for experimentations on animals.
Histological analysis
For histological examination, the embryoswere gently immersed in
Bouin solution (picric acid, 37% formaldehyde, 100% acetic acid
15:5:1). Sections (6mm thick) were stained with hematoxylin and
eosin according to standard procedures.
MEF growth and BrdU-FACS analysis
PrimaryMEFs, obtained from12.5-day-old embryos, were cultured
at 378C (5%CO2) in Dulbecco’s Modified Eagle’s Medium (DMEM)
containing 10% fetal bovine serum (Hyclone, Logan, UT)
supplemented with penicillin/streptomycin. To determine the cell
doubling time, each cell line (4 105 cells) was plated in 6-cm
culture dishes and counted daily with a hemocytometer. MEFs in
logarithmic growth were incubated for 2 h with 30mM BrdU
(Becton Dickinson, San Jose, CA) and then trypsinized and fixed in
70% ethanol for cell cycle analysis by FACS. Afterwashingwith PBS,
cells were re-suspended in 250ml of PBS and incubated with 250ml
of 4M HCl for 30min at RT followed by two washes with PBS-
Tween 0.1%. Subsequently, the cells were stained, first, with 20ml
anti-BrdU-FITC (Becton Dickinson) for 1h at RT in the dark, and
then washed twice with PBS-Tween 0.1% and re-stained with
5mg/ml propidium iodide containing RNase (20mg/ml), for 20min
at RT in the dark, and analyzed with a FACScan flow cytometer
(Becton Dickinson) interfaced with a Hewlett-Packard computer
(Palo Alto, CA). Gating excluded cell debris and fixation artifacts,
and the G1, S, and G2/M populations were quantified using
CellQuest software. In each experiment, a similar number of
events was analyzed.
Senescence associated-b-galactosidase assay
Cells (4 104), plated 24 h before the assay, were washed twice
with PBS and immersed in fixation buffer [2% (w/v) formaldehyde,
0.2% (w/v) glutaraldehyde in PBS] for 7min. After three additional
PBS washes, the cells were stained overnight in staining solution
(40mM citric acid/sodium phosphate pH 6.0, 150mM NaCl,
2.0mM MgCl2, 1 mg/ml X-gal) at 378C without CO2 to avoid
modification of the PH. The next day, the stained solution was
replaced with PBS, and all of the cells in at least 24 fields of view
were counted under the light microscope.
RNA extraction and qRT-PCR
Total RNA was extracted using TRI-reagent solution (Sigma,
St Louis, MO) according to the manufacturer’s protocol, treated
with DNAse I (Invitrogen/Life Technologies Italia, Monza, Italy),
and reverse-transcribed using random hexanucleotides as primers
and MuLV reverse transcriptase (Perkin-Elmer, Waltham, MA),
following manufacturer’s instructions. For quantitative RT-PCR
each reaction was performed three times in triplicate using SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA), as
previously described (Pero et al., 2012).
Protein extraction and immunoblot analysis
Protein extraction and Western blot analysis were carried out as
previously described (Melillo et al., 2001). The antibodies used
were as follows: anti-p27 (610241; BectonDickinson), anti-vinculin
(sc-7649; Santa Cruz Biotechnology, Santa Cruz, CA), anti-p21
(sc-397, Santa Cruz Biotechnology), anti-p16Ink4a (ab-54210;
Abcam, Cambridge, UK), anti-cyclin D2 (sc-754; Santa Cruz
Biotechnology), anti-p19arf (ab-80; Abcam), anti-cyclin E (sc-481;
Santa Cruz Biotechnology), anti-p53 (sc-126; Santa Cruz
Biotechnology), anti-cdk1 (Ab-1; Calbiochem, San Diego, CA),
anti-cdk2 (sc-748; Santa Cruz Biotechnology), anti-cdk4 (sc-260;
Santa Cruz Biotechnology), anti-cyclin A (sc-751; Santa Cruz
Biotechnology), anti-HMGA1 (Melillo et al., 2001), and anti-HMGA2
(Fedele et al., 2006).
Statistics
The one-way ANOVA followed by Tukey’s multiple comparison
test was used to compare groups of experiments. The statistical
significant difference was considered when P-value was <0.05.
Results
Developmental expression of Patz1 gene
To define the temporal and spatial profile of Patz1 expression,
we performed an in situ hybridization analysis on mouse
embryos between 8.5 and 17.5 days dpc, the period during
which the most critical events of organogenesis take place. In
general, the expression of Patz1 gene was ubiquitous at early
stages of development and became more restricted at later
stages. Interestingly, Patz1 was expressed at high levels in the
central nervous system (CNS) becoming confined at later
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stages to actively proliferating neuroblasts belonging to the
ventricular zones (Figs. 1 and 2).
Early gestation (8.5–10.5 dpc). At 8.5 dpc Patz1
transcripts were widely distributed in all embryonic tissues
(Fig. 1, Panel A). At 9.5 dpc Patz1 was still expressed in the
majority of the embryonic tissues even though it was markedly
transcribed along the CNS, throughout the branchial arches, in
the otic vescicles and in stomach primordium (Fig. 1, Panels B
and C). All the other tissues showed a reduced level of
expression. At 10.5 dpc (Fig. 1, Panels D and E) Patz1 mRNA
was detected at high level in the differentiating spinal and
cephalic ganglia. A lower expression was also detected through
the limb buds, branchial arches, stomach and the epato-biliary
primordium.
Midgestation (12.5–14.5 dpc) and late gestation
(17.5 dpc). At 12.5 dpc Patz1 transcripts were detected at
high level in the cephalic and spinal ganglia as well as in the brain,
hindbrain, and spinal cord (Fig. 2, Panels A and B). Their
distribution along the CNS was not uniform and resulted more
abundant in the proliferating neuroblasts belonging to the
ventricular zones (Fig. 2, Panels A–D). Additional sites of
strong expression were the olfactory and respiratory
epithelium in the nasal pit (Fig. 2, Panels A and B), the retina
(Fig. 2, Panel C), kidney (Fig. 2, Panel A), and Rathke’s pouch
(Fig. 2, Panel D). At 17.5 dpc Patz1 was detected at high level
along the CNS and in specific organs such as lung, liver, and
kidney (Fig. 2, Panels E–G). In the CNS, its high expression
appeared at this stage clearly confined to the actively
proliferating neuroblasts in the periventricular neocortical
neuroepithelium. Moreover, in the telencephalon it was
expressed also in the cortical plate, in the hippocampus, and in
the striatal neuroepithelium and subventricular zone (Fig. 2,
Panels F andG). A high expressionwas also found in the thymus,
thyroid, salivary glands (Fig. 2, Panels E and F), and in the tooth
primordia (Fig. 2, Panel G).
Embryonic lethality and developmental defects in
Patz1-null mice
To gain insights into the physiological role of Patz1 during
development and adult life, we generated mice carrying a null
mutation at the Patz1 locus.
Mice heterozygous for the Patz1 null allele appeared normal
and were fertile. Homozygous mutant pups totaled only 4% of
the newborn offspring from heterozygous intercrosses, instead
of the expected 25%, indicating that most Patz1-null mice
died during embryogenesis. Embryos from timed matings
between heterozygotes were analyzed at different gestation
stages (Table 1). Until 15.5 dpc all the embryos analyzed had
beating hearts with no gross abnormalities except for a slight
body size decrease inmost of the homozygousmutant embryos
(data not shown) and exencephaly in 4 out of 15 at 13.5 dpc
(Fig. 3 and Supplementary Fig. 2A). Exencephaly is a cranial
Fig. 1. Expression of the Patz1 gene in early gestation. Patz1
expression at 8.5 dpc (A), 9.5 dpc (B) and 10.5 dpc (D) in sagittal (A, B,
D) and frontal (C, E) sections. Abbreviations stand as follows: fb
andmb indicate the fore- andmid-brain, respectively; Te, Di, Ms, and
Mt indicate the telencephalon, diencephalon, mesencephalon, and
metencephalon, respectively; he, heart; sc, spinal cord; sg, spinal
ganglia; so, somites; ov, otic vescicles; ma, mandibular arch; st,
stomach.
Fig. 2. Expression of the Patz1 gene inmid- and late gestation. Patz1
expression at 12.5 dpc (A–D) and 17dpc (E–G) in sagittal (A, E, F) and
frontal (B–D, G) sections. Abbreviations stand as in the previous
figureplus: lu, lung; ki, kidney; np, nasal pit; ey, eye;Rp, rathke’s pouch;
tg, trigeminal ganglion; sa, salivary gland; li, liver; th, thymus; tp, tooth
primordium.
TABLE 1. Embryonic lethality in Patz1ÿ/ÿ mice
Litters Patz1þ/þ Patz1þ/ÿ Patz1ÿ/ÿ Deada Readsorbed Total
E8.5 2 4 11 5 0 0 20
E9.5 2 5 8 5 0 0 18
E10.5 2 2 10 3 0 0 15
E11.5 2 5 12 3 0 0 20
E12.5 5 5 10 9 0 4 24
E13.5 7 13 30 15 0 5 59
E14.5 2 4 9 3 0 2 16
E15.5 10 15 50 15 12 (80%) 10 80
E16.5 10 20 70 1 0 15 91
E18.5 10 10 40 0 — 20 50
3Wb 24 50 (38%) 76 (58%) 5c (4%) 0 — 131
Embryos were isolated at the indicated time of gestation and analyzed for viability by
observing heart beating. E, embryonic day; 3W, 3 weeks after birth.
aPercent of total Patz1ÿ/ÿ embryos given in parentheses.
bPercent of total pups given in parentheses.
cGrowth retarded.
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neural tube defect, resulting from failed closure of the neural
folds during neurulation. In the mouse, the neural tube initiates
closure at 8.5 dpc, beginning at the cervical/hindbrain boundary.
Two additional de novo closure sites occur at the caudal and
rostral limits of the forebrain. Closure then spreads along the
neural folds in the rostral and caudal directions. By 9.5 dpc,
closure is normally complete (Juriloff et al., 1991). Differently
from theWTcontrols, the Patz1ÿ/ÿ embryoswith exencephaly
(Fig. 3A and Supplementary Fig. 2A) had failure of closure of the
anterior neuropore and severe malformation of the brain with
the possible exception of the most caudal region of the
hindbrain (caudal medulla oblongata). Histological examination
of all the other 13.5 dpc homozygous mutant embryos with no
exencephaly (11 out of 15) revealed some anomalies of brain
development with a size and configuration roughly
corresponding to 12.5–13 dpc. In particular, the brain of the
mutants is smaller, the whole ventricular system is larger and,
although the pattern of folding is preserved, the structures that
bulge out such as the ganglionic eminence and the diencephalon
are less pronounced (Fig. 3B and Supplementary Fig. 2B).
Moreover, the thickness of the nervous tissue around the
ventricular cavities is reduced overall, and it is particularly
evident at the level of the telencephalon and diencephalon. The
choroid plexus of the 4th ventricle is hypoplasic. The
neuroepithelium of the isthmus and prospective cerebellum
remains apart caudally (Fig. 3Bg), although in more cranial
sections the ventral part comes together (Fig. 3Bb) and
eventually fuses (Fig. 3Ba). Interestingly, in some mutant
embryos (7 out of 15) a tongueof cells projects from themidline
(median sulcus) of the floor of the rhomboencephalon within
the ventricular cavity, extending rostrally to the region of the
mesencephalon (arrows in Fig. 3B and Supplementary Fig. 2B).
Another anomaly, common to all the Patz1ÿ/ÿ embryos
analyzed, is the origin of the aorta. In mutant embryos there is a
clear malformation of the great vessels that exit the ventricular
chambers of the heart. In contrast to WT embryos, where the
descending aorta is located in the midline towards the left
behind the esophagus (Fig. 4A, left), in 5 out of 15 mutant
embryos the descending aorta is located towards the right of
themidline (Fig. 4A, right). This suggests an origin from the right
primitive dorsal aorta, in contrast to the normal development,
in which the descending aorta originates from the left primitive
dorsal aorta. From these histological sections it is not clear the
real identity of the ascending aorta and pulmonary trunk. A
possibility is that the identity of the two outflow trunks is the
same as in theWT based on its relative position to each other.
In this case, the ductus arteriosus assumes a left to right
orientation, whereas the junction between the ascending aorta
and the aortic arch is locatedon the right side. The course of the
ascending aorta follows a ventral to dorsal direction with
minimal displacement to the side. An alternative possibility is
that the identity of the ascending aorta and pulmonary trunk is
reversed in the mutant embryo, in such a way that the vessel
occupying the position of the WT aorta is in reality the
pulmonary trunk, and vice versa, the vessel that should be the
pulmonary trunk is the ascending aorta. This malformation
would be a transposition of the great vessels. In either case, the
aortic arch would derive from the 4th right branchial arch
artery and the ductus arteriosus from the 6th right branchial
arch artery. In all the other mutants, the descending aorta is
normally located in the left side of the esophagus but the aorta
appears always ventral to the pulmonary trunk at its origin
(Fig. 4B), suggesting outflow-tract (OFT) defects possibly
including transposition or malposition of the great vessels.
Consistent with these histological data, the cardiac OFT
macroscopically analyzed in two agonizing newborn Patz1ÿ/ÿ
pups appeared impaired by different types of vessels anomalies
(Supplementary Fig. 3).
Growth retardation in Patz1-null mice
Almost all the Patz1ÿ/ÿ mice were 10–20% smaller than sex-
matched littermate controls following weaning and these
differences were kept almost unchanged throughout the whole
of their lives (Fig. 5A,B). Similarly, their mean body weight was
significantly lower than that of Patz1þ/þ mice in both sexes
(P< 0.01), as depicted by the growth curves in
Figure 5C. Conversely, the mean body weight of Patz1þ/ÿmice
did not differ from that of WT mice (Fig. 5C). To examine
whether visceral organ size was proportional to the body
weight we measured the wet weight of the heart, liver, spleen,
kidney, and lung. The ratio of organ to body weight was
consistently smaller in Patz1ÿ/ÿmice as compared toWTmice
(Fig. 5D).
Cell cycle profile alterations and premature senescence
in Patz1-knockout MEFs
MEFs were prepared from Patz1þ/þ, Patz1þ/ÿ, and Patz1ÿ/ÿ
embryos at 12.5 dpc. The growth properties of the MEFs were
assessed at passage 4 by growth curves and cell-doubling time.
As shown in Figure 6A–C, Patz1ÿ/ÿ MEFs grew significantly
slower than theirWT counterparts. Conversely, heterozygous
Patz1-knockout MEFs grew significantly faster than WT MEFs.
Fig. 3. CNS developmental defects in Patz1ÿ/ÿ embryos.
A: Macroscopic comparison of a Patz1ÿ/ÿ embryo at 13.5 dpc with
exencephaly (right side) with a normal WT embryo from the same
littermate (left side). Lateral (a), dorsal (b), frontal (g), and apical
views (d) are shown. B: Series of brain cross sections, progressively
more caudal, of representative WT and Patz1ÿ/ÿ (without
exencephaly) embryos at 13.5 dpc. For each panel, parallel sections
are compared. Ca, cerebral aqueduct; d, diencephalon; tv, third
ventricle; lvU lateral ventricle; fv, fourth ventricle; M,
neuroepithelium of the isthmus; arrow indicates a tongue of cells
projecting from the floor of the rhomboencephalon within the
ventricular cavity.
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To determine whether the growth alterations observed in
Patz1
ÿ/ÿ and Patz1þ/ÿ MEFs were due to altered progression
through the different phases of the cell cycle, proliferating MEFs
in the logarithmic phase were analyzed by bromodeoxyuridine
(BrdU) incorporation and flow cytometry. A drastic reduction
in BrdU incorporation was observed in Patz1ÿ/ÿ compared to
bothWT and Patz1þ/ÿ cells, suggesting a significant decrease in
S phase entrance in Patz1-null MEFs. Consistently, staining with
propidium iodide for DNA content confirmed that the cell
population in S phase was significantly decreased in Patz1ÿ/ÿ
compared to both WT and heterozygous cells (Fig. 6D).
Conversely, an increased number of Patz1ÿ/ÿ cells in both
G0/G1 and G2/M has been observed compared to WT and
Patz1
þ/ÿ MEFs (Fig. 6D).
We next examined the susceptibility to senescence of the
MEFs at different culture passages by measuring senescence-
associated b-gal activity. As shown in Figure 6, Panels E and F,
Patz1
ÿ/ÿ MEFs entered into premature cellular senescence
when they were cultured beyond seven passages.
To further investigate the mechanisms underlying the cell
cycle profile alterations of Patz1-knockout MEFs, we examined
the expression of cyclins, CDKs and CDK-inhibitor proteins in
Patz1
þ/þ, Patz1þ/ÿ, and Patz1ÿ/ÿ cells. Proteins involved in cell
cycle activation, such as HMGA1 and HMGA2, were also
examined. Consistent with the slow growth rates (Fig. 6A–C)
and the increased susceptibility to senescence of Patz1ÿ/ÿMEFs
(Fig. 6E,F), an increased expression of cell cycle inhibitors,
including p53, p21, p27, p16, and p19, was observed in Patz1ÿ/ÿ
MEFs compared to their WT and heterozygous counterparts.
Paradoxically, Patz1ÿ/ÿ cells also showed increased expression
of various proteins involved in cell cycle activation, including
cyclin D2, CDK4, Cyclin E, HMGA1, and HMGA2 (Fig. 6G). It is
likely that conflicting signals could account for cell cycle arrest
(hypermitogenic arrest) that might then induce premature
senescence (Blagosklonny, 2003).
Collectively, these data suggest that cells devoid of two Patz1
alleles enter the cell cycle more slowly thanWT cells do, arrest
in both G0/G1 and G2/M phases of the cell cycle and undergo
premature cellular senescence. Conversely, heterozygous
MEFs cells grow faster than WT controls but do not show
significant differences in BrdU uptake and cell cycle profile,
compared to WT cells.
Discussion
PATZ is an emerging cancer-related transcription factor,
whose role in cancer pathogenesis is not clear, due to
controversial reports supporting either a tumor suppressive or
a tumor inducing activity (Mastrangelo et al., 2000; Fedele et al.,
2008; Tian et al., 2008; Tritz et al., 2008; Yang et al., 2010; Pero
et al., 2012). From the analysis of Patz1-null mice, we previously
reported an important role for the PATZ1 gene in testis
development and spermatogenesis. Indeed, the lack of the Patz1
gene led to increased apoptosis of the spermatocytes and total
absence of spermatids and spermatozoa, with the subsequent
loss of tubular structure andmale infertility (Fedele et al., 2008).
Consistent with these data, among the germ cells, PATZ1 is
exclusively expressed in spermatogonia (Fedele et al., 2008), in
which, as Plzf, another member of the POK family, it could
regulate the maintaining of a stem cell pool (Buaas et al., 2004;
Costoya et al., 2004). Also by generating Patz1-null mice, but
focusing on T-cell development, it has been subsequently
Fig. 4. Outflow-tract defects in Patz1ÿ/ÿ embryos. A:Cross sections, at theheart level, of representativeWTandPatz1ÿ/ÿembryos at 13.5 dpc.
Parallel sectionsarealigned forcomparison.B:Cross section,at theheart level, of aPatz1ÿ/ÿembryoat13.5 dpcdifferent fromthat shown inA.All
sections shown are progressivelymore cranial going from the top to the bottom (A) and for the left to the right (B). M, descending aorta and aortic
arch; a, ascending aorta; p, pulmonary trunk; d, ductus arteriosus.
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shown that PATZ regulates transcription of the cd8 gene and is
part of the transcription factor network that controls the fate of
double positive thymocytes (Sakaguchi et al., 2010).
In the present work, we have more deeply studied the
expression of PATZ during development, extending the
analysis to the whole embryo. Interestingly, we found that it is
widely expressed at high levels during embryogenesis, especially
in the CNS, where it is clearly restricted to the actively
proliferating neuroblasts in the periventricular neocortical
neuroepithelium, in the telencephalic cortical plate, in the
hippocampus, and in the striatal neuroepithelium and
subventricular zone, suggesting the involvement of PATZ in
CNS development, as then validated by the phenotype of
Patz1
ÿ/ÿ embryos. In fact, they show defects in the CNS with a
clear reduction of periventricular cells. The critical role of
PATZ in CNS development is consistent with previously
published data reporting that PATZ is strongly expressed in the
midbrain region (Kobayashi et al., 2000) and that it is one of the
transcriptional factors that regulate a group of candidate genes
for susceptibility to the fetal alcoholic syndrome, which is
characterized by severe defects at the CNS (Lombard et al.,
2007).
Interestingly, most of the CNS districts, where PATZ1
expression is confined at later stages of development, harbor
embryonic neural stem cells (NSCs; Temple, 2003), once
again suggesting a crucial role of PATZ1 in maintaining a stem
cell pool. This is consistent with the reduction of the
subventricular zone, which is one of the key neurogenic sites
harboring the adult NSC niche (Doetsch, 2003), in Patz1-null
embryos. It is noteworthy that in adult mammals, NSCs
generate new neurons that are important for specific types of
learning andmemory (Yamasaki et al., 2007; Zhang et al., 2008).
The control of adult NSC number and function is fundamental
for preserving the stem cell pool and ensuring proper levels of
neurogenesis throughout life. Indeed, decreased neurogenesis
is implicated in the development of pre-mature aging and
disorders in learning, memory, and cognition (Lemaire et al.,
2000; Drapeau and Abrous, 2008; Kitamura et al., 2009).
Therefore, the definition of the mechanisms underlying NSC
maintaining may open the possibility of preventing the onset or
progression of these disorders by therapeutically enhancing
neurogenesis.
Another interesting phenotype, observed by the
morphological analysis of Patz1ÿ/ÿ embryonic tissues at
12.5 dpc, and subsequently confirmed by macroscopic
observations in newborn pups, was the altered positioning of
the cardiacOFT. It is likely that these defects are responsible for
the intrauterine or early neonatal death ofmost Patz1-nullmice.
In fact, the wrong positioning of the vessels that carry blood to
and from the heart can cause birth asphyxia due to respiratory
distress following the transition from placental to pulmonary-
based breathing (Ranjit, 2000). Similar cardiovascular defects
are reminiscent of common congenital heart defects, most of
them known as DiGeorge syndrome, seen in human newborns.
Fig. 5. Growth retardation of Patz1ÿ/ÿmice. A: Gross appearance of a representative 1-year-old Patz1-null mouse (right) in comparison with a
sex-matched wild-type sibling (left). B: Naso-anal length of cohorts of 10 mice, males or females, was measured at 12 months of age. Values are
meanWSD,MP<0.05.C:Bodyweightscurvesofcohortsof10WT,10Patz1R/ÿand10Patz1ÿ/ÿ female(left)andmale(right)miceasafunctionofage.
Value are meanWSD. The curves of Patz1ÿ/ÿmice were significantly lower than both Patz1R/R and Patz1R/ÿmice (P<0.01), as calculated by
ANOVARTukey test. D: Ratio of organ to body weight on mean values of four mice for each genotype above indicated. MP<0.05.
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This disease has an incidence of 1 of 4,000 born and is caused
by the alteration of several genes located in 22q11-22q12
(Schinke and Izumo, 2001). Since PATZ1 is also located on
chromosome 22q12, and many human newborns with aortic
arch and/or OFT defects do not display characteristic
mutations in well known genes associated to the DiGeorge
syndrome (DGS), such as TBX1, PATZ1 might be a good
candidate among the genes responsible for some types of DGS.
It is noteworthy, at this regard, that many experimental models
of DSG focus on the cardiac neural crest cells, a unique subset
of cells that migrate from the dorsal aspect of the neural tube
to remodel the pharyngeal arch arteries and the septation
of the cardiac OFT into two individual vessels: the
pulmonary trunk and ascending aorta (Hutson andKirby, 2007).
Therefore, the two main pathological phenotypes observed in
Patz1ÿ/ÿ embryos (neural tube and cardiac OFT defects)
could be linked by a common pathological event in the neural
crest cells.
Fig. 6. Growth alterations in Patz1-knockout embryonic fibroblasts. A: MEFs were prepared from Patz1R/R, Patz1R/ÿ, and Patz1ÿ/ÿ embryos at
12.5 dpc. At passage 4 their growth properties were examined in vitro. Representative clones from each genotype, as indicated in the figure,
are shown 3 days after plating an equal number of cells from each. B: Growth curves of MEFs as described in (A). MEFs were plated equally and
counted daily for 8 days. The values are themeanWSEof three different cell clones (each originating fromadifferent embryo) for each genotype.
C:Cell-doublingtimeofMEFsasdescribedin(A),calculated4daysafterplating.ThevaluesrepresentthemeanWSDofthreedifferentcellclonesas
described in(B).D:BrdURPropidiumiodideflowcytometryofasynchronousMEFsasdescribed in(A).Thepercentage(expressedasmeanWSD)
of cells in each phase of the cell cycle is indicated. E: Light microscopy of representativeWT and homozygous Patz1-knockout MEFs stained for
b-galactosidase activity at culture passage 8 (Scale bare: 10mm). F: Quantification of the percent of cells positive for b-galactosidase activity
(i.e., senescent cells) in Patz1R/R, Patz1R/ÿ, and Patz1ÿ/ÿMEFs is expressed as meanWSD of three independent experiments. G: Expression of
cell cycle and senescence regulators in representative MEFs from each genotype, as indicated on the bottom, was determined byWestern blot.
Relative expression levels, compared toWT cells and normalized with respect to vinculin, are indicated on the top of each panel. H: Relative
Patz1 expression inMEFs as in the previous panels, evaluated by qRT-PCR. Values are themeanWSDof three independent experiments in three
different clones for each genotype.
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The fewmice Patz1ÿ/ÿ that survive to the birth harbor no or
just slight cardiovascular defects (decrease in the diameter of a
vessel), having a quite normal life expectancy, except for those
which die prematurely for the onset of lymphomas (Pero et al.,
2012). Interestingly, most of these adult mice are growth-
retarded since they are 10–20% smaller and 40–50% lighter
than theirWTand Patz1þ/ÿ sex and age-matched controls. This
phenotype is compatible with defects in the CNS development
(Shanske et al., 1997). Nevertheless, the analysis of MEF growth
properties suggest that this phenotype may be due, at least in
part, to alterations in cell cycle progression and premature
senescence. Indeed, cell cycle analysis of Patz1ÿ/ÿMEFs shows
arrest at or beyond the restriction point, in either G1 or G2
phase, which is compatible with a hypermitogenic arrest
(Blagosklonny, 2003). Indeed, Patz1-null MEFs showed
conflicting signals due to increased levels at the same time of
both mitogenic cyclins and CDK inhibitors. This could
conceivably create an oncogenic stress, which would be
responsible for premature senescence (Serrano et al., 1997).
The results obtained on the Patz1-null MEFs are consistent
with very recent data showing growth inhibition and
accelerated senescence in human endothelial cells interfered
for PATZ1 expression (Cho et al., 2011). Apparently, this anti-
senescence function seems to conflict with the role of tumor
suppressor that we envisaged for PATZ (Pero et al., 2012).
However, the different cellular context may play a critical role
in the effect of PATZ on cell fate. Moreover, a dual tumor
suppressor/anti-senescence role has been previously reported
for other genes (Pan et al., 2011). Indeed, differently from
apoptosis that leads cells to death, senescence is a stable and
metabolically active state, which in fibroblasts is associatedwith
resistance to apoptosis caused by radiation (Yeo et al., 2000).
In conclusion, our findings in Patz1-knockout mice highlight
the critical role that PATZ plays during neural and cardiac OFT
development, deficiencies of which dramatically impact on
embryonic development and postnatal growth. Moreover, they
also indicate that PATZ1 gene can affect cell-cycle decision,
supporting its cancer-related function.
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Abstract
Impairment of the p27kip1 function, caused by a drastic reduction of its expression or cytoplasmic
mislocalization, has been frequently observed in thyroid carcinomas. To understand the role of
p27kip1 impairment in thyroid carcinogenesis, we investigated the consequences of the loss of
p27kip1 expression in the context of a mouse modeling of papillary thyroid cancer, expressing the
TRK-T1 oncogene under the transcriptional control of thyroglobulin promoter. We found that
double mutant mice homozygous for a p27 kip1 null allele (TRK-T1/p27K/K) display a higher
incidence of papillary thyroid carcinomas, with a shorter latency period and increased
proliferation index, compared with p27 kip1 wild-type compounds (TRK-T1/p27C/C). Consistently,
double mutant mice heterozygous for a p27 kip1 null allele (TRK-T1/p27C/K) show an incidence
of thyroid carcinomas that is intermediate between TRK-T1/p27K/K and TRK-T1/p27C/C mice.
Therefore, our findings suggest a dose-dependent role of p27 kip1 function in papillary thyroid
cancer development.
Endocrine-Related Cancer (2009) 16 483–490
Introduction
Thyroid tumors include a wide spectrum of lesions with
different phenotypic characteristics and biological
behavior: benign adenomas, differentiated carcinomas,
and anaplastic carcinomas (Hedinger et al. 1989).
Several genetic lesions have been already identified in
human thyroid carcinomas. In fact, RET/PTC onco-
genes have been found in about 20% of human papillary
thyroid carcinomas (PTCs). They are chimeric genes
generated by the fusion of the catalytic domain of the
RET receptor tyrosine kinase with the N-terminal
region encoded by heterologous genes. In the most
prevalent variants, RET/PTC1 (Grieco et al. 1990)
and RET/PTC3 (Santoro et al. 1994), the fusion
occurs between RET and the H4 (D10S170) or RFG
(Ele1/ARA70/Ncoa4) genes respectively. TRK-T onco-
genes have been detected in about 5% of PTCs. They
are generated by structural rearrangements of the
NTRK1 (TRKA) gene, coding for the high affinity
nerve growth factor (NGF) receptor. The TRK-T1 and
TRK-T2 oncogenes are both generated by NTRK1
fusion with the TPR gene. NTRK1 and TPR are both
located on human chromosome 1 (Greco et al. 1997).
Recently, it has been demonstrated that specific point
mutations in the activation segment of the BRAF kinase
are present in about 40% of adult PTCs (Kimura et al.
2003). Furthermore, a novel oncogene, designated
AKAP9-BRAF, deriving from the in-frame fusion of
the first eight exons of the A-kinase anchor protein 9
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(AKAP9) gene with the carboxyl-terminal encoding-
region (exons 9–18) of BRAF, has been isolated from
PTCs developed in irradiated patients after a short
latency period (Ciampi et al. 2005). As far as ras genes
are concerned, mutations of codon 61 of N-RAS (N2)
were significantly more frequent in follicular tumors
(19%) than in papillary cancers (5%).H-RASmutations
in codons 12/13 (H1) were found in 2–3% of all types of
thyroid tumors, but H-RAS mutations in codon 61 (H2)
were observed in only 1.4% of tumors (Vasko et al.
2003). K-RAS mutations in exon 1 were found more
often in papillary carcinomas (De Micco 2003). The
genetic lesions described above are mutually exclusive,
since no tumors have been found bearing more than one
of these lesions. PAX8-PPAR-g rearrangements are
frequent in follicular thyroid carcinomas (Kroll et al.
2000, Dwight et al. 2003), whereas impaired function
of the p53 tumor suppressor gene is a feature of
anaplastic thyroid carcinomas (Donghi et al. 1993). It
is interesting to observe that all these oncogenes
identified in thyroid cancer activate a signaling
pathway that results in an increased MAPK activity,
according to which one specific signaling pathway
that leads to MAPK activation plays a major role in
the generation of PTC. However, other genetic lesions
have also been reported in PTCs: decreased levels of
PTEN and PTPRJ, a dual-specific phosphatase and a
receptor type tyrosine phosphatase respectively (Bruni
et al. 2000, Trapasso et al. 2000), and alterations of the
p27kip protein function (Baldassarre et al. 1999)
represent frequent features of thyroid malignancies.
p27kip1 has classically been regarded as a cell-cycle
inhibitor based on its potent inhibitory activity of
cyclin E/cdk2 and the observation that its forced
expression results in G1 arrest (Toyoshima & Hunter
1994). Low levels of the p27kip1 protein have been
frequently found in human carcinomas, and these low
levels directly correlate with both a high histological
tumor grade and a poor outcome (Lloyd et al. 1999).
In several cases, the impairment of the p27 function is
due to its cytoplasmic mislocalization induced by
AKT activation (Viglietto et al. 2002, Motti et al.
2005, Chu et al. 2008). Also in thyroid malignant
neoplasias, the impairment of the p27 function is very
frequent: a reduction in p27kip1 protein levels has
been previously described in 10 out of 28 papillary
carcinomas, 3 out of 9 follicular carcinomas, and 6
out of 8 anaplastic carcinomas. Moreover, 80% of
p27kip1-expressing tumors shows an uncommon
cytoplasmic localization of p27kip1 protein, associated
with a high cdk2 activity (Baldassarre et al. 1999).
Several components account for the reduced p27
protein levels in thyroid malignant neoplasias: both
PTEN and PTPRJ, whose expression is drastically
reduced in thyroid malignant neoplasias (Bruni et al.
2000, Trapasso et al. 2000), increase the stability of
the p27 protein. Recent data show increased miR221
and 222 levels in PTCs that correlate with low levels
of p27 (Visone et al. 2007). However, a causal link
between p27 impairment and thyroid carcinogenesis
has not been established yet.
The aim of the present work was to validate the role
of the loss of p27 function in thyroid carcinogenesis
crossing transgenic mice carrying the TRK-T1 trans-
gene under the control of the bovine thyroglobulin
(TG) promoter (Russell et al. 2000) with mice carrying
targeted germline deletions of one or two p27kip1
alleles (Fero et al. 1996). Despite the limited
involvement of the NTRK gene in human PTCs in
comparison with RET/PTC, the TRK-T1 mouse model
develops follicular hyperplasia and papillary carci-
noma similarly to RET/PTCs mice (Jhiang et al. 1996,
Santoro et al. 1996, Powell et al. 1998, Russell et al.
2000), thus representing a valid system in the study of
thyroid carcinogenesis mechanisms. p27 null mice
show a syndrome of multiorgan hyperplasia with
features of gigantism and develop pituitary adenoma
with high incidence, lung, gonadal, and intestinal
tumors at an increased frequency compared with wild-
type mice (Fero et al. 1996), but no thyroid tumors
or anomalies. Here, we report that loss-of-function
of p27kip1 in mice with targeted overexpression of
TRK-T1 in thyroid cells increases the penetrance of
thyroid cancer and shortens the latency period of tumor
incidence.
Materials and methods
Mouse strains, handling, and genotyping
TRK-T1 transgenic mice in a B6C3F1 genetic back-
ground (Russell et al. 2000) were crossed with p27kip1-
null (p27K/K) mice from a mixed C57BL/6J and 129
genetic background (from Dr M L Fero; Fero et al.
1996) to obtain p27C/C, p27C/K, and p27K/K mice
containing the TRK-T1 transgene (TRK-T1/p27C/C,
TRK-T1/p27C/K, and TRK-T1/p27K/K respectively).
The TRK-T1 and p27kip1 genotypes were analyzed by
the PCR with genomic DNA isolated from w1 cm
section of mouse tail. For p27kip1 genotyping, the
following PCR primers were used: p27-K3 (common)
TGGAACCCTGTGCCATCTCTAT; p27 F-N
(generates mutant fragmentZ800 bp), CCTTCTATGG-
CCTTCTTGACG; and p27-K5 (generates wild-type
fragmentZ900 bp), GAGCAGACGCCCAAGAAGC.
The primer sequences for TRK-T1 were forward,
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CACATCATCGAGAACCCACAA and reverse,
GCTCATGCCAAAATCACCAAT, which generate a
550 bp product.
All mice were maintained under specific pathogen-
free conditions in our Laboratory Animal Facility
(Istituto dei Tumori di Napoli, Naples, Italy) and all
studies were conducted in accordance with Italian
regulations for experiments on animals.
Histological and immunohistochemical
procedures
Cohorts of 40 TRK-T1/p27C/C, 52 TRK-T1/p27C/K,
and 40 TRK-T1/p27K/K live mice, equally distributed
between males and females, were examined for tumor
formation by observation and palpation every week
beginning 1 month after birth. They were killed at the
gross appearance of a neck mass or at 20 months of age
and thyroid was removed for pathological analysis. In
parallel, cohorts of 18 mice for each of the above
genotypes, equally distributed between males and
females, were killed in a time window of 12–14
months of age and their thyroids histologically
examined. Tissues were fixed by immersion for 24 h
in Bouin’s solution and embedded in paraffin using
standard procedures. Sections (5 mm) were stained
with hematoxylin and eosin using standard histological
techniques. To determine the proliferative status,
tumor sections were incubated with monoclonal
antibody to Ki-67 (Dako, Milano, Italy) at a 1:15
dilution following microwave antigen retrieval with
citrate buffer on an autostainer (Dako) using the
LSABCkit (Dako). The percentage of apoptotic cells
in the same tumor sections was determined by terminal
deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) using the TdT-FragEL DNA
fragmentation Detection Kit (Calbiochem, Beeston,
Nottinghamshire, UK). Micrographs were taken on
Kodak Ektachrome film with a photo Zeiss system.
Protein extraction and western blot analysis
Frozen pieces from normal and tumoral thyroid samples
were resuspended in NIH lysis buffer (1%Nonidet P-40;
1 mM EDTA; 50 mM Tris–HCl (pH 8.0); 150 mM
NaCl; 2 mM phenylmethylsulfonyl fluoride; 50 mM
NaF; 10 mM Na3V4; 20 mM NaPP; 1.5 mM aprotinin).
Tissue lysates were clarified by centrifugation at
10 000 g for 20 min at 4 8C. The supernatant was then
used for immunoblotting. Western blotting was per-
formed by standard procedures using the following
primary antibodies: anti-p27 (sc-528; Santa Cruz,
Heidelburg, Germany), anti-trk (sc-11; Santa Cruz),
and anti-g-tubulin (sc-8035; Santa Cruz). Briefly, the
protein extracts were separated by SDS-PAGE and
transferred to nitrocellulose membranes (BioRad).
Membranes were blocked with 5% nonfat milk in
TTBS (Tris-buffered saline containing Tween-20) and
incubated with antibodies diluted in the same solution.
Bound antibodies were detected by the appropriate
HRP–conjugated secondary antibodies followed by
enhanced chemiluminescence (Amersham).
Statistical analysis
Kaplan–Meyer survival curves were used to analyze the
percentage of tumor-free mice in all groups examined
during the 20 months of monitoring. Differences were
analyzed by Logrank test. For the comparison of cases
and controls within and across the groups, normal,
hyperplastic or tumoral frequencies were calculated for
all participants and compared using c2 analysis. Ki67
data are expressed as meanGS.E.M. Differences were
analyzed by Student’s t-test. P values %0.05 were
considered significant for all the above statistical assays.
Results
The onset of PTCs is accelerated in p27-null mice
Mice carrying the TRK-T1 transgene under the control
of the bovine TG promoter (Russell et al. 2000) were
mated with mice carrying targeted germline deletions
of one or two p27kip1 alleles (Fero et al. 1996). From the
above intercross, mice of all the three genotypic
combinations (TRK-T1/p27C/C, TRK-T1/p27C/K, and
TRK-T1/p27K/K) were obtained, and cohorts of
40 TRK-T1/p27C/C, 52 TRK-T1/p27C/K, and 40
TRK-T1/p27
K/K plus 20 wild-type and 20 p27K/K
mice were included in our study and monitored daily
for the appearance of a thyroid phenotype. Each
mouse was killed at the gross observation of a neck
mass and within 20 months of age, all the remaining
mice were killed. Histopathological analyses of each
thyroid lobe were performed on thyroids of all mice.
On the strength of criteria previously described (Russell
et al. 2000), we classified all the specimens in three
categories: normal, hyperplasia, and papillary carci-
noma. As shown in Fig. 1, differently from normal
thyroid characterized by regular monolayered follicles
containing colloid (panel A), hyperplasia was charac-
terized by increased follicular cellularity together with
the presence of irregular or colloid-deficient follicles
(panel B), whereas PTC was diagnosed on the presence
of proliferation of follicular epithelial cells containing
scant cytoplasm and papillae containing fibrovascular
stalks (panel C). As shown in Fig. 2A, we found
that TRK-T1/p27K/K develop PTCs more precociously
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as compared with compound TRK-T1/p27C/C and
TRK-T1/p27C/K mice. In particular, the comparison
of tumor incidence curves (here representing the PTC-
free mice) by Logrank test showed highly significant
differences between TRK-T1/p27K/K and TRK-T1/p27C/C
mice (P!0.0001). Similarly, significant differenceswere
found between TRK-T1/p27C/K and TRK-T1/p27C/C
mice (PZ0.0328), as well as between TRK-T1/p27K/K
and TRK-T1/p27C/K mice (PZ0.0348). No wild-type
or p27K/K mice, lacking the TRK-T1 transgene
expression, develop PTCs by 20 months of age
(Fig. 2A, dotted line).
p27 deficiency resulted in increased malignant
thyroid transformation
On the basis of the histopathological results obtained
from the above criteria on the thyroids of the mice
killed in a time window of 12–14 months of age
(18 mice for each genotype, equally distributed between
males and females), we found significant pathological
differences in bothTRK-T1/p27C/K andTRK-T1/p27K/K
mice compared with TRK-T1/p27C/C. In particular, as
summarized in Fig. 2B and analytically described in
Supplementary Table 1, which can be viewed online at
http://erc.endocrinology-journals.org/supplemental/, the
total number of PTCs developed by TRK-T1/p27K/K
mice was significantly higher than those observed in both
compounds heterozygous for the p27 null mutation
(P!0.005) and wild type (P!0.0005). Interestingly,
the carcinoma incidence in TRK-T1/p27C/K mice was
statistically higher than in TRK-T1/p27C/C (P!0.01),
but intermediate between compound p27K/K and
p27C/C mice, indicating a dose-dependency of p27 in
TRK-induced tumor development (Fig. 2B). In addition,
the data in Fig. 2B also show that TRK-T1/p27C/K and
TRK-T1/p27K/K mice do not significantly differ from
each other for the incidence of a normal phenotype,
being in both of them significantly lower than in
TRK-T1/p27C/C mice (P!0.0005). Consequently, dif-
ferently from TRK-T1/p27K/K mice (P!0.005),
compound mice heterozygous for the p27-null mutation
show a high incidence of hyperplasias that likely
represent a pre-malignant stage toward the development
of PTCs, as suggested by the delayed onset of PTCs in
TRK-T1/p27
C/K compared with TRK-T1/p27K/K mice
(Fig. 2A). No sex-related differences were observed
(Supplementary Table 1). As a control, we also analyzed
similar cohorts of wild-type and p27K/Kmice finding no
thyroid transformation in any of them (Fig. 2B and
Supplementary Table 1).
Loss of p27 confers an increased proliferation
rate to PTCs
Histological analyses of the PTCs arising in
TRK-T1/p27C/C, TRK-T1/p27C/K, and TRK-T1/p27K/K
mice did not show any significant differences and no
Figure 1 Histopathological features of normal, hyperplastic,
and carcinomatous mouse thyroids. (A) Representative
example of a normal thyroid as it appeared in a wild-type
mouse. Uniform colloid-filled follicles, composed of a one cell
thick layer of cuboidal epithelium are present. (B) Representa-
tive example of a hyperplastic thyroid lesion as it appeared in a
TRK-T1/p27C/Kmouse. Increased numbers of thyroid follicular
epithelial cells surrounding large colloid-deficient follicles are
present. (C) Representative example of PTC developed in a
TRK-T1/p27K/K mouse. Follicular epithelial cells cluster
together forming continuous sheets or papillae that surround
a fibrovascular stalk. The arrow indicates a fibrovascular stalk
in a papillary structure. Bar scaleZ100 mm.
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abnormalities or tumor metastases in local cervical
lymph nodes, peripheral lymph nodes or lungs were
observed in any group (data not shown). Then, we
analyzed in a comparative manner the proliferation
index in PTCs developed by TRK-T1 mice
homozygous, heterozygous or wild type for the p27
gene. The proliferation marker Ki67 was increased in
PTC cells from both TRK-T1/p27C/K (23.5%G2.1)
and TRK-T1K/K (25%G2) mice compared with p27
wild-type compounds (9%G1.7; Fig. 3 and data not
shown). Regardless of p27kip1 dosage, Trk-induced
PTCs contained a similar percentage of apoptotic cells
(as determined by TUNEL analysis) as did normal
thyroid tissues (data not shown). These findings
indicate that loss of p27kip1 enhances tumor growth
by increasing the percentage of cycling cells (rather
than the percentage of surviving cells) in the tumors.
Finally, to exclude the possibility that the loss of
p27kip1 may act on the transgene expression, leading to
an increased mitogenic stimulus, thus assessing that the
increased malignant phenotype is caused by the
impairment of the p27 function, we have analyzed
the transgene expression in PTCs from two mice for
each genotypic combination. As shown in Fig. 4, no
significant differences have been observed in TRK
protein expression between p27 null and p27 wild-type
mice. The expression of the p27 protein was also
analyzed as control.
Discussion
Decreased expression and altered subcellular locali-
zation of p27 have been observed in thyroid cancers
(Motti et al. 2005), but the functional relevance of
this observation in vivo is not addressed yet. For
this reason, we used a mouse experimental model of
thyroid carcinogenesis to investigate in vivo the role
of p27 inactivation in such neoplasm. In particular,
we used transgenic mice for the TRK-T1 gene, a well-
described murine model of thyroid carcinogenesis
(Russell et al. 2000), to investigate the relation-
ship between the overexpression of the TRK-T1
transgene and p27kip1 deletion in inducing thyroid
carcinomas. Here, we report that the loss of p27kip1
Figure 2Deficiency of p27 alters cancer incidence of TRK-T1mice. (A) Kaplan–Meyer tumor incidence analysis of TRK-T1mice with
different p27 genotypes. Cohorts of at least 40 mice were monitored and harvested when they exhibited symptoms of disease.
As assessed by Logrank test, the curves were significantly different (PZ0.0009). Dotted line represents either wild-type or p27K/K
mice. (B) The incidence of mice bearing normal, hyperplastic or cancerous thyroid was reported for each genotype, including
negative controls, during a time-window of 12–14 months of age. Differences between two frequencies were statistically compared
using c2 analysis. *P!0.005; **P!0.0005 versus TRK-T1/p27C/C controls.
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function increases the malignant phenotype of mice
expressing the TRK-T1 oncogene under the
transcriptional control of TG promoter. Indeed, the
TRK-T1/p27K/Kmice show an increased number of
carcinomas appearing with a shorter latency period
compared with TRK-T1/p27C/C mice. The analysis of
PTCs arising in TRK-T1/p27K/K mice shows an
increased Ki67 positivity that indicates an increased
proliferation rate in comparison with the PTCs arising in
compound p27 wild type. Conversely, TRK-T1/p27C/K
mice show a phenotype that can be considered inter-
mediate between TRK-T1/p27K/Kand TRK-T1/p27C/C
mice: their incidence of thyroid carcinomas
was higher than TRK-T1/p27C/C mice, but lower
than TRK-T1/p27K/K mice. Equally, TRK-T1/p27C/K
mice have an incidence of PTCs that was earlier than
TRK-T1/p27C/Cmice, but significantly later than
TRK-T1/p27K/K mice. Finally, PTCs developing in
these mice show a proliferative index statistically
increased compared with that shown by PTCs
arising in TRK-T1/p27C/C mice, but lower than
TRK-T1/p27K/K mice.
Interestingly, our results appear in contrast with
those previously published regarding the p27-null
mice carrying the ErbB2/Neu oncogene (MMTV-
neu/p27K/K; Muraoka et al. 2002). The mammary
glands of these mice showed decreased proliferation,
as well as markedly prolonged tumor latency,
compared with MMTV-neu/p27C/C glands. Conver-
sely, the TRK-T1/p27-null mice showed a great
similarity with the MMTV-neu/p27C/K mice, whose
mammary glands exhibited alveolar hyperplasia,
enhanced proliferation, decreased apoptosis, and
accelerated tumor formation compared with MMTV-
neu/p27C/C mammary glands (Muraoka et al. 2002).
It is likely that in MMTV-neu/p27K/K mice, the
complete absence of the p27 protein leads to an
impairment of cyclin D1/Cdk4 function, that makes
these mice more resistant to transformation. Results
very similar to those described for the MMTV-neu/
p27
C/K and MMTV-neu/p27K/K have also been
described in a mouse model of prostate carcinogenesis
(Gao et al. 2004): in p27 minus mice there is an
inhibition of tumor progression, whereas the hetero-
zygous compounds display enhanced prostate carcino-
genesis. However, we must consider that p27 plays
both a permissive and an inhibitory role in normal
thyroid cell proliferation (Paternot et al. 2006),
suggesting that also in carcinomas it can behave in
both ways depending on the cellular context.
Figure 3 Ki67 staining of PTCs arising in TRK-T1/p27C/C and
TRK-T1/p27K/K mutants. (A and B) Representative Ki67
immunostaining of PTCs occurring in TRK-T1/p27C/C and
TRK-T1/p27K/Kmice. A higher positivity is evident in the latter
specimen (B) as better described in the text. Bar scaleZ
100 mm.
Figure 4 Western blot analyses on PTCs arising in TRK-T1
mice with different p27 genotypes. The proteins detected are
indicated on the side. The g-tubulin protein expression was
analyzed as a loading control. Two normal thyroids from wild-
type animals were also included as control.
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Therefore, the results shown here demonstrate that
loss of p27 has a role on thyroid tumor development
and that p27 behaves as a haploinsufficient tumor
suppressor gene since even the loss of only one allele
of p27 is sufficient to confer a proliferative advantage
to PTC growth.
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A B S T R A C T
HMGA1 gene rearrangements have been frequently described in human lipomas. In vitro
studies suggest that HMGA1 proteins have a negative role in the control of adipocyte cell
growth, and that HMGA1 gene truncation acts in a dominant-negative fashion. Therefore,
to define better the role of the HMGA1 alterations in the generation of human lipomas, we
generated mice carrying an Hmga1b truncated (Hmga1b/T) gene. These mice develop a giant
phenotype together with a drastic expansion of the retroperitoneal and subcutaneous
white adipose tissue. We show that the activation of the E2F pathway likely accounts, at
least in part, for this phenotype. Interestingly, the Hmga1b/T mice also develop B-cell lym-
phomas similar to that occurring in Hmga1-knockout mice, supporting a dominant-nega-
tive role of the Hmga1b/T mutant also in vivo.
Ó 2010 Elsevier Ltd. All rights reserved.
1. Introduction
HMGA1 belongs to the High Mobility Group A (HMGA) gene fam-
ily, which also includes the closely related HMGA2 gene. The
HMGA1 gene codes, through alternative splicing, for two pro-
tein isoforms, HMGA1a and HMGA1b, which differ from
each other for few aminoacids. The HMGA proteins are
characterised by three DNA-binding domains containing
short basic repeats, the so-called AT-hooks, capable of
binding AT-rich sequences in the minor groove of the DNA,
and an acidic carboxy-terminal tail that is believed to be
important for protein–protein interactions.1 They are non-
histone chromatin-associated factors known as ‘architectural
transcription factors’: by interacting with the transcription
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machinery they alter chromatin structure and thereby regu-
late, negatively or positively, the transcriptional activity of
several genes.2 Both HMGA genes are widely expressed during
embryogenesis, but expression becomes more restricted as
foetal development progresses and is absent or low in adult
tissues,3,4 except for the stem cell compartment. In fact, it
has been recently shown that HMGA2 is highly expressed in
foetal and young-adult stem cells, being required for the
self-renewal of foetal and young-adult stem cells relative to
old-adult stem cells by negatively regulating p16In4a and
p19Arf expression in foetal and young-adult, but not old-adult
stages.5
This protein family is implicated, through different mech-
anisms, in both benign and malignant neoplasias.6 In fact,
unrearranged HMGA overexpression is a feature of malignant
tumours and is also causally related to neoplastic cell trans-
formation, as demonstrated by the ability of HMGA1 and
HMGA2 overexpression to transform cells in culture and in-
duce tumours in vivo.7,8 Conversely, rearrangements of HMGA
genes, mainly the HMGA2 gene, are a feature of most benign
human mesenchymal tumours.9
Indeed, they are frequent in human benign neoplasias of
mesenchymal origin, including lipomas, uterine leiomyomas,
pulmonary chondroid hamartomas and others9; breakpoints
in HMGA2 preferentially cluster in the third large intron of
the gene, resulting in deregulation of its expression, trunca-
tion or, more frequently, generation of fusion genes encoding
chimeric transcripts containing the first three exons of
HMGA2 and ectopic sequences from other genes. Truncation
of HMGA2 with the loss of its carboxy-terminus, including
the 3 0 untranslated region (3 0 UTR), seems to account for
HMGA2 gene overexpression in these tumours.7,10,11 Indeed,
3 0 UTR of HMGA2 contains multiple target sites for let-7
microRNA, and therefore, its loss would result in the lack of
the let-7 negative regulation of HMGA2.12,13
Rearrangements of HMGA1 in various benign mesenchy-
mal tumours consist of breakpoints located either upstream
or downstream of the gene sequence, and molecular analyses
of HMGA1 transcripts revealed common deletions of the car-
boxy-terminal region and/or parts of the 3 0 UTR.14,15 The gen-
eration of transgenic mice overexpressing HMGA1 and
HMGA2 genes confirmed an oncogenic role for these genes.
In fact, transgenic mice carrying wild-type forms of either
Hmga2 or Hmga1 develop NK/T-cell lymphomas and pituitary
adenomas.16,17 Conversely, the generation of knockout mice
for the Hmga1 gene revealed an unsuspected tumour-
suppressor potential since they develop B-cell lymphomas
and myelo-proliferative disorders.18
Several observations support a critical role for HMGA pro-
teins in the development, and particularly, in the process of
adipogenesis.19 In fact, Hmga2–/–mice express a pygmy pheno-
type together with a drastic reduction (87%) in adipose tis-
sue,3 whereas transgenic animals overexpressing either
wild-type or truncated Hmga2 show an opposite phenotype
with a significant increase in weight and size, characterised
by lipomas or abdominal/pelvic lipomatosis.11,16,20 Moreover,
the lack of Hmga2 expression prevents both diet- and gene-
induced obesity.21 Conversely, HMGA1 proteins exert a nega-
tive role on adipocytic cell growth.22,23 In fact, Hmga1 gene
expression is induced in mouse 3T3-L1 fibroblasts, which rap-
idly differentiate to adipocytes upon treatment with several
agents,24 soon after differentiation.22 Further, suppression of
Hmga1 or expression of a truncated Hmga1b (Hmga1b/T) gene,
deprived of both the acidic tail and the 3 0 UTR, dramatically
increased growth rate and impaired adipocytic differentia-
tion,22,23 also suggesting that the Hmga1b/T mutant acts in
a dominant-negative fashion.23 Data obtained from our labo-
ratory on Hmga1b-transgenic animal models, which do not
develop lipomas, have so far supported this model.17 To vali-
date in vivo the putative lipomagenic activity of the HMGA1b/T
gene, we generated transgenic mice carrying this mutant
gene under transcriptional control of the cytomegalovirus
promoter (Hmga1b/T mice). These mice are overgrown and
accumulate abundant ectopic fat depots. Increased E2F activ-
ity has been detected in the transgenic mice compared to
wild-type littermates, likely accounting, at least in part, for
the phenotype of the Hmga1b/T mice. We also show that
Hmga1b/T mice develop B-cell lymphomas with morphologi-
cal, histological and molecular features similar to those ob-
served in Hmga1–/– mice, again supporting the hypothesis of
a dominant-negative role of HMGA1/Ton theHMGA1 function.
2. Materials and methods
2.1. Generation of transgenic mice
The construct carrying the cDNA encoding the truncated
form of the murine Hmga1b gene (pRc/CMV-Hmga1/T) was ob-
tained by sub-cloning a 243-bp cDNA fragment (from +196 bp
to +438 bp downstream the transcriptional starting site (TSS)
of the mouse hmga1b cDNA) into the HindIII and XbaI sites of
the expression vector pRc/CMV (Invitrogen), as previously de-
scribed.23 It was electroporated into ES AB2.2 cells,25 and
G418-resistant clones were selected and analysed by South-
ern blot hybridisation with a CMV promoter probe on geno-
mic DNA digested with SspI (Fig. 1A). Seven positive clones
were selected on the basis of the unique Southern band of
2000 bp corresponding to the expected length of the SspI frag-
ment including the CMV-Hmgab1/T insert (asterisks in
Fig. 1B). These clones were expanded and the expression of
Hmga1b/Twas evaluated by a semiquantitative RT-PCR assay,
using a construct-specific primer set described in the follow-
ing paragraph. The highest two Hmga1b/T expressing ES cell
clones (asterisks in Fig. 1C) were microinjected into C57BL6/J
mouse blastocysts and then transferred to pseudopregnant
foster mothers (Thomas Jefferson University, Philadelphia,
PA). Chimeric mice were crossed to wild-type C57BL6/J mice
(Taconic Farm), and germ-line transmission of the transgene
was checked by Southern blot analysis of tail DNA from agou-
ti coat-coloured F1 offspring.
2.2. RT-PCR analyses
Tissues from transgenic animals were rapidly dissected, fro-
zen on dry ice, and stored at –80 °C. Total RNA was extracted
using TRI-reagent solution (Molecular Research Center,
Cincinnati, OH) according to the manufacturer’s protocol
and treated with DNase I (Invitrogen). One micrograms of
RNA was reverse transcribed using random exonucleotides
as primers (100 mM) and MuLV reverse transcriptase (Applied
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Biosystems). Five microlitres of cDNAwere amplified as previ-
ously described.11 Primers designed to amplify specifically the
transcripts of the transgenic construct, as well as primers
specific for the expressed enzyme glyceraldehyde 3-phos-
phate-dehydrogenase (GAPDH) that was used as an internal
control of the amount of cDNA tested, and primers to amplify
V-preB and rag2 genes were previously described.18,23
2.3. Quantitative RT-PCR
Each reaction was performed in duplicate in a final volume of
20 ll using 10 ll of 2· Power SYBR Green PCR Master Mix
(Applied Biosystems), 200 nM of each primer and 1 ll of each
cDNA, using the following conditions: 10 min at 95 °C and then
45 cycles of 30 s at 95 °C and 1 min at 60 °C. At the end of the
PCR run, a dissociation curvewas constructed using a ramping
temperature of 0.2 °C/s from 65 °C to 95 °C and a singlemelting
point was obtained for each promoter. The 2–DDCT method was
used to calculate relative expression levels.26 The following
primer sequences were used: CMV-forward, 5 0-tggcagtacatc-
tacgtattagtcatc-3 0; CMV-reverse, 5 0-atccacgcccattgatgta-30;
hmga1-endog-forward, 5 0-caagacccgggaaagtca-3 0; hmga1-
endog-reverse, 5 0-cagaggactcctgggagatg-3 0; cyclin E-forward,
5 0-ctgagagatgagcactttctgc-3 0; cyclin E-reverse, 5 0-gagcttata-
gacttcgcacacct-3 0; hprt-forward, 5-tcctcctcagaccgctttt-3 0 and
hprt-reverse, 5 0-cctggttcatcatcgctaatc-3 0.
2.4. Protein extraction and Western blot
Total protein lysates were obtained from transgenic (both nor-
mal and neoplastic) and wild-type spleens that had been
homogenised in a solution containing 1% NP40, 1 mmol/l
EDTA, 50 mmol/l Tris–HCl (pH 7.5) and 150 mmol/l NaCl, sup-
plemented with complete protease inhibitors mixture
Fig. 1 – Generation of Hmga1b/T transgenic mice. Schematic representation of the CMV-Hmga1b/T transgene vector
construction (A). Analysis, by Southern blot, of the integration of the CMV-Hmga1b/T transgene in ES cell clones.
Asterisks = selected clones for further analyses and CN = copy number (B). RT-PCR analysis of the expression of the CMV-
Hmga1b/T transgene in the selected ES cell clones. Asterisks = selected clones for blastocysts microinjection (C). RT-PCR
analysis of the expression of the CMV-Hmga1b/T transgene in a panel of adult tissues from transgenic mice (D). Quantitative
RT-PCR for the relative expression of the Hmga1b/T and Hmga1b transgenes in Hmga1b/T (A1b/T) and Hmga1b (A1b) mice,
respectively. The relative expression of the two transgenes in comparison to the endogenous Hmga1b gene is also shown in
the two trangenic mouse models. The data represent the mean values ± SD of two spleens from each mouse line performed
in duplicate (E).
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(Roche). Total proteins were separated by SDS–PAGE and
transferred to nitrocellulose membrane. Membrane was
blocked with 5% BSA in Tris Buffered Saline (TBS) and incu-
bated with the specific primary antibodies (Ab) recognising
the HMGA1 protein.22 Bound Ab was detected by the appropri-
ate secondary Ab, diluted in 5% nonfat milk in TBS solution
containing 0.05% Tween 20 (TTBS), and revealed with an en-
hanced chemiluminescence system (Amersham Biosciences,
Cologno Monzese, Italy).
2.5. MRI
Magnetic Resonance Imaging was performed at the ‘Istituto
dei Tumori di Napoli G. Pascale’ on a 1.5-T magnet system
using local receiver coils and an 8-cm field view. Coronal
slices 3 mm thick were obtained with T1 weighting (TR/
TE = 400/11 ms).
2.6. Plasmids, cell transfections and luciferase activity
assay
The cyclin E-luciferase vector (cyclin E-luc) was generously pro-
vided by K. Helin (Biotech Research and Innovation Centre,
University of Copenhagen, Denmark). Transfections for lucifer-
ase assays were carried out in 3T3-L1 mouse pre-adipocytes by
using Lipofectamine 2000method (Invitrogen), according to the
manufacturer’s instructions. A total of 2 · 105 cells were tran-
siently transfected with 0.2 lg of cyclin E-luc and with 1 lg of
each pCEFLHa-HMGA1,22 pCEFLHa-HMGA1/T,23 pCEFLHa-
HMGA2 and pCEFLHa-HMGA2/T,27 together with 0.5 lg of CMV-
bgal and various amounts of the pCEFLHa plasmid (backbone
vector) to keep the total DNA concentration constant. Cellswere
harvested 24 h post-transfection and lysates were analysed for
luciferase activity. Transfection efficiencywas normalised using
the b-galactosidase activity. The assay was performed in dupli-
cate and repeated in three independent experiments.
2.7. Electrophoretic mobility-shift assay
Protein/DNA-binding was determined by electrophoretic
mobility-shift assay (EMSA) for E2F1 with protein extracts
from wild-type and Hmgab1/T fat. Seven micrograms of each
extract were pre-incubated in a buffer containing 20 mM
Hepes pH 7.6, 1 mM MgCl2, 0.1 mM EGTA, 0.02% NaN3,
40 mM KCl, 10% glycerol and 1 lg of sonicated salmon sperm
for 10 min at RT. Then, 2 ll of the radiolabelled oligonucleo-
tide was added and the mixture was incubated for 20 min.
For supershift analysis, pre-incubation was run for 30 min
in ice in the presence of the specific antibody. The DNA-pro-
tein complexeswere resolved on 4% non-denaturing acrylam-
ide gels and visualised by autoradiography. The double-strand
oligonucleotide used was the E2F1-responsive element
(sc-2508, Santa Cruz Biotech, Santa Cruz, CA). The antibodies
used for the supershift analysis were: anti-E2F1 (sc-193, Santa
Cruz) and anti-Rb (sc-50, Santa Cruz).
2.8. Histological analysis and immunohistochemistry
For histological examination, dissected tissues were fixed by
immersion in 10% formalin and embedded in paraffin.
Mounted sections (5 lm thick) were stained with haematoxy-
lin and eosin using routine procedures.
2.9. Analysis of splenocyte cell surface antigens
Spleens removed from mice were dissociated into single cells
and RBCs were lysed by hypotonic shock using Tris–NH4Cl
buffer (NH4Cl 0.14 M, Tris 0.017 M, pH 7.2). Cells were washed
in PBS supplemented with 2% FCS, 0.2% sodium azide and la-
belled with FITC-, PE- and Cy5-conjugated appropriate anti-
bodies for 30 min at 4 °C. Cells were then washed and
analysed on FACS-Calibur flow cytometer (Becton Dickinson,
Buccinasco, Italy). All the Abs used were obtained from
Pharmingen/BD Biosciences (Buccinasco, Italy).
2.10. Statistics
The results are expressed as mean ± SD. For the comparison
of statistical significance between two groups, Student’s t-test
was used. A P-value < 0.05 was considered statistically
significant.
3. Results
3.1. Generation of transgenic mice with Hmga1b/T
An ES cell-mediated strategy has been used to generate
transgenic mice, as previously described.18 A truncated
Hmga1b cDNA (Hmga1b/T), deprived of the COOH-terminal
tail, under the transcriptional control of the CMV promoter
(Fig. 1A) was transfected into the ES cells AB2.2. G418-resis-
tant clones were selected and analysed by Southern blot
hybridization with a CMV promoter probe (Fig. 1B). Seven po-
sitive clones were selected on the basis of the expected
2009 bp fragment recognised by the Southern blot assay
(asterisks in Fig. 1B). The expression of the Hmga1b/T trans-
gene was evaluated by RT-PCR. As shown in Fig. 1C, all se-
lected clones expressed the transgene. The two clones with
the highest levels of Hmga1b/T mRNA (asterisks in Fig. 1C)
were microinjected into C57BL6/J mouse blastocysts, which
were then transferred to pseudopregnant foster mothers.
Several chimeric mice, identified by the mixed black/agouti
coat colour, were obtained and crossed with wild-type
C57BL6/J mice. Two independent Hmga1b/T strains, identified
by Southern blot hybridization, were generated and exam-
ined. Both mouse lines showed the same phenotype. The
Hmga1b/T expression was detected by RT-PCR in all the ana-
lysed tissues of transgenic animals (Fig. 1D), without any sig-
nificant difference among them. Western blot analyses
confirmed the expression of the Hmga1b/T protein in trans-
genic mice (data not shown). Expression of the Hmga1b/T
transgene was compared to that of the Hmga1b transgene
from Hmga1b/T and Hmga1b mice, previously generated in
our laboratory,16 respectively. The results, shown in Fig. 1E,
indicate a higher expression of the transgene in Hmga1b
mice then in Hmga1b/T mice. Moreover, we also show that
the expression of the endogenous Hmga1b gene is not chan-
ged with respect to wild-type littermates in both transgenic
mice models (Fig. 1E).
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3.2. Hmga1b/T mice exhibit a giant phenotype associated
with abdominal/pelvic lipomatosis
Most Hmga1b/T mice (derived from both lines) exhibited a
giant and obese phenotype. At 12 months of age, 70% of them,
both males and females, showed an average 10% increase in
body length (naso-anal), compared to sex-matched wild-type
littermates (Fig. 2B). The remaining 30% of Hmga1b/T mice
was indistinguishable from the wild-types. Moreover, starting
from the third month of age, both male and female transgenic
mice revealed a significant increase of the body-weight
growth curves compared to the controls (Fig. 2C and D). MRI
of the transgenic and wild-type mice was performed to eval-
uate the extent of fat deposition and the presence of other
abnormalities (Fig. 2A). Transgenic mice showed a drastic
expansion of the abdominal and subcutaneous white adipose
tissue. To confirm MRI results regarding fat mass, 14-month-
old male and female mice were sacrified and three
Fig. 2 – Hmga1b/T mice develop a giant and obese phenotype. MRI of representative one-year-old wild-type and Hmga1/T
transgenic mice. A frontal section of each is shown. rpf = retroperitoneal fat and sf = subcutaneous fat (A). Naso-anal length of
a cohort of 20 mice, equally distributed between males and females, was measured at 12 months of age and the mean
values ± SD were plotted as histograms. *P < 0.05 (B). Increasedweight of transgenic mice. Mean and 95% confidence intervals
of weights of 10 wild-type (o) and 10 Hmga1b/T transgenic (·) male (C) and female (D) mice as a function of age. Weights of
dissected fat pads in wild-type and Hmga1b/T mice. Abdominal fat includes gonadal, retroperitoneal and mesenteric fat
pads; subcutaneous fat represents the inguinal fat pad. Values, expressed in grams (E) and % body weight (F) represent the
means ± SD of 12-month-old male and female mice.
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intra-abdominal fat pads (gonadal, retroperitoneal, and mes-
enteric) and one subcutaneous fat pad (inguinal, in the groin)
were dissected and weighed. As shown in Fig. 2D and E, the
absolute and relative weights of the abdominal and subcuta-
neous fat depots were increased in transgenic mice compared
with that in wild-type controls. Histological examination of
the abundant abdominal fat mass observed in Hmga1b/T
mice showed an overall hypertrophy of the adipose tissue in
the abdominal/pelvic area of these mice, consistent with a
diagnosis of abdominal/pelvic lipomatosis.
3.3. Enhanced E2F activity in Hmga1b/T mice
Retinoblastoma proteins (pRB) are known to be critical in
controlling cell cycle in most cell types, including adipocyte
cells. They prevent the entry of cells into S phase by bind-
ing, and thereby inactivating the E2F transcription factors.28
We have recently reported that HMGA2 activates E2F1 by
binding pRB and displacing HDACs from the inhibitory com-
plex recruited by pRB onto E2F-responsive elements.27 A
similar mechanism has also been demonstrated in 3T3-L1
adipocytic cells by HMGA1.29 We have also previously
shown that the truncated Hmga1b gene dramatically in-
creased the growth rate of the 3T3-L1 cells and is able to
enhance the free E2F (i.e. not complexed with pRB) DNA-
binding activity highly.23 Herein, we demonstrate that cyclin
E promoter, a common E2F target, was significantly induced
upon transfection of a truncated Hmga1b gene, similarly to
what occurs for both wild-type and truncated Hmga2 genes
(Fig. 3A). Interestingly, a wild-type Hmga1b construct is not
able to enhance cyclin E promoter (Fig. 3A), and this result
is consistent with the phenotype of the Hmga1b-transgenic
mice, which are not overgrown and do not gain weight
compared to their wild-type littermates.17 Next, we ana-
lysed the E2F activity in Hmga1b/T mice by EMSA assays
with white adipose tissue (WAT) lysates from transgenic
and wild-type animals. The results show an increase of
the faster migrating complex, corresponding to the free
E2F1-DNA-binding, in transgenic versus wild-type mice
(Fig. 3B, lanes 1 and 4), confirming in vivo the capacity of
the Hmga1b/T mutant to enhance E2F1 activity. Supershift
analyses with antibodies directed against pRB and E2F1 con-
firmed the specificity of the protein-DNA complexes (Fig. 3B,
lanes 2, 3, 5 and 6). In accordance with these data, cyclin E
was found overexpressed in adipose tissue of these trans-
genic animals (Fig. 3C).
3.4. Hmga1b/T mice develop B-cell lymphomas
From 12months of age, a high percentage (75%) of transgenic
Hmga1b/T mice showed splenomegaly. This was histologi-
cally and cytologically diagnosed as B-type lymphoma (51%)
(Fig. 4, Panels Aa and b, and C) or lymphoid/myeloid hyper-
plasia (24%) (Table 1). In a cohort of 37 transgenic mice, the
B lymphoma subtypes, as defined by Morse et al.30 were: 11
pre B-cell, 4 follicular B-cell, 3 diffuse large B-cell histiocyte-
associated and 1 small B-cell lymphomas, as defined by
immunohistochemical analysis with antibodies against spe-
cific B and T surface antigens and cytoplasmic proteins and
further confirmed by flow cytometric analysis (data not
shown). In most of the cases, lymphomas were also observed
in other organs such as lymph nodes, liver (Fig. 4Ac), biliary
tract, prostate, pancreas, kidney, lung and thymus. We further
characterised transgenic spleens by semiquantitative RT-PCR,
looking at genes specifically altered in their expression. As
shown in Fig. 4D, similarly to what we previously described
for lymphomas developed by Hmga1-knockout mice,18
Hmga1b/T splenocytes showed up-regulation of both V-preB
and Rag2 genes compared to wild-type controls. These results
support a positive role of the Hmga1b/T mutant gene in B-cell
expansion and strongly suggest its dominant-negative role,
with respect to the wild-type Hmga1 protein, in the pathogen-
esis of this lymphoproliferative disease.
Finally, as summarised in Table 1, in our cohort of animals,
analysed between the ages of 18 and 22 months, we also
Fig. 3 – Hmga1b/T mutant protein enhances E2F1 activity.
Cyclin E transactivation, by luciferase assay, in 3T3-L1 cells
transfected with the indicated gene expression vectors or
the backbone vector (mock). The data represent the mean
values ± SD of three independent experiments performed in
duplicate. *P < 0.05 and **P < 0.001 (A). EMSA of white adi-
pose tissue extracts fromwild-type (lanes 1–3) and Hmga1b/
T transgenic mice (lanes 4–6) using an E2F-responsive
element sequence (E2FRE) as a probe. Samples in lanes 2, 3,
5 and 6 were pre-incubated with the indicated antibodies
before the addition of the probe. Supershifted bands con-
firmed the presence of E2F1 and pRB in the protein/DNA
complexes as indicated on the left (B). qRT-PCR of white
adipose tissue samples as in B to detect expression of cyclin
E (C).
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found a certain number of other neoplastic lesions, including
lung adenocarcinomas and spleen angiosarcomas (Fig. 4Ad),
further supporting the oncogenic potential of this mutant
form of the Hmga1 gene.
4. Discussion
Rearrangements of HMGA1 by chromosomal aberrations of
6p21 have been frequently described in human benign
Fig. 4 – B-cell lymphomas in Hmga1/T mice. Histologic analyses of representative neoplasms developed by Hmga1b/T mice
(A): spleen early lymphoma (a); higher magnification of sample shown in a (b); liver lymphoma (c); hemangiosarcoma (d). Scale
bars: 100 lm (a), 50 lm (b, c, d). Analysis of B- and T-cell surface antigens by flow cytometry. The relative percentages of CD19+
(B-lymphocytes) and CD3+ (T-lymphocytes) cells were plotted as histograms, showing their changes in transgenic (TG) versus
wild-type (WT) samples. The results represent the mean ± SE of seven different spleens for each genotype (P < 0.05) (B). The
ratio between B- and T-cells has been represented to show the increase of the B-cell population in TG versus WTanimals (C).
RT-PCR analysis showing the expression of V-preB and Rag2 genes in TG and WT spleens. Gapdh expression was evaluated
as an internal control of RNA used (D).
Table 1 – Neoplastic lesions in Hmga1b/T transgenic mice.
Pathology TG WT
Females Males Total Females Males Total
B-type lymphoma 13/19 6/18 19/37 2/16 1/16 3/32
Spleen lymphoid/myeloid hyperplasia 1/19 8/18 9/37 1/16 1/16 2/32
Heart hypertrophy 3/19 1/18 4/37 0/16 0/16 0/32
Spleen angiosarcoma 1/19 2/18 3/37 0/16 0/16 0/32
Lung adenocarcinoma 2/19 0/18 2/37 0/16 0/16 0/32
Lung adenoma 1/19 0/18 1/37 0/16 0/16 0/32
Uterine leiomyosarcoma 1/19 NA 1/19 0/16 NA 0/16
Endometrial hyperplasia 1/19 NA 1/19 0/16 NA 0/16
Mammary adenocarcinoma 1/19 0/18 1/37 0/16 0/16 0/32
Hepatocellular carcinoma 1/19 0/18 1/37 1/16 0/16 1/32
T-type lymphoma 0/19 1/18 1/37 0/16 0/16 0/32
Brain choroid papilloma 1/19 0/18 1/37 0/16 0/16 0/32
NA = not applicable.
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tumours of mesenchymal origin, including lipomas, uterine
leiomyomas and pulmonary chondroid hamartomas.6 The
chromosomal breakpoints were located either upstream or
downstream of the gene sequence, and sometimes within
an 80 kb region surrounding HMGA1, but no intragenic rear-
rangements have ever been reported.15 Therefore, it has been
hypothesised that truncation of HMGA1 is not a pre-requisite
to gain oncogenic potential. In contrast with this, we previ-
ously demonstrated the capacity of a construct expressing a
truncated Hmga1b gene, devoid of the C-terminal tail
(Hmga1b/T), to enhance proliferation of 3T3-L1 mouse fibro-
blasts.23 A similar finding was obtained by blocking expres-
sion of Hmga1.18 These data prompted us to hypothesise
that the truncated Hmga1b mutant might have an oncogenic
potential probably acting with a dominant-negative effect on
the wild-type protein function. To validate this hypothesis we
generated transgenic mice for the Hmga1b/T mutant gene.
Characterisation of their phenotype confirmed the key role
of the truncation of HMGA1 in the development of adipose
tissue and in the acquisition of a neoplastic phenotype. In-
deed, these mice are giant, obese and develop lymphomas
of the same subtype developed by Hmga1-knockout mice,18
once again suggesting a dominant-negative effect of this
truncated form on wild-type HMGA1 proteins.
These mice represent one more wedge in the studies that
independent groups have previously reported about Hmga1-
and Hmga2-transgenic mice. Indeed, it has been reported
that: (i) transgenic mice overexpressing either a wild-type or
a truncated Hmga2 cDNA, under two strong and essentially
ubiquitous promoters, developed abdominal/pelvic lipomato-
sis and/or an abnormally high incidence of lipomas, NK-T/NK
cell lymphomas and mixed growth hormone/prolactin cell
pituitary adenomas10,11,16,20; (ii) transgenic mice with Hmga1b
under control of the CMV promoter developed the same phe-
notype apart from the absence of lipomatosis17; (iii) trans-
genic mice that misexpressed full-length or truncated
human HMGA2 transcript under control of the differentiated
mesenchymal cell (adipocyte)-specific promoter of the adipo-
cyte P2 (Fabp4) gene, produced neoplastic phenotype, includ-
ing fibroadenomas of the breast and salivary gland
adenomas31; and (iv) transgenic mice overexpressing Hmga1a
flanked by the H-2K promoter and immunoglobulin intronic
enhancer develop T-cell lymphoid malignancy and uterine
sarcomas.32,33
Consistent with the behaviour of 3T3-L1 cells overexpress-
ing the Hmga1b/T mutant,23 mice expressing the Hmga1b/T
transgene show enhanced E2F activity and accumulation of
fat tissue, likely due to the enhanced adipocyte proliferation.
This phenotype, not present in mice transgenic for the wild-
type Hmga1b gene,17 is quite similar to that observed in mice
transgenic for either Hmga2 or Hmga2/T.11,16 Accordingly, in
3T3-L1 cells, overexpression of Hmga1b/T, Hmga2 and
Hmga2/T but not Hmga1b is able to enhance the activity of
an E2F-responsive element, such as cyclin E promoter. More-
over, differently from Hmga2-, Hmga2/T- and Hmga1b-
transgenic mice, all the sharing the development of pituitary
adenomas and T/NK lymphomas,10,16,17 Hmga1b/T mice de-
velop neither pituitary adenomas nor T- but B-type lympho-
mas, like Hmga1-knockout mice.18
Therefore, it appears that HMGA1b/T mutant has different
biological effects in comparison to wild-type HMGA1b pro-
tein, depending on the cellular context. In adipocyte cells,
even though both Hmga1b and Hmga1b/T are able to interact
with pRB and displace HDAC1 from E2F1-responsive promot-
ers,27 only Hmga1b/T is able to enhance E2F1 activity, result-
ing in accumulation of fat tissue in vivo. Conversely, it
appears that in lymphocytes Hmga1b/T has a dominant-neg-
ative effect on the endogenous Hmga1 protein. In fact, as for
Hmga1–/– mice,18 Hmga1b/T animals show higher levels of B-
cell-specific genes and up-regulation of the Rag2 gene expres-
sion compared with wild-type compounds, suggesting that
B-cell lymphomas in Hmga1b/T mice may develop as a result
of deficient T-cell function, as already hypothesised in
Hmga1–/– mice.18
In conclusion, we validated in vivo the oncogenic role of
the truncated HMGA1 gene and its key role in the control of
adipocyte proliferation. Moreover, our data indicate that
HMGA1b/T might behave as a dominant-negative mutant in
lymphocytic cells.
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ORIGINAL ARTICLE
HMGA proteins promote ATM expression and enhance cancer
cell resistance to genotoxic agents
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DNA-damaging therapies represent a keystone in cancer
treatment. Unfortunately, many tumors often relapse
because of a group of cancer cells, which are resistant to
conventional therapies. High-mobility group A (HMGA)
proteins has a key role in cell transformation, and their
overexpression is a common feature of human malignant
neoplasias, representing a poor prognostic index often
correlated to anti-cancer drug resistance. Our previous
results demonstrated that HMGA1 is a substrate of ataxia-
telangiectasia mutated (ATM), the main cellular sensor of
genotoxic stress. Here we also report thatHMGA2, the
other member of the HMGA family, is a novel substrate of
ATM. Interestingly, we found that HMGA proteins
positively regulate ATM gene expression. Moreover,
induction of ATM kinase activity by DNA-damaging
agents enhances HMGA-dependent transcriptional activa-
tion of ATM promoter, suggesting that ATM expression is
modulated by a DNA-damage- and HMGA-dependent
positive feedback loop. Finally, inhibition of HMGA
expression in mouse embryonic fibroblasts and in cancer
cells strongly reduces ATM protein levels, impairing the
cellular DNA-damage response and enhancing the sensitiv-
ity to DNA-damaging agents. These findings indicate this
novel HMGA-ATM pathway as a new potential target to
improve the effectiveness of conventional anti-neoplastic
treatments on the genotoxic-drug resistant cancer cells.
Oncogene advance online publication, 21 February
2011; doi:10.1038/onc.2011.21
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Introduction
The high-mobility group A (HMGA) protein family
includes four members: HMGA1a, HMGA1b and
HMGA1c (encoded by the HMGA1 gene through
alternative splicings) and HMGA2 (encoded by the
HMGA2 gene) (Johnson et al., 1989; Nagpal et al.,
1999). HMGA proteins bind the minor groove of
AT-rich DNA regions, through their amino-terminal
DNA-binding domain, which consists of three short
basic repeats, the so-called AT-hooks (Reeves and
Nissen, 1990).
HMGAs are involved in several cellular processes
such as gene and micro-RNA expression, chromatin
and nucleosome remodeling, DNA replication, apopto-
sis and DNA repair (Wood et al., 2000; Reeves and
Adair, 2005; Fusco and Fedele, 2007; Fedele and Fusco,
2010). HMGAs also has a causal role in cellular
transformation (Wood et al., 2000), mainly through
the regulation of expression of genes and micro-RNA
involved in the control of cellular proliferation, invasion
and apoptosis (Reeves and Adair, 2005; Fusco and
Fedele, 2007; Fedele and Fusco, 2010).
Expression of both HMGA genes is restricted to
the embryogenesis, resulting low or absent in normal
adult tissues (Zhou et al., 1995; Chiappetta et al., 1996),
while their overexpression is commonly found in
almost all human malignant neoplasias, representing a
poor prognostic marker correlated with the presence
of metastasis, reduced survival and resistance to anti-
cancer therapies (Fusco and Fedele, 2007; Fedele and
Fusco, 2010).
We have previously shown that HMGA1 is a novel
target of the ataxia-telangiectasia mutated (ATM)
protein (Pentimalli et al., 2008), the main cellular sensor
of DNA damage. Following the exposure to genotoxic
agents, the serine/threonine kinase ATM directly and
indirectly phosphorylates several substrates in order to
orchestrate the cellular DNA-damage response (DDR),
activating a signaling cascade which induces DNA
repair, cell-cycle checkpoint activation and, eventually,
apoptosis or senescence (Lavin, 2008). Interestingly,
ATM-deficient cells display an increased sensitivity
to genotoxic agents (Meyn et al., 1994; Savitsky et al.,
1995; Ku¨hne et al., 2004), and chemical inhibition of
ATM induces cellular chemo- and radio-resistance
(Sarkaria et al., 1998, 1999; Sarkaria and Eshleman
2001).
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In the present study, we demonstrate that HMGA2
also binds and is phosphorylated by ATM. Moreover,
based on the widely described role of HMGAs in the
regulation of gene expression (Reeves and Adair, 2005;
Fusco and Fedele, 2007; Fedele and Fusco, 2010), we
investigated their ability to bind and regulate the ATM
gene promoter. Our results indicate that HMGAs
positively regulate ATM expression and that ATM
kinase activity on HMGA proteins can enhance their
transcriptional activity on this promoter, activating a
HMGA-dependent positive feedback loop in response
to DNA damage. Accordingly, Hmga1/2 double knock-
out mouse embryonic fibroblasts (MEFs) display very
low levels of ATM and an impaired DDR.
Finally, we report that block of HMGA expression
in anaplastic thyroid cancer cells reduces cellular
levels of ATM, impairs the DDR and enhances the
cellular sensitivity to genotoxic agents such as ionizing
radiations.
Results
HMGA2 interacts with and is phosphorylated by ATM
The carboxy-terminal domain of HMGA2 harbors a SQ
motif (O’Neill et al., 2000) (serine 102/glutamine 103),
which corresponds to the serine 88/glutamine 89 of
HMGA1, phosphorylated by ATM (Pentimalli et al.,
2008). Therefore, we investigated whether HMGA2 is
also a novel target of ATM kinase activity (Figure1
and Supplementary Figure S1). For this purpose, we
evaluated the ability of HMGA2 to interact with ATM
transfecting HEK-293 cells with hemagglutinin (HA)-
tagged-HMGA2 and FLAG-tagged-ATM expression
vectors (Figure 1a). Cell extracts were immunopreci-
pitated with anti-FLAG antibody and immuno-
blotted with anti-HA antibody. Co-transfection of both
HMGA2 and ATM resulted in co-immunoprecipitation
of the two proteins. Conversely, HMGA2 was not
immunoprecipitated by the anti-FLAG antibody when
HA-HMGA2 expression vector was transfected alone.
Co-immunoprecipitation experiments performed also in
the presence of ethidium bromide demonstrated that the
co-immunoprecipitation between HMGA2 and ATM
did not depend on the contaminating DNA.
Moreover, we immunoprecipitated cell extracts from
HEK-293 transfected with HA-HMGA2 expression
vector alone using the anti-HA antibody, and immuno-
precipitates were analyzed by western blot using anti-
ATM antibody. As shown in Supplementary Figure S1,
HA-HMGA2 was also able to interact with the
endogenous ATM protein. Then, we verified that
HMGA2, as HMGA1, is a novel substrate of ATM
kinase activity in response to DNA damage. HEK-293
were transfected with HA-HMGA2 expression vector,
and endogenous ATM kinase activity was induced
by treating cells with 10Gy of infrared (IR). Cells
were collected 30min after the treatment and total cell
lysates were immunoprecipitated using antibodies
raised against phospho-serine and phospho-threonine
residues phosphorylated by ATM (Anti-P-Sub-ATM).
Immunoprecipitated ATM substrates were analyzed by
immunoblot using anti-HA antibody, which revealed
a band corresponding to the HA-HMGA2 protein
(Figure 1b). Conversely, HA-HMGA2 was immuno-
precipitated by the Anti-P-Sub-ATM also in cells not
treated with IR. However, IR treatment significantly
increased the amount of immunoprecipitated HA-
HMGA2, and selective inhibition of ATM kinase
activity, treating cells with 10 mM KU-55933, a specific
inhibitor of ATM (Hickson et al., 2004), for 1 h before
the IR exposure, abrogated the binding of Anti-P-Sub-
ATM antibody to HA-HMGA2. These data indicate
that HMGA2 is phosphorylated also in undamaged
cells, but ATM activation have a key role in this
phosphorylation following DNA-damaging agents
exposure.
HMGA1 and HMGA2 positively regulate ATM
expression
It is well known that HMGA proteins positively or
negatively regulate the transcriptional activity of several
genes (Fedele et al., 2001a, b; Fusco and Fedele, 2007;
Fedele and Fusco, 2010). Therefore, we evaluated the
possible role of HMGA proteins in the regulation of
ATM expression (Figure 2). To this aim, we analyzed
the expression levels of ATM mRNA and protein in
MEFs lacking one or both Hmga genes (De Martino
et al., manuscript in preparation). Expression levels of
ATM are strongly influenced by the presence of HMGA
proteins. In fact, ATM mRNA and total protein levels
were strongly reduced in MEFs carrying one disrupted
Figure 1 HMGA2 interacts with and is phosphorylated by ATM.
(a) HEK-293 cells were transfected as indicated, and total cell
extracts were immunoprecipitated using anti-FLAG antibody.
Immunoprecipitated proteins were analyzed by western blot using
anti-HA or anti-FLAG antibodies. Where indicated, ethidium
bromide (EtBr) was added during immunoprecipitations. Cells
transfected with the HA-HMGA2 vector alone were used as
negative control. (b) HEK-293 cells transfected with the HA-
HMGA2 vector were treated or not with a 10Gy dose of IR and
harvested after 30min. Cell extracts were immunoprecipitated
using the anti-P-Sub-ATM antibody. Inputs (upper panel) and
immunoprecipitates (lower panel) were analyzed by western blot
using anti-HA antibody. As a control of the specificity of
phosphorylation, cells were also pre-treated with 10 mM KU-
55933 for 1 h before the treatment with IR.
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Hmga gene (Hmga1 KO and Hmga2 KO), and almost
absent in double knock-out MEFs (Hmga1/2 DKO)
compared with wild-type controls, as demonstrated by
semi-quantitative(sq)RT–PCR (Figure 2a) and western
blot analysis (Figure 2b). Accordingly, reduced levels of
active ATM, assessed using an antibody directed against
its phophorylated serine 1981 (ATMser1981), were also
observed in Hmga1/2 double knock-out (DKO) MEFs
compared with wild-type controls. The faint signal that
is observed in wild-type and Hmga1 or Hmga2 single
knock-out MEFs is likely due to the minimal ATM
activation often observed in primary culture cells,
particularly when grown in a typical cell culture
incubator with 20% pO2 (Parrinello et al., 2003).
Moreover, we treated wild-type, Hmga1 KO, Hmga2
KO and Hmga1/2 DKO MEFs with 5Gy of IR to
evaluate the activation of ATM using the anti-ATM-
ser1981 antibody, and we found that ATM activation
following the IR treatment was significantly decreased in
Hmga1-KO and Hmga2-KO MEFs, and almost absent
in Hmga1/2-DKO MEFs as shown in Supplementary
Figure S2. These observations suggested that both
HMGA proteins have a positive role in the control of
ATM expression, leading us to further investigate a
possible impairment of ATM-downstream pathways in
Hmga1/2 DKO MEFs.
To investigate whether HMGA proteins bind ATM
promoter, we performed chromatin-immunoprecipi-
tation experiments using both human HEK-293T
(Figure 2c) and murine NIH-3T3 (Supplementary
Figure S3) cells transiently transfected with either HA-
HMGA1 or HA-HMGA2 expression vectors. Chroma-
tin was immunoprecipitated using anti-HA or normal
rabbit IgG antibodies. As shown in Figure 2c and
Supplementary Figure S3, the ATM promoter was
amplified only from the DNA recovered with anti-HA
antibody in both 293T and NIH-3T3 cells transfected
with HA-HMGA1 or HA-HMGA2, but not in cells
transfected with the empty vector pCEFL-HA, used as a
negative control. No amplification was obtained in the
samples immunoprecipitated using normal rabbit IgG.
To better characterize the region of ATM promoter
bound by HMGA proteins, we used different sets of
PCR primers to amplify the DNA immunoprecipitated
in the experiment described in Figure 2c. As shown in
Supplementary Figure S4, we demonstrated that the
main binding region by HMGA proteins on ATM
promoter is located between ÿ400 and ÿ600 bp from the
transcription start site of ATM gene. However, we
found that HMGA1 was also able to bind the region
located between ÿ50 and ÿ400 bp from the transcrip-
tion start site, while HMGA2 binding was selective for
the region ÿ400 to ÿ600 bp from the transcription start
site. The specificity of the HMGA binding to ATM
promoter was demonstrated as no amplification was
observed using primers able to amplify the ATM
promoter region between ÿ800 and ÿ1000 bp from the
transcription start site.
To confirm the positive effect of HMGA proteins on
the ATM promoter, we performed luciferase assays
transfecting a construct expressing the luciferase repor-
ter gene under the transcriptional control of the
human ATM promoter (pLuc-ATM, region ÿ512 to
þ 9) (Berkovich and Ginsberg, 2003) along with HA-
Figure 2 HMGA proteins positively regulate ATM expression. (a) sqRT–PCR on mRNA fromMEFs of the indicated genotypes was
used to assess ATM gene expression levels. Actin gene expression was evaluated to normalize RNA levels. (b) Total cell extracts from
cells as in (a) were analyzed by western blot using the indicated antibodies. Vinculin was analyzed as loading control. (c) HEK-293T
cells, transfected with the indicated vectors, were subjected to chromatin-immunoprecipitation using the anti-HA antibody. Normal
rabbit IgGs (N-IgG) were used as immunoprecipitation negative control. Immunoprecipitates were analyzed by PCR using primers
specific for human ATM promoter. (d) MEFs of the indicated genotypes were transfected with pLuc-ATM and luciferase activity was
assessed. The data reported are the mean±s.d. of three independent experiments performed in triplicate. **Significance values of
Po0.01 relative to wild-type MEFs.
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HMGA1 or HA-HMGA2 expression vectors or the
empty vector (pCEFL-HA). As ATM promoter activity
is dependent on the cellular context (Gueven et al.,
2003), as well as HMGA protein transcriptional activity
(Martinez Hoyos et al., 2004), therefore we performed
luciferase assays in different cell lines, including
HeLa, SAOS-2, NIH-3T3, MCF-7 and PC Cl 3 cells.
As shown in Supplementary Figure S4, HA-HMGA1
has a positive effect on ATM promoter activity in
MCF-7 (Supplementary Figure S5A) and SAOS-2
(Supplementary Figure S5B) cells while HA-HMGA2
activates ATM promoter in HeLa (Supplementary
Figure S5C) and NIH-3T3 (Supplementary Figure
S5D). Both HA-HMGA1 and HA-HMGA2 upregulate
ATM promoter in PC Cl 3 cells, which express very low
levels of endogenous HMGAs (Supplementary Figure
S5E). Moreover, we also transfected PC Cl 3 cells
with C-terminal deletion mutants of HA-HMGA1
(HA-HMGA1 (1–43)) and HA-HMGA2 (HA-HMGA2
(1–73)), as shown in Supplementary Figure S6, these
mutants were unable to activate ATM promoter.
To confirm the results obtained with the previously
shown cell lines, we transfected the pLuc-ATM reporter
plasmid in wild-type, Hmga1 KO, Hmga2 KO and
Hmga1/2 DKO MEFs. Figure 2d shows that transcrip-
tional activity of ATM promoter is strongly dependent
on the presence of HMGA proteins. In fact, absence of
HMGA1, HMGA2 or both HMGA proteins signifi-
cantly reduces ATM promoter activity, accordingly with
the results obtained from semi-quantitative RT–PCR
and western blot experiments (Figures 2a and b).
Finally, we transfected the HA-HMGA1, HA-HMGA2
and their transcriptionally inactive deletion mutants
HA-HMGA1 (1–43) and HA-HMGA2 (1–73) expression
vectors in Hmga1/2 DKO MEFs, and evaluated ATM
mRNA levels by real time–PCR. As shown in Supple-
mentary Figure S7, re-expression of the full-length
HMGA proteins, but not the transcriptionally inactive
mutants, rescued ATM expression.
Phosphorylation of HMGA proteins by ATM enhances
their transcriptional activity on ATM promoter
ATM activation by DNA-damaging agents determines
the phosphorylation of many substrates, in order to
trigger an effective cellular response to the DNA
damage (Lavin and Kozlov, 2007). Therefore, we
hypothesized that ATM-dependent phosphorylation
of HMGA1 and HMGA2 could have a role in the
modulation of their function following the exposure to
DNA-damaging agents. Then, we performed luciferase
assays in PC Cl 3 cells transfected with HA-HMGA1
(Figure 3a) or HA-HMGA2 (Figure 3b) expression
vectors along with the reporter construct pLuc-ATM,
and assessed ATM promoter activity following the
exposure to IR. Twenty-four hours after the transfec-
tion, cells were treated or not with 3Gy of IR, in order
to activate ATM kinase activity. As a specificity control,
cells were also pre-incubated with KU-55933 for 1 h. As
shown in Figures 3a and b, both IR and KU-55933 do
not affect the transcriptional activity of ATM promoter
in the absence of HMGA proteins, while IR enhanced
HMGA-dependent upregulation of this promoter
in cells transfected with either HA-HMGA1 or HA-
HMGA2. Conversely, the KU-55933 prevents the
IR-dependent increase of HMGA activity on ATM
promoter, indicating that this effect depends on ATM.
MEFs null for both Hmga genes display low levels of p21
mRNA and reduced phosphorylation of p53.
Previous studies on Atmÿ/ÿ MEFs have indicated a
significant involvement of p53 and p21 in cellular defects
dependent on the absence of ATM (Xu et al., 1996,
1998). In fact, following DNA damage, ATM phos-
phorylates p53 and enhances its transcriptional activity
on several target promoters, such as p21 (Lavin and
Kozlov 2007). Therefore, we first analyzed the levels of
p53 phosphorylation on the residue (serine 15) that is
phosphorylated by ATM (Canman et al., 1998).
Accordingly to the reduced expression of ATM in
Hmga1/2 DKO MEFs, we found that the absence of
HMGA proteins reduces the levels of p53-pSer15
(Figure 4a). Conversely, p53 phosphorylation levels in
Hmga1 KO MEFs are comparable to those observed in
wild-type MEFs, while we observed a significant
reduction of p53ser15 in Hmga2 KO MEFs in compar-
ison with wild-type MEFs. Moreover, the absence of
both Hmga genes almost abolishes the levels of p21
mRNA (Figure 4a). However, Hmga1 KO MEFs
show a slight reduction of p21 mRNA, while Hmga2
KO MEFs express p21 mRNA levels comparable to
Figure 3 ATM kinase activity enhances HMGA-dependent ATM gene expression. PC Cl 3 cells were transfected with HA-HMGA1
(a) or HA-HMGA2 (b) vectors along with the luciferase reporter vector pLuc-ATM. Twenty-four hours after transfection, cells were
treated or not with 10mM KU-55933 for 1 h and then with 3Gy of IR. Twenty-four hours later, luciferase activity was assessed. Data
reported are the mean±s.d. of three independent experiments performed in triplicate. **Significance values of Po0.01 relative to cells
not treated with IR.
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Hmga1/2 DKO MEFs. These data clearly indicate
that disruption of both Hmga genes drastically affects
the ATM-dependent p53/p21 pathway, reducing p53
phosphorylation and p21 gene expression.
MEFs lacking Hmga genes display an altered ability
to repair DNA damage
The data discussed above led us to investigate the
biological effect of the HMGA proteins in DDR. To this
aim, we analyzed the DNA-repair ability following IR
exposure of MEFs lacking one or both Hmga genes.
Wild-type, Hmga1 KO, Hmga2 KO and Hmga1/2 DKO
MEFs were either treated or not with 4Gy of IR to
induce DNA-double strand breaks (DSBs) and activate
cellular DDR. Cells were harvested before or immedi-
ately after the treatment, or were allowed to repair DNA
damage for 3 h. Then, we analyzed the amount of
damaged DNA in each cell type by comet assay,
evaluating the comet tail moment as a measure of the
DNA damage. MEFs of all four genotypes display
similar levels of DNA damage before and immediately
after the treatment with IR compared with wild-type
MEFs (Figure 4b and Supplementary Figure S8).
However, after 3 h, wild-type and single knock-out
MEFs almost completely recover the damage, while
Hmga1/2 DKO MEFs still show significant levels of
damaged DNA (Figure 4b and Supplementary Figure
S8). These observations suggest that absence of both
HMGA proteins determines a significant impairment of
the DNA-damage repair machinery, and reduced ATM
levels might, at least in part, account for this phenotype.
However, the presence of at least one of the two Hmga
genes is sufficient to sustain the cellular DNA-damage
repair.
Absence of HMGA proteins prevents stress-induced
senescence
As previously described, ATM also have a key role in
cellular senescence, following genotoxic stress (Crescenzi
et al., 2008; d’Adda di Fagagna, 2008; Viale et al., 2009).
Figure 4 Altered ATM-downstream pathways and DNA-damage repair in MEFs lacking Hmga genes. (a) mRNA and protein
extracts from MEFs of the indicated genotypes were analyzed by sqRT–PCR and western blot to evaluate p21 mRNA levels and p53
phosphorylation on serine 15 residue. Total p53 levels are also reported. Actin gene expression was evaluated to normalize RNA levels.
Vinculin was evaluated as western blot loading control. (b) MEFs of the indicated genotypes, not exposed (NT) or exposed to 4Gy of
IR, were allowed to repair for 0 and 3 h and processed for comet assay. Comets were stained with SYBR Green, visualized
by fluorescence microscopy and analyzed by COMET Score software. A representative comet for each experimental point is shown.
(c) Early-passage MEFs of the indicated genotype were not treated (NT) or treated with different doses (1–2Gy) of IR. Ninety-six
hours after IR exposure, SA-b-gal-staining was performed and light microscope cell images were acquired. A representative image of
each experimental point is reported. (d) Quantitative analysis of the experiment is shown in (c). The percentage of SA-b-gal positive
cells is reported. Values are the mean±s.d. of three independent experiments. At least 20 different fields were analyzed for each
experimental point in each experiment. *Significance values of Po0.01 relative to wild-type MEFs.
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Therefore, we decided to investigate whether absence of
HMGA proteins could affect stress-induced senescence
in early-passage MEFs. MEFs of all the four genotypes
were treated with sub-lethal doses of IR (1–2Gy)
and senescence-associated b-galactosidase (SA-b-gal), a
marker of cellular senescence, was assessed 72 h after the
treatment (Figures 4c and d). As shown in Figures 4c
and d, untreated MEFs, regardless of the genotype,
show similar levels of SA-b-gal positive cells. Conver-
sely, following IR exposure, we observed a significant
increase in SA-b-gal positive cells only in wild-type and
Hmga2 KO MEFs, while Hmga1 KO and Hmga1/2
DKO MEFs were almost refractory to the stress-
induced senescence. This result suggests that absence
of both HMGA1 and HMGA2 prevents stress-induced
senescence, likely because of the low cellular levels of
ATM. Moreover, HMGA1 seems to be more involved
than HMGA2 in this process, because only Hmga1 KO,
but not Hmga2 KO cells, are resistant to stress-induced
senescence.
Downregulation of HMGA1 protein enhances cancer cell
sensitivity to DNA damage
An accumulating body of evidence indicates that
inhibition of ATM kinase activity enhances cellular
sensitivity to DNA-damaging agents (Jackson et al.,
2009). These findings suggest that inhibition of HMGA
proteins, affecting ATM expression, may result in the
reduction of the ATM-mediated DDR and improve-
ment of cell sensitivity to DNA-damaging agents.
To validate this hypothesis, we analyzed the DDR of
FRO (human thyroid anaplastic cancer cells, which
express high levels of HMGA1 but not HMGA2) and
FRO-asHMGA1 cells, that stably express an anti-
HMGA1 antisense construct (Berlingieri et al., 2002).
As shown in Figure 5a, FRO-asHMGA1 display
reduced levels of HMGA1 and of ATM protein com-
pared with FRO parental cells. Accordingly, following
the exposure of parental FRO and FRO-asHMGA1
to 5Gy of IR, we found a reduced activation of ATM
and its downstream pathways. In fact, IR treatment
significantly increased ATMpSer1981, CHK2pThr68
and total p21 levels only in parental FRO but not in
FRO-asHMGA1 cells, as shown by western blot
analysis (Supplementary Figure S9).
Subsequently, we confirmed HMGA-dependent upre-
gulation of ATM also in this cellular system. Indeed, we
treated parental FRO and FRO-asHMGA1 cells with
5Gy of IR and cells were then harvested at 72 h from the
treatment to evaluate ATM mRNA levels by real time–
PCR. As shown in Supplementary Figure S10, IR
exposure increased ATMmRNA levels only in FRO but
not in FRO-asHMGA1.
Then, we performed a clonogenic assay on FRO and
FRO-asHMGA1 following the exposure to 2.5 or 5Gy
Figure 5 Downregulation of HMGA1 reduces ATM expression levels and enhances cancer cell sensitivity to DNA damage.
(a) Western blot analysis of protein extracts from parental FRO cells and FRO-asHMGA1 cells, using the indicated antibodies.
Vinculin was evaluated as loading control. (b) Clonogenic assay following IR exposure on FRO and FRO-asHMGA1 cells. Cells were
not treated or treated with 2.5 or 5Gy, cultured for 10 days and stained with crystal violet. Values are the mean±s.d. of three
independent experiments. *Significance values of Po0.01 relative to parental FRO cells. (c) Parental FRO and FRO-asHMGA1 were
not treated (NT) or treated with 5Gy of IR, allowed to repair for 0 and 3 h and processed for comet assay. Cells were stained with
SYBR Green, visualized by fluorescence microscopy and then analyzed by COMET Score. A representative comet for each
experimental point is shown. (d) Quantitative analysis of the experiment shown in (c) 3 h following the exposure to IR, using the
COMET Score software. Mean tail moment values±s.d. of three independent experiments are reported. At least 100 comets
for experimental point were analyzed in each experiment. *Significance values of Po0.01 relative to mean tail moment of parental
FRO cells.
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of IR. Accordingly with their lower levels of ATM,
FRO-asHMGA1 formed a much lower number of
colonies, compared with parental FRO, following IR
exposure (Figure 5b). Similar results were also obtained
treating cells with different DNA-damaging agents such
as UV-light (data not shown). This result suggests that
inhibition of HMGA proteins expression affects cell
proliferation and/or apoptosis following DNA damage.
To analyze the efficacy of the DNA-damage repair
machinery in the absence of HMGA1, we performed a
comet assay using parental FRO and FRO-asHMGA1
cells, treated or not with 5Gy of IR. Cells were analyzed
immediately or 3 h after the exposure to IR, and the tail
moment of comets was analyzed. As shown in Figures
5c and d, we found significant differences in damaged
DNA between wild-type FRO and FRO-asHMGA1
cells 3 h after the treatment with IR, while the amount of
damaged DNA is almost comparable in untreated cells
or immediately after the exposure to IR. These results
indicate that, following the exposure to DNA-damaging
agents, FRO-asHMGA1 activate a less effective DNA-
repair machinery compared with wild-type FRO cells.
To further confirm that the reduced survival and
DNA-repair ability of FRO-asHMGA1 cells following
IR exposure was dependent on the lack of the
transcriptional activation of ATM by HMGA1, we
stably transfected FRO-asHMGA1 cells with the
pFLAG-ATM expression vector (FRO-asHMGA1-
ATM) or the pFLAG empty vector (FRO-asHMGA1-
FLAG) (Supplementary Figure 11A). Then, we per-
formed a clonogenic assay following the exposure to
5Gy of IR on FRO-asHMGA1-ATM, FRO-asHM-
GA1-FLAG and parental FRO cells. As shown in
Supplementary Figure S11B, the number of colonies
formed by FRO and FRO-asHMGA1-ATM cells
following the IR treatment was significantly higher
compared with FRO-asHMGA1-FLAG cells. More-
over, we analyzed the DNA repair ability of FRO-
asHMGA1-ATM cells by comet assay as previously
described, following the exposure to 5Gy of IR.
Supplementary Figure S11C and S11D show that,
3 h after the IR treatment, the tail moment of FRO-
asHMGA1-ATM cells was similar to parental FRO cells
and significantly lower compared with FRO-asHM-
GA1-FLAG cells.
Next, we analyzed cell-cycle progression following IR
exposure, in order to evaluate the ATM-dependent
activation of cell-cycle checkpoints in response to DNA
damage. Asynchronously growing FRO and FRO-
asHMGA1 cells were harvested at different time-points
following the exposure to 5Gy of IR, fixed and stained
with propidium iodide, and analyzed by flow cytometry.
As shown in Figure 6, 16 and 24 h after IR treatment,
parental FRO cells arrests cell-cycle progression in G1
and S phase more efficiently compared with FRO-
asHMGA1. Accordingly, activation of the G1/S check-
point following the exposure to UV-light was less
efficient in FRO-asHMGA1 than in wild-type FRO
cells (data not shown). These data suggest that abroga-
tion of HMGA1 expression in cancer cells reduces the
DDR, affecting the ATM-dependent activation of cell-
cycle checkpoints. To focus our attention on G1/S and
intra-S checkpoints, FRO and FRO-asHMGA1 were
treated with 0.2mg/ml of nocodazole following the
exposure to 5Gy of IR, in order to prevent cells from
exiting G2/M phase and re-entering in G1. Wild-type
FRO were also treated with 10 mM of KU-55933 to
assess the effects of ATM inhibition. Cells were
harvested 8 h after the nocodazole treatment, and
analyzed by flow cytometry. As shown in Supplemen-
tary Figure S12, cell-cycle progression from G1 to G2
is significantly slower in FRO cells than in FRO
cells treated with KU-55933 and FRO-asHMGA1 cells,
following the treatment with IR and nocodazole.
To better quantify the G1 checkpoint activation in
FRO and FRO-asHMGA1 cells, we performed BrdU
incorporation assays in these cells following IR
exposure. Cells were synchronized in G1 phase by
thymidine double block, then treated with 5Gy of IR
and released in complete medium containing 1mM
Figure 6 Downregulation of HMGA1 affects G1/S cell-cycle checkpoint in response to DNA damage. Cell-cycle analysis of parental
FRO and FRO-as HMGA1. Cells were not treated (NT) or treated with 5Gy of IR, harvested at the indicated time-points and
analyzed by flow cytometry. Cells in G1 and in G2 phase of cell cycle are reported in red, cells in S phase are indicated with white and
blue bars. Reported data are representative of three independent experiments.
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BrdU. Cells were harvested at different time-points and
stained using an anti-BrdU antibody. BrdU incorpora-
tion was then evaluated by flow cytometry analysis.
As shown in Supplementary Figure S13, BrdU incor-
poration was significantly higher in FRO-asHMGA1
compared with parental FRO cells after the IR
treatment. These results further support the idea that
block of HMGA1 expression in cancer cells prevents
ATM induced G1/S checkpoint.
Then, we hypothesized that HMGA1, sustaining the
expression levels of ATM, promotes the activation of
G1/S checkpoint in response to DNA damage to
slow down the cell-cycle progression in order to repair
DNA and prevent DNA-damaging agents-induced
apoptosis. To verify this hypothesis, we analyzed
apoptotic markers such as annexin-V staining and
caspase 3/7 activation in FRO and FRO-asHMGA1
cells, following IR treatment (Figure 7). Parental FRO
and FRO-asHMGA1 cells were treated with 5Gy of IR,
harvested after 24 h, stained with anti-annexin-V fluor-
escent antibody and analyzed by flow cytometry.
Annexin-V staining confirmed that FRO-asHMGA1
cells display a higher percentage of apoptotic cells
already in untreated cells, compared with parental FRO
(Figure 7a). However, following IR exposure, both FRO
and FRO-asHMGA1 cells undergo apoptosis, but a
significant higher percentage of annexin-V positive cells
was found in FRO-asHMGA1 than in parental cells
(Figure 7a). Consistently with this result, FRO-asHM-
GA1 cells display an increased basal caspase 3 and 7
activity compared with parental cells following the
exposure to 2.5 and 5Gy of IR (Figure 7b). However,
8 h after IR treatment, we observed a significant increase
in caspase 3 and 7 activation, which increased until
24 h after the exposure only in FRO-asHMGA1 cells.
Conversely, parental FRO cells show a slower and less
intense activation of apoptotic pathways (Figure 7b).
Therefore, these data clearly indicate that inhibition of
HMGA expression in cancer cells effectively enhances
DNA-damage-dependent apoptosis.
Discussion
HMGAs has a causal role in the process of carcinogen-
esis, and their overexpression is often correlated with
resistance to conventional anti-cancer therapies and a
poor prognosis (Fusco and Fedele, 2007). Previously, we
reported that HMGA1 is a novel target of ATM
following DNA damage (Pentimalli et al., 2008). Here,
Figure 7 Downregulation of HMGA1 enhances DNA-damage-induced apoptosis. (a) Annexin-V staining of parental FRO and
FRO-asHMGA1, not treated (NT) or treated with 2.5 and 5Gy of IR. Cells were harvested 24 h after the exposure, stained using anti-
annexin V antibody and analyzed by flow cytometry to quantify the amount of apoptotic, annexin-V positive cells (M2). Reported
results are representative of three independent experiments. (b) Colorimetric caspase 3/7 activity assay, performed on FRO and FRO-
asHMGA1 treated as in (a) and harvested at the indicated time-points. Values are the mean±s.d. of three independent experiments
performed in triplicate. *Significance values of Po0.01 relative to parental FRO cells. **Significance values of Po0.01 relative to
untreated cells.
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we demonstrate that also HMGA2, the other member of
HMGA family, interacts and is specifically phosphory-
lated by ATM following the exposure to IR, and that
this phosphorylation can be prevented by chemical
inhibition by ATM kinase activity.
Then, we investigated the potential role of HMGA
proteins in the activation of ATM expression. Our
results show that HMGA proteins bind and positively
regulate the ATM promoter. Accordingly, MEFs null
for Hmga1 or Hmga2 display reduced levels of ATM,
compared with wild-type control, while the absence of
both Hmga genes completely impairs ATM expression.
As it has been widely demonstrated that HMGA1 and
HMGA2 show overlapping functions (Fusco and
Fedele, 2007), our results strongly suggest that HMGA
proteins have an additive effect also in the regulation of
ATM promoter.
Moreover, our data suggest that ATM activation
by IR might trigger a positive feedback loop on its
own promoter, which is dependent on the presence of
HMGA proteins. In fact, luciferase, real time and
western blot experiments performed in different cellular
systems showed that, following IR exposure, ATM
promoter activity and ATM mRNA and protein levels
are enhanced in an ATM- and HMGA-dependent
manner. However, the model that we hypothesize will
require further studies in order to be clearly confirmed
and clarified.
Absence of both Hmga genes results in the abrogation
of the p53 phosphorylation on the serine 15 residue
and of p21 expression, downstream targets of ATM.
Conversely Hmga1 KO MEFs did not show a reduction
in the p53/p21 pathway, while Hmga2 KO MEFs
displayed reduced levels of p21 mRNA and p53ser15
compared with wild-type MEFs. The absence of
Hmga1-dependent inhibition of p53 (Pierantoni et al.,
2006; Pierantoni et al., 2007) may account for this
difference between Hmga1 and Hmga2 single knock-out
MEFs. Our results also indicate a key role for HMGA
proteins in the cellular DDR. In fact, Hmga1/2 DKO
MEFs repair DNA less efficiently than wild-type MEFs
following IR exposure. Moreover, we show thatHmga1/
2 DKO MEFs fail to undergo stress-induced senescence
following IR treatment, further supporting the pre-
viously reported role of HMGA proteins in the process
of cellular senescence (Narita et al., 2006). We hypothe-
size that reduced levels of ATM observed in Hmga1/2
DKO cells may be, at least in part, responsible of this
phenotype. However, it is very likely that HMGA1 and
HMGA2 might differently affect ATM-downstream
pathways and the DDR through the regulation of
several other genes or transcription factors such as
p16INK4, p21 and p53.
Finally, inhibition of HMGA1 expression through
antisense approach drastically decreases cellular levels
of ATM in anaplastic thyroid cancer cells, resulting in
increased sensitivity of these cells to DNA-damaging
agents. In fact, block of HMGA1 enhances the pro-
apoptotic effects of IR, and cell-cycle analysis following
the exposure to DNA-damaging agents showed that
absence of HMGA proteins affects the activation of the
G1/S checkpoint. These findings further support the
idea that abrogation of HMGAs results in the accumu-
lation of DNA damages and in an enhanced sensitivity
to DNA-damaging agents.
The data reported here suggest the hypothesis that
HMGAs might enhance the cellular response to DNA
damage, increasing ATM protein levels, and through
their previously described anti-apoptotic activity (Pier-
antoni et al., 2007), could shift ATM signaling from cell
death to cell survival and resistance to genotoxic drugs.
However, further experiments are requested to be clearly
confirmed and elucidated.
Our data present important clinical implications. As
the depletion of HMGA proteins increases the sensitiv-
ity of cancer cells to radio- and chemo-therapeutic
drugs, the block of the HMGA expression could
represent a new therapeutic tool to reduce the resistance
of cancer cells to genotoxic anti-cancer therapies. The
differential expression of HMGA in neoplastic and
normal cells should also allow for the specificity and low
toxicity of such therapy. Moreover, as HMGA proteins
are overexpressed in cancers of different origins,
HMGA-based therapy should have a wide spectrum of
anti-cancer applications.
Materials and methods
Chemicals and treatments
For g-irradiation experiments, cells were irradiated by 6MV
X-ray of a linear accelerator with doses ranging from 0 to
10Gy. For ATM inhibition experiments, cells were treated
with KU-55933 (10 mM) for 1 h before the induction of ATM
kinase activity.
Cell cultures, transfections and plasmids
HEK-293T, HEK-293, MCF-7, SAOS-2, HeLa and FRO cells
were cultured in Dulbecco’s modified eagle medium (DMEM)
with 10% fetal bovine serum (FBS), L-glutamine and
antibiotics (Invitrogen, Carlsbad, CA, USA). PC Cl 3 cells
were grown as previously described (Fedele et al., 2001a, b).
MEFs were established from 14.5 dpc embryos following
standard procedures, and cultured in DMEM with 10%
FBS, L-glutamine, antibiotics and 1% non-essential amino
acids (Invitrogen). NIH-3T3 cells were grown in DMEM with
10% FCS and antibiotics. MEFs and FRO cells were
transfected using Neon Electroporation System (Invitrogen)
according to the manufacturer’s instructions. All the other
transfections were performed by using Lipofectamine 2000
(Invitrogen), as suggested by the manufacturer. The pCEFL-
HA-HMGA1, pCEFL-HA-HMGA2, pCEFL-HA-HMGA1
(1–43) and pCEFL-HA-HMGA2 (1–73) vectors were pre-
viously described (Fedele et al., 2006; Pierantoni et al., 2001;
Pentimalli et al., 2008). The anti-HMGA1 antisense construct
was described elsewhere (Berlingieri et al., 2002). The pFLAG-
ATM previously described (Bakkenist and Kastan, 2003) was
kindly provided by Dr MB Kastan. The pLuc-ATM reporter
plasmid was a kind gift of Dr D Ginsberg (Berkovich and
Ginsberg, 2003). Stable clones (FRO-asHMGA1, FRO-as-
HMGA1-FLAG and FRO-as-HMGA1-ATM) were generated
by co-transfection of the indicated plasmids along with the
pBabe-Puro vector, containing the puromycin resistance gene.
Following the transfection, stable clones were selected
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for puromycin resistance in medium containing 1 mg/ml of this
antibiotic.
Immunoprecipitation and western blot
Protein extraction, western blots and immunoprecipitations
were performed as previously described (Pentimalli et al.,
2008). Antibodies used were anti-FLAG M2 (Sigma, St Louis,
MO, USA), anti-HA Clone 12CA5 (Roche, Branford, CT,
USA), anti-P-ATM-substrate (phospho-Ser/Thr antibody),
anti-CHK2pThr68 (Cell Signalling Technology, Danvers,
MA, USA), anti-ATM S1981p (Rockland, Philadelphia, PA,
USA), anti-p53 DO-1, anti-p-p53 (Ser15), anti-ATM and
anti-vinculin (7F9) (Santa Cruz, Santa Cruz, CA, USA). Anti-
HMGA1 and anti-HMGA2 polyclonal antibodies were
described elsewhere (Pierantoni et al., 2001; Fedele et al.,
2006).
RNA extraction and semi-quantitative (sq)RT–PCR
Total RNA was isolated using TRI-reagent solution (Sigma)
and treated with DNase (Invitrogen). Reverse transcription
was performed according to standard procedures (Applied
Biosystems, Foster City, CA, USA). cDNA was amplified by
PCR using the following primers:.
mmuATM-F: 50-ATTGGGATGCTGTTTTCAGG-30
mmuATM-R: 50-TAGCCTGGGTGCTCTTTTGT-30
mmup21-F: 50-TCCACAGCGATATCCAGACA-30
mmup21-R: 50-GGCACACTTTGCTCCTGTG-30
mmuActin-F: 50-TCAGAAGGACTCCTATGTGG-30
mmuActin-R: 50-CGCAGCTCATTGTAGAAGGT-30
Quantitative real time–PCR
Total RNAs were treated with Dnase-I (Invitrogen) and
reverse-transcribed using random hexanucleotides as primers
and MuLV reverse transcriptase (Perkin-Elmer, Waltham,
MA, USA), following manufacturer’s instructions. Quantita-
tive real time–PCR was performed with the SYBR Green PCR
Master Mix (Applied Biosystems) under the following condi-
tions: 10min at 95 1C followed by 40 cycles (15 s at 95 1C and
1min at 60 1C). Subsequently, a dissociation curve was run to
verify amplification specificity. We used the 2–CT method to
calculate the relative expression levels (Livak and Schmittgen,
2001). All the experiments were performed three times in
triplicate and the mean±s.d. was reported. Primers specific for
the glucose-6-phosphate dehydrogenase (G6PD) were used for
normalization of real time–quantitative PCR data. The
following primer sequences were used to amplify the indicated
genes:
ATM-F: 50-TCTCAAGCAGATGATCAAGAAGTT-30
ATM-R: 50-TGACTTTGAGACCTGCATCATT-30
G6PD-F: 50-CAGCGGCAACTAAACTCAGA-30
G6PD-R: 50-TTCCCTCAGGATCCCACAC-30.
Luciferase assay
Cells were transfected with 1 mg of pLuc-ATM and with
pCEFL-HA-HMGA1 or pCEFL-HA-HMGA2 expression
vectors, together with 0.5-mg of pCMV-Renilla. Luciferase
and Renilla activity were assessed with the Dual-Light
Luciferase system (Promega, Fitchburg, WI, USA), 48 h after
the transfection. The Luciferase activity was normalized for
the Renilla activity. All the experiments were performed three
times in triplicate and the mean±s.d. was reported.
Chromatin-immunoprecipitation assay
Chromatin-immunoprecipitation assays were carried out with
a chromatin-immunoprecipitation assay kit (Upstate Biotech-
nology, Lake Placid, NY, USA) according to manufacturer’s
instructions. Chromatin was sonicated on ice to an average
length of about 400 bp with a Branson sonicator. Sonicated
chromatin was then immunoprecipitated using anti-HA anti-
body (Santa Cruz) or normal rabbit IgG as negative control.
Input and immunoprecipitated DNA were analyzed by PCR
with AmpliTaq gold DNA polymerase (Applied Biosystems).
Primers used were:
mmuATMprF: 50-ATTGGGATGCTGTTTTCAGG-30
mmuATMprR: 50-TAGCCTGGGTGCTCTTTTGT-30
hsaATMprF: 50-AACACAGCGACAGCTCCTG-30
hsaATMprR: 50-AGTGACGACAGTTCCGAAGG-30
hsaATMpr-1000F: 50-GGGCTAGAAAACGTTCAAC-30
hsaATMpr-800R: 50-CTTTGTAGAGAGACCTTCCTG-30
hsaATMpr-800F: 50-CAGGAAGGTCTCTCTACAAAG-30
hsaATMpr-600R: 50-GGATTCGGAAGGAAAGTCAG-30
hsaATMpr-600F: 50-CTGACTTTCCTTCCGAATCC-30
hsaATMpr-400R: 50-GCCAAAGGTTTTCCCTTGG-30
hsaATMpr-400F: 50-CCAAGGGAAAACCTTTGGC-30
hsaATMpr-200R: 50-GTCGCTGTGTTTGCTTTAAC-30
hsaATMpr-200F: 50-GTTAAAGCAAACACAGCGAC-30
hsaATMpr-50R: 50-CAAGTCTGAGGACGGAAGTG-30.
Comet assay
MEFs and FRO cells irradiated or not with 4 and 5Gy of IR,
respectively, were allowed to repair the DNA for 0 and 3 h in
complete medium and then processed for the COMET assay
(Trevigen, Helgerman, CT, USA) following manufacturer’s
instructions. Cell images were analyzed using COMET Score
(TriTek, Annandale, VA, USA). Comet tail moment was used
as the measure of DNA damage. In each experiment, 100
comets were measured per experimental point and the
mean±s.d. was reported.
Senescence assay
Early-passage MEFs were treated as described in results, and
SA-b-gal activity was assessed by using Senescent Cells
Staining kit (Sigma) following the manufacturer’s instructions.
Cells were analyzed with light microscopy to determine the
percentage of senescent cells. At least 20 fields for each
experimental point were analyzed. Reported values are the
mean±s.d. of three independent experiments.
Clonogenic assay
Cells were seeded at a density of 103 cells per 35-mm dish. After
1 day, cells were treated with different doses of IR. After 10
days, cells were stained with 500mg/ml of crystal violet in 20%
methanol, and resulting colonies were counted. The colony
counts obtained were normalized for the untreated controls.
The mean±s.d. of three independent experiments performed
in triplicate was reported.
Cell-cycle analysis
Twenty-four hours following the seeding, cells were exposed to
5Gy of IR. Where indicated, cells were also treated with
0.2mg/ml of nocodazole, following the IR treatment. Cells
were harvested at different time-points, fixed with ice-cold
70% ethanol, treated with RNase-I (Invitrogen) and stained
with 10 mg/ml of propidium iodide. Cells were sorted on a
FACS-Calibur flow cytometer (Becton Dickinson, San Diego,
CA, USA), and the results were analyzed with ModFit
software, 3.2 version (Verity Software House). Experiments
were performed in triplicate and representative cell-cycle
profiles were reported.
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BrdU incorporation analysis
Twenty-four hours following the seeding, cells were treated
with 2mM thymidine for 16 h, then washed twice with PBS and
cultured for 8 h in complete medium. Cells were then treated
again with 2mM thymidine for 17 h, to synchronize them in G1
phase of the cell cycle. Following the thymidine double block,
cells were treated with 5Gy of IR, and then cultured in
complete medium containing 1mM BrdU and harvested at
different time-points. Harvested cells were fixed and stained
using the BrdU Flow Kit (BD Pharmingen, San Diego, CA,
USA), according to the manufacturer’s instructions. Stained
cells were analyzed by flow cytometry, as described above.
The assay was performed three times in triplicate and the
mean±s.d. was reported.
Apoptosis assays
Twenty-four hours after the seeding, FRO and FRO-
asHMGA1 were untreated or exposed to 5Gy of IR. Cells
were then harvested after 24 h and stained with 10 mg/ml of
propidium iodide and FITC-annexin-V antibody (BD Bios-
ciences, San Diego, CA, USA), following manufacturer’s
instructions. Annexin-V-propidium iodide positive cells were
analyzed using FACS-Calibur flow cytometer (Becton Dick-
inson). Experiments were performed in triplicate and repre-
sentative annexin-V profiles were reported. Apoptosis was also
quantified by measuring caspase 3 and 7 activation following
the exposure to 2.5 or 5Gy of IR, using Caspase-Glo 3/7 assay
(Promega) according to the manufacturer’s instructions
on a Bio-Tek Synergy HT multi-detection microplate reader.
The assay was performed three times in triplicate and the
mean±s.d. was reported.
Statistical analysis
Student’s t-test was used to determine significance. All error
bars represent the s.d. of the mean. Statistical significance for
all the tests, assessed by calculating the P-value, was o0.01.
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Downregulation of HMGA-targeting microRNAs has a critical role in
human pituitary tumorigenesis
D Palmieri1, D D’Angelo1, T Valentino1, I De Martino1, A Ferraro1,4, A Wierinckx2, M Fedele1,
J Trouillas3 and A Fusco1,4
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Previous studies have demonstrated that high mobility
group A proteins have a critical role on the onset of
human pituitary adenomas. Indeed, both high mobility
group A (HMGA) genes are overexpressed in pituitary
adenomas, and consistently transgenic mice overe-
xpressing either the Hmga1 or the Hmga2 gene develop
mixed growth hormone/prolactin (GH-PRL)-secreting
pituitary adenomas. Trisomy of chromosome 12, where
HMGA2 is located, and/or amplification of the HMGA2
gene locus account for the HMGA2 overexpression in
most human prolactinomas. Conversely, HMGA1 over-
expression is not associated to any rearrangement or
amplification of the HMGA1 locus. We have first
identified micro RNAs (miRNAs) able to target both
HMGA1 and HMGA2 messenger RNAs. Then, all of
these miRNAs have been found downregulated in
pituitary adenomas of different histotypes, compared
with normal pituitary. Interestingly, their downregulation
was also observed in nonfunctioning pituitary adenomas
where HMGA2 overexpression is not associated to any
alteration of the HMGA2 locus. Functional studies
show that all these HMGA-targeting miRNAs inhibit
the proliferation of the rat pituitary adenoma cell line
GH3. Therefore, these results indicate that the down-
regulation of the miRNAs able to target the HMGA genes
could contribute to increase HMGA protein levels in
human pituitary adenomas, and then to pituitary tumor-
igenesis.
Oncogene advance online publication, 5 December 2011;
doi:10.1038/onc.2011.557
Keywords: HMGA; pituitary adenoma; microRNA
Introduction
Autoptic and radiological imaging studies have demon-
strated that pituitary adenomas are very common in the
general population, accounting for 10–15% of all
intracranial tumors (Kovacs and Horvath, 1986; Mon-
son, 2000; Daly et al., 2009; Melmed, 2011). Pituitary
adenomas are clinically classified on the basis of their
hormonal activity in vivo. Prolactin (PRL)-, gonado-
tropin (luteinizing hormone/follicle-stimulating hor-
mone)- and growth hormone (GH)-secreting adenomas
are the most frequent type of pituitary adenomas,
whereas adenocorticotroph (ACTH (adrenocorticotro-
pic hormone))- and tireotroph (TSH (thyroid-stimulat-
ing hormone))-secreting adenomas are very rare (Daly
et al., 2006, 2009; Melmed, 2011). Moreover, about one-
third of pituitary adenomas are not associated to
hormone hypersecretion, and are classified as nonfunc-
tioning pituitary adenomas (NFPA) (Daly et al., 2006,
2009; Fernandez et al., 2010). Commonly, both func-
tioning and nonfunctioning adenomas are noninvasive,
and their morbidity is mainly because of inappropriate
secretion of pituitary hormones or symptoms of
an intracranial mass, such as visual disturbance and
headaches (Melmed, 2011).
Several studies indicate that high mobility group A
(HMGA) proteins have a causal role in pituitary cell
transformation. HMGAs are a family of small non-
histone chromatin proteins that include four members,
HMGA1a, HMGA1b, HMGA1c (encoded by the
HMGA1 gene through alternative splicings) and
HMGA2 (encoded by the homonymous gene) (Johnson
et al., 1989). HMGA proteins do not have transcrip-
tional activity per se, however by interacting with the
transcriptional machinery they alter the chromatin
structure and, thereby, regulate, negatively or positively,
the transcriptional activity of several genes and micro
RNAs (miRNAs) (Thanos and Maniatis, 1992; Thanos
et al., 1993; De Martino et al., 2009a).
HMGA expression is almost undetectable in differ-
entiated adult tissues, whereas it is expressed highly
during embryogenesis (Zhou et al., 1995; Chiappetta
et al., 1996). Conversely, HMGA overexpression is
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a constant feature of human malignant neoplasms, and
rearrangements of the HMGA genes are frequently
associated with human benign tumors of mesenchymal
origin (Ashar et al., 1995; Schoenmakers et al., 1995;
Fedele and Fusco, 2010). Several studies have demon-
strated that HMGA proteins have a critical role in
neoplastic transformation. In fact, blockage of HMGA
synthesis prevents rat thyroid cell transformation by
murine-transforming retroviruses (Berlingieri et al.,
1995, 2002), and an adenovirus carrying the HMGA1
gene in the antisense orientation induces apoptotic cell
death in anaplastic human thyroid carcinoma cell lines,
but not in normal thyroid cells (Scala et al., 2000).
Moreover, transgenic mice overexpressing the Hmga1 or
the Hmga2 gene under an ubiquitous promoter develop
several malignant or benign neoplasias, including mixed
GH/PRL pituitary adenomas (Baldassarre et al., 2001;
Fedele et al., 2002, 2005). The involvement of the
HMGA proteins also in human pituitary adenomas was
further confirmed by the observed overexpression of
both HMGA genes in these neoplasias (Finelli et al.,
2002; Pierantoni et al., 2005; De Martino et al., 2009b;
Wang et al., 2010). In the case of HMGA2, its
overexpression is associated, in most of the PRL tumors,
but less frequently in NFPAs, with gain of chromosome
12 (trisomy/tetrasomy), the most frequent cytogenetic
alteration in PRL adenomas, and overrepresentation of
the HMGA2 locus (region 12q14-15) or structural
rearrangements of chromosome 12 (Fedele et al.,
2010). Conversely, no rearrangement or amplification
of the HMGA1 locus have been detected in pituitary
adenomas, even though HMGA1 overexpression is a
constant feature of these tumors (De Martino et al.,
2009b; Wang et al., 2010).
Recent studies have shown that HMGA protein levels
are regulated by miRNAs (Lee and Dutta, 2007; De
Martino et al., 2009a), a class of small (19–25 nucleo-
tides) noncoding RNAs involved in temporal and tissue-
specific eukaryotic gene regulation (Lagos-Quintana
et al., 2002) by binding the 30-untranslated region
(UTR) of target messenger RNAs (mRNAs) and
inducing mRNA degradation or inhibition of its
translation (Bartel, 2004; Calin and Croce, 2006).
Indeed, the loss of HMGA2 30-UTR, frequently
detected in benign tumors of mesenchymal origin,
results in the lack of inhibitory control of HMGA2
expression by different miRNAs (Hebert et al., 2007;
Lee and Dutta, 2007), thereby leading to HMGA2
protein overexpression that accounts for cell transfor-
mation.
Therefore, the aim of our work has been to investigate
whether HMGA1/2 overexpression occurring in human
pituitary adenomas may be also dependent on altered
expression of miRNAs that are able to target the
HMGA1/2 genes. The validation of such a hypothesis
would account for the overexpression of the HMGA
proteins in NFPAs, where modifications at the HMGA2
locus are rarely observed, and in all the pituitary
adenomas where the HMGA1 overexpression is asso-
ciated neither to rearrangements nor to amplification of
the HMGA1 locus.
Starting from a bioinformatic approach using the
miRo’ web system (Lagana` et al., 2009, http://ferrolab.
dmi.unict.it/miro/), we identified and validated new
miRNAs targeting highly evolutionarily conserved
sequences of the 30-UTR of HMGA1 and HMGA2
mRNAs. Then, we found a downregulated expression of
these miRNAs, and other previously described HMGA-
targeting miRNAs, in human pituitary adenomas in
comparison with the normal pituitary gland. Finally,
functional studies demonstrated that all the analyzed
HMGA-targeting miRNAs inhibit the proliferation of a
rat pituitary adenoma cell line, suggesting a critical role
of their downregulation in pituitary tumorigenesis.
Results
Identification of HMGA-targeting miRNAs
In order to identify potentially conserved miRNAs
being able to downmodulate the expression of both the
HMGA proteins, we used the miRo’ web system that
includes Targetscan, Pictar and Miranda, and provides
miRNA phenotype associations in humans (Lagana`
et al., 2009). This analysis identified miR-15ab, miR-16,
miR-26ab, miR-196ab and Let-7a as potential HMGA-
targeting miRNAs. Interestingly, the targeting sites of
these HMGA-targeting miRNAs on the 30-UTR of
HMGA1 and HMGA2 are extremely conserved in
human, mouse and rat. Moreover, it is noteworthy that
these five miRNAs were associated by the web system to
57 cellular processes, including those in which HMGA
proteins have been previously demonstrated to be
involved, such as cell proliferation, differentiation,
DNA-repair, chromatin modification and regulation of
transcription (Fusco and Fedele, 2007; Fedele and
Fusco, 2010). The direct targeting of HMGA1 by
miR-16 (Kaddar et al., 2009), and of HMGA2 by
Let-7a (Lee and Dutta, 2007) and miR196ab (De
Martino et al., 2009a) was previously reported. More-
over, previous studies showed that miR-26a regulates
HMGA2 expression (Lee et al., 2011). The targeting
sites of miRo’-predicted miRNAs on HMGA1 and
HMGA2 30-UTR are represented in Figure 1. Then, to
validate that HMGA1 and HMGA2 were targets of the
selected microRNAs, MEG-01 cells, which express
significant levels of both HMGA1 and HMGA2
proteins, were transfected with miR-15a, miR-16,
miR-26a, miR-196a2 and Let-7a synthetic precursors,
and HMGA protein levels were evaluated after 72 h by
western blotting (Figure 2a). As shown in Figure 2a,
HMGA1 and HMGA2 protein levels were significantly
reduced in cells transfected with each of the predicted
miRNAs, in comparison with the cells transfected with
the scrambled oligonucleotide. Interestingly, quantita-
tive real-time (qRT)–PCR (qRT–PCR) experiments
(Figure 2b) showed that both HMGA1 and HMGA2
mRNAs were reduced following the transfection of
all the analyzed miRNAs (Figure 2b). Interestingly, Let-
7a resulted the most efficient miRNA in the down-
regulation of both HMGA1 and HMGA2 mRNAs.
Conversely, miR-196a2 and miR-15 showed the lowest
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efficiency of downregulation of HMGA1 and HMGA2
mRNAs, respectively.
To validate the direct inhibition of HMGA proteins
by these miRNAs, we used two pGL-3-CTRL vectors
containing the HMGA1 or HMGA2 30-UTR cloned
downstream the firefly luciferase gene. These reporter
vectors were transfected in MEG-01 cells along
with synthetic precursor of miR-15, miR-16, miR-26a,
miR-196a2 and Let-7a, and luciferase activity was
assessed 24 h after the transfection. As shown in
Figures 2c and d, overexpression of all the predicted
HMGA-targeting miRNAs significantly reduced lucifer-
ase activity, demonstrating that the inhibition of
HMGA protein expression by these miRNAs was
dependent on their direct binding to the 30-UTR of
HMGA1 and HMGA2. Moreover, as our findings
indicate that miR-15 was able to target both HMGA
mRNAs, we also performed luciferase assays using
pGL-3-CTRL vectors containing the HMGA1 or
HMGA2 30-UTR where the miR-15 and miR-16
targeting sites were deleted. Our results show that both
HMGA1 and HMGA2 30-UTR deletion mutants were
not affected by miR-15 or miR-16 transfection (Supple-
mentary Figure 1).
Taken together, our data clearly demonstrate that
both HMGA proteins are direct targets of miR-15,
miR-16, miR-26a, miR-196a2 and Let-7a.
Figure 1 Binding sites of HMGA1/2-targeting miRNAs. Sche-
matic representation of human HMGA1 and HMGA2 30UTR, and
the relative position of the predicted binding sites for HMGA-
targeting miRNAs, according to Targetscan. White and black bars
indicate previously described and novel identified binding sites,
respectively.
Figure 2 Direct inhibition of HMGA1 and HMGA2s by HMGA-targeting miRNAs. (a) Western blot using anti-HMGA1 and
HMGA2 antibodies on MEG-01 total cellular extracts previously transfected with the indicated synthetic miR precursor or scramble
oligonucleotide. b-Actin was used for normalization. (b, c) qRT–PCR on total mRNA from MEG-01 cells transfected as in
(a). HMGA1 (b) and HMGA2 (c) mRNA levels were normalized for endogenous G6PD levels. The mean±s.d. of three independent
experiments is reported. (d, e) Luciferase assay on MEG-01 cells co-transfected with the indicated Luc-HMGA1-30UTR (d) or Luc-
HMGA2-30UTR (e), and pCMV renilla (d, e) reporter vectors along with the indicated synthetic miRNA precursors. Relative firefly
luciferase activity levels were normalized for Renilla luciferase activity. The mean±s.d. of three independent experiments performed in
triplicate is reported. *Po0.05 compared with scramble transfected cells.
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HMGA-targeting miRNAs are downregulated in human
pituitary adenomas
Cytogenetic alterations accounting for the increased
HMGA2 gene dosage have been frequently observed
only in prolactinomas (Finelli et al., 2002) and in a
subset of NFPA (Pierantoni et al., 2005), whereas
neither rearrangement nor amplification of the HMGA1
locus has been detected in human pituitary adenomas.
Then, the next step of our work was to analyze the
expression of miR-15, miR-16, miR26a, miR-196a2 and
Let-7a in a panel of 41 human pituitary adenomas,
including 14 prolactinomas, 9 GH pituitary adenomas
and 18 NFPA, by qRT–PCR. As shown in Figures 3a-e,
all the selected HMGA-targeting miRNAs were drasti-
cally reduced in almost all the analyzed human pituitary
adenomas, regardless of the histotype, when compared
with the normal pituitary gland. Consistently, with the
downregulation of these HMGA-targeting miRNAs that
act also at mRNA level, an increase in the HMGA1 and
HMGA2-specific mRNAs was observed in all the
analyzed pituitary adenomas. In fact, the analysis of
the HMGA1 and HMGA2 expression in the same
samples studied herein for miRNA expression has been
already reported in another recent study from our group
(De Martino et al., 2009b).
This result further suggests that reduced levels of
HMGA-targeting miRNAs could represent a novel
potential mechanism accounting, at least in part, for
HMGA upregulation in human pituitary adenomas.
HMGA-targeting miRNAs negatively regulate pituitary
cell proliferation
To investigate the functional role of HMGA-targeting
miRNA downregulation in pituitary tumorigenesis, we
determined the effects of the overexpression of these
miRNAs on the cell growth of a GH/PRL rat pituitary
cell line (GH3), which expresses high levels of HMGA1
but not of HMGA2.
The overexpression of HMGA-targeting miRNAs
was achieved by transfecting different expression vectors
(pMIRNA1) containing the precursor sequences of
the miRNAs of our interest and the gene encoding the
green fluorescent protein (GFP), in order to identify
the efficiently transfected cells. As far as the expression
Figure 3 HMGA-targeting miRNAs downregulation in human pituitary adenomas. Quantification of HMGA-targeting miRNAs
from human pituitary adenoma samples. Data reported are expressed in log scale, and mean±s.d. is reported. RNU6 was used for
normalization.
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vector for miR-15 and miR-16 is concerned, we used a
pMIRNA vector, which contains the entire miR-15-16
cluster. The expression levels of the analyzed miRNAs
are reported in Figure 4a.
First, GH3 cells were transfected with the indicated
miRNA expression vectors or the empty vector, and
HMGA1 protein and mRNA levels were assessed by
western blot and qRT–PCR. As shown in Figures 4b
and c, overexpression of all the HMGA-targeting
miRNAs reduced both HMGA1 protein and mRNA,
compared with the empty vector-transfected cells.
Second, we analyzed the growth and the viability of
GH3 cells following the overexpression of HMGA-
targeting miRNAs. GH3 cells were transiently trans-
fected with the synthetic precursors of miR-15, miR-16,
miR-26a, miR-196a2 and Let-7a, and counted each day
for 4 days. Figures 5a–d show that the growth rate
of GH3 following the transfection of the HMGA-
targeting miRNAs was lower compared with the cells
transfected with the scrambled miRNA. Similar results
were also obtained by transfecting synthetic precursors
of miR-15, miR-16, miR-26a, miR-196a2 and Let-7a in
MEG-01 cells (Supplementary Figure 2A). Moreover,
GH3 cells were also transfected during the seeding in 96-
wells, and cell viability was measured by XTT prolifera-
tion assay 24 and 72 h following the transfection. As
shown in Figure 5e, GH3 cells overexpressing HMGA-
targeting miRNAs displayed, at 72 h, a lower number of
viable cells compared with the empty vector-transfected
cells. Third, we performed a colony assay co-transfect-
ing the pMIRNA miR-expression vectors or the
corresponding empty vector in GH3 cells along with a
pBABE-Puro plasmid, containing the puromycin-resis-
tance gene. Cells were cultured in puromycin-containing
medium, and 15 days after the transfection the number
of GFP-positive colonies was counted. As shown in
Figure 5f and Supplementary Figure 3, the transfection
of each HMGA-targeting miRNA led to a drastic
reduction of the number of colonies in comparison with
the GH3 cells transfected with the empty vector. The
same experiment was also performed co-transfecting the
pMIRNA miR-expression vectors or the corresponding
empty vector in MEG-01 cells. Interestingly, HMGA-
targeting miRNAs reduced the colony formation ability
also in this cellular context, even though the inhibitory
effects were less drastic than those observed on pituitary
GH3 cells (Supplementary Figure 2B).
These results indicate that HMGA-targeting miRNAs
are able to impair cell growth, and that they have a
critical role in the control of pituitary cell proliferation.
Discussion
Overexpression of HMGA proteins is a common feature
of human pituitary tumors. Indeed, it has been shown that
HMGA2 gene is frequently amplified and overexpressed
in human prolactinomas (Finelli et al., 2002) and, less
often, in NFPAs (Pierantoni et al., 2005), and over-
expression of theHMGA1 gene has been constantly found
in human pituitary adenomas (De Martino et al., 2009b;
Fedele et al., 2010; Wang et al., 2010). Accordingly,
Figure 4 HMGA-targeting miRNAs affect HMGA expression in rat pituitary adenoma cells. (a) GH3 cells were transfected with the
indicated pMIRNA1 miR-expression vectors and relative miRNA levels were analyzed by qRT–PCR. miRNA levels were normalized
for endogenous RNU6 levels. The mean±s.d. is reported. (b) Western blot analysis of HMGA1 protein levels in cells transfected as in
(a). b-Actin was used for normalization. (c) qRT–PCR analysis of HMGA1 mRNA levels in cells transfected as in (a). mRNA levels
were normalized for endogenous G6PD levels. The meanþ s.d. of three independent experiments is reported. *Po0.05 compared with
scramble transfected cells.
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transgenic mice ubiquitously overexpressing Hmga1,
Hmga2 or the truncated form of Hmga2 (Hmga2/T)
spontaneously develop GH/PRL pituitary adenomas
(Fedele et al., 2002, 2005), suggesting that both these
genes might be considered as specific oncogenes for
pituitary cell transformation (Fedele et al., 2010).
Several studies have widely explored the potential
mechanisms of HMGA-dependent pituitary oncogen-
esis, and our group has demonstrated the involvement
of HMGA proteins in the positive regulation of E2F1
activity (Fedele et al., 2006) and Ccnb2 expression
(De Martino et al., 2007) resulting in pituitary cell cycle
dysregulation and development of pituitary adenomas.
However, the so far identified cytogenetic alterations
(gene amplifications, chromosome overrepresentation
or formation of derivative chromosomes) affecting
HMGA1 and HMGA2 loci or the chromosomes where
HMGA genes are located have not been detected in all the
human pituitary adenomas even though almost all of them
overexpress the HMGA proteins. Therefore, in the present
study, we propose that overexpression of HMGA1 and
HMGA2 in pituitary tumors might be dependent on the
downregulation of HMGA-targeting miRNAs. Indeed, by
using the miRo’ bioinformatic tool for the prediction of
miRNA-targeting sites, we identified miR-15, miR-16,
miR-26ab, miR-196ab and Let-7a targeting sites on the
30-UTRs of both HMGA1 and HMGA2.
The direct targeting of HMGA1 by miR-16 (Kaddar
et al., 2009), and of HMGA2 by Let-7a (Lee and Dutta,
2007) and miR-196a2 (De Martino et al., 2009a) has
been previously described. Moreover, reduced levels of
HMGA2 upon miR-26a transfection were also observed
(Lee et al., 2011). However, our present results clearly
indicate that miR-16 is also able to directly target
HMGA2, and that Let-7a and miR-196a2 target
HMGA1. Finally, we first demonstrate the direct
targeting of both HMGA genes by miR-26a and
miR-15. It is noteworthy that all these HMGA-inhibit-
ing miRNAs are able to affect the stability of the
HMGA1 and HMGA2-specific mRNAs.
Based on these findings, we analyzed the expression
levels of HMGA-targeting miRNAs in a panel of 41
human pituitary adenomas including different histo-
types. Our data show that all the analyzed miRNAs
resulted strongly downregulated in all the samples
analyzed, regardless of the pituitary tumor histotype,
and their expression is inversely correlated with that of
the HMGA genes.
These results are in agreement with previously
published data indicating the downregulation of miR-
15/16 (Bottoni et al., 2005) and of Let-7a (Qian et al.,
2009) in human pituitary adenomas.
Transfection experiments demonstrated that HMGA-
targeting miRs are able to reduce HMGA1 levels also in
GH3, a rat GH/PRL pituitary cell line, and that all
the analyzed HMGA-targeting miRNAs significantly
reduced cell growth. These results were also confirmed
by colony assay experiments showing that GH3 cells
transfected with the HMGA-targeting miRNAs did not
form colonies, unlike the empty vector-transfected cells,
but remained in a single-cell state. These data suggest
that HMGA-targeting miRNAs are able to negatively
regulate the pituitary cell cycle progression through the
downregulation, at least in part, of HMGA proteins,
whose overexpression, as discussed above, results in
pituitary cell cycle dysregulation.
Figure 5 HMGA-targeting miRNAs negatively affect rat pituitary adenoma cell growth and viability. (a–d) GH3 cells were transiently
transfected with synthetic miRNA precursor for miR-15 (a), miR-16 (a), miR-26a (b), miR-196a2 (c) and let-7a (d), and counted at
different time points. The mean±s.d. of three independent experiments is reported. *Po0.05 compared with scramble transfected cells.
(e) MTT assay on GH3 cells transfected as in Figure 4, 72 h after the transfection. Metabolic activity at 24 h was used for
normalization. The mean±s.d. of three independent experiments is reported. *Po0.05 compared with empty vector transfected cells.
(f) GH3 cells were transfected with the indicated pMIRNA miR-expression vectors or the empty vector, along with the pBABE-puro
plasmid, and cultured in puromycin-containing medium for 15 days. Fluorescent colonies (>30 cells) were counted. Data reported are
the mean±s.d. of three independent experiments performed in triplicate. *Po0.05 compared with empty vector transfected cells.
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These results present potential clinical implication,
suggesting a new therapeutic approach for the most
aggressive forms of pituitary adenomas based on the
downregulation of HMGA proteins through the re-
storation of HMGA-targeting miRNAs. Moreover, as
HMGA proteins have been found overexpressed in
almost all human malignant neoplasias, where their
abundance correlates with a poor prognosis (Fusco and
Fedele, 2007), it is likely that downregulation of
HMGA-targeting miRNAs might be also involved in
the pathogenesis of several highly aggressive human
malignancies, and, therefore, a miRNA-based abroga-
tion of HMGA expression could represent a novel
approach for the therapy of human neoplasias.
Materials and methods
Cell lines and transfections
MEG-01 were cultured in Rosewell Park Memorial Institute
medium containing 10% fetal bovine serum supplemented with
penicillin and streptomycin. GH3 cells were grown in Dulbec-
co’s Modified Eagle medium containing 10% fetal bovine serum
supplemented with penicillin and streptomycin. Cell lines were
grown in a humidified atmosphere of 95% air and 5% CO2, at
37 1C. For transfection of miRNA oligonucleotides, cells were
transfected with 50nmol/ml pre-miR miRNA precursors or a
control non-targeting scrambled oligonucleotides (Ambion,
Austin, TX, USA) using siPORT neoFX Transfection Agent
(Ambion). For pMIRNA1 expression vectors, cells were
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’s instructions.
Plasmids and constructs
The 30-UTR region of HMGA2 gene, including binding sites
for miR-15, miR16, miR26ab, miR-196a and let-7a was
previously described (De Martino et al., 2009a). The 30-UTR
region of the HMGA1 gene, including binding sites miR-15,
miR16, miR26ab, miR-196a and let-7a was amplified by PCR
from human genomic DNA by using the following primers:
30-UTR-HMGA1-F 50-GGCCTCTAGATTCCTCTGTTC
ACAAACTAC-30
30-UTR-HMGA1-R 50-GGCCTCTAGATTCAAGTAACT
GCAAATAGG-30
The amplified fragment was cloned into pGL3-Control Firefly
luciferase vector (Promega, Fitchburg, WI, USA) at the XbaI
site immediately downstream from the stop codon of luciferase.
The Renilla luciferase vector (pRL-CMV) was purchased from
Promega. MiRNA Precursor Constructs expressing the miR-15/
16 cluster, miR-26a, miR-196a2 and let-7a under the transcrip-
tional control of the CMV promoter and the GFP gene were
purchased from SBI System Biosciences (Mountain View, CA,
USA). HMGA1 and HMGA2 30-UTR deletion mutants, where
the miR-15/16 targeting sites were deleted, were generated by
site-directed mutagenesis using the QuikChange II Site-Directed
Mutagenesis Kits (Stratagene, Santa Clara, CA, USA), accord-
ing to the manufacturer’s instructions. Primers used were:
30-UTR-HMGA1-MutF: 50-CTTCGACATCCGTCATGC
TACCAGCGCCA-30
30-UTR-HMGA1-MutR: 50-TGGCGCTGGTAGCATGA
CGGATGTCGAAG-30
30-UTR-HMGA2-MutF: 50-AACGAATTTACAGTCTAGTA
CTTATTACATACACAAGCAATGCAAGAAAAAAAC-30
30-UTR-HMGA2-MutR: 50-GTTTTTTTCTTGCATTGCT
TGTGTATGTAATAAGTACTAGACTGTAAATTCGTT-30
Protein extraction, western blotting and antibodies
Cells were lysed in lysis buffer containing 1% NP40, 1mM
EDTA, 50mM Tris–HCl (pH 7.5) and 150mM NaCl,
supplemented with complete protease inhibitors mixture
(Roche, Branford, CT, USA). Total proteins were separated
by SDS–polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes (Amersham, Piscataway, NJ, USA).
Membranes were blocked with 5% non-fat dry milk and
incubated with anti-HMGA1 and anti-HMGA2 polyclonal
antibodies, previously described (Pierantoni et al., 2001;
Fedele et al., 2006).
Luciferase target assays
MEG-01 cells were co-transfected in 12-well plates with the
modified firefly luciferase vectors described above, along with
the Renilla luciferase reporter plasmid and the RNA
oligonucleotides. Firefly and Renilla luciferase activities were
measured 24 h after transfection with the Dual-Luciferase
Reporter Assay System (Promega). Firefly activity was
normalized to Renilla activity as the control of transfection
efficiency. Data reported are the averageþ s.d. of three
independent experiments performed in triplicate.
Tissue collection and RNA isolation
Pituitary adenomas were obtained from patients operated
by E Jouanneau Service de Neurochirurgie U300, GHE
Hospices Civils de Lyon. The tumors were selected from the
pathological collection of one of us (JT). For each tumor,
fragments were fixed in the Bouin–Holland fluid and
embbeded in paraffine for pathological diagnosis, including
immunocytochemistry. From the results of pituitary hormone
immunoreactivity, the tumors were classified according to the
WHO classification 2004 into GH-, PRL-, ACTH-, TSH- and
gonadotropin-adenomas. Other fragments were immediately
frozen and stored at ÿ80 1C (Neurobiotec bank, Lyon,
France). We declare that informed consent for the scientific
use of biological material was obtained from all patients.
Total RNA isolation from human-pulverized tumors was
performed with TRIzol reagent (Invitrogen) according to
manufacturer’s instructions. Three samples of total RNA from
human normal pituitary glands obtained at autopsies were
used as controls. The integrity of the RNA was assessed by
denaturing agarose gel electrophoresis (virtual presence of
sharp 28S and 18S bands).
Reverse transcription and (qRT–)PCR
Reverse trascription and qRT–PCR for mature miRNA was
carried out according to manufacturer’s instructions of the
miScript System Kits (Qiagen, Valencia, CA, USA). Reactions
contained miScript Primer Sets (Qiagen), specific for each
analyzed miR and U6 (used to normalize RNA levels). qRT–
PCR analysis for HMGA1 and HMGA2 gene expression was
performed as already described (De Martino et al., 2009b). To
calculate the relative expression levels we used the 2-DDCT
method (Livak and Schmittgen, 2001). Each reaction was
carried out in triplicate and the averageþ s.d. was reported.
Primers specific for the glucose-6-phosphate dehydrogenase
(G6PD) were used for normalization of qRT–PCR data. The
following primer sequences were used to amplify the indicated
genes:
hsa-HMGA1-F 40-CAACTCCAGGAAGGAAACCA-30
hsa-HMGA1-R 50-AGGACTCCTGCGAGATGC-30
hsa-HMGA2-F 50-TCCCTCTAAAGCAGCTCAAAA-30
hsa-HMGA2-R 50-ACTTGTTGTGGCCATTTCCT-30
G6PD-F 50-CAGCGGCAACTAAACTCAGA-30
G6PD-R 50-TTCCCTCAGGATCCCACAC-30
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Growth curves
Exponentially growing GH3 and MEG-01 cells were plated in
6-well plates and transfected with the indicated synthetic
mircroRNA precursors. Cell numbers were determined in
triplicate at daily intervals with a Burker hemocytometer
chamber.
MTT cell proliferation assay
GH3 cells were transfected with 50 nmol/ml pre-miR miRNA
precursor or a control non-targeting scrambled oligonucleo-
tide (Ambion) using siPORT neoFX Transfection Agent
(Ambion). At each time point, 20 ml of Promega’s CellTiter
96 AQueous One Solution was dispensed into each well, and
absorbance at 595 nm was measured to evaluate cell viability.
Data reported are the averageþ s.d. of three independent
experiments performed in triplicate.
Colony assay
Sub-confluent GH3 and MEG-01 cells were transfected with
the above described miR expression vectors along with the
pBabe-Puro plasmid, containing the puromycin-resistance
gene, and selected by using 1mg/ml puromycin. After 15 days,
cells were stained with 500mg/ml of crystal violet in 20%
methanol, and resulting colonies were counted. The
meanþ s.d. of three independent experiments performed in
triplicate was reported.
Statistical analysis
Student’s t-test was used to determine the significance for all
the quantitative experiments. All error bars represent the s.d.
of the average. Statistical significance for all the tests, assessed
by calculating the Po0.05.
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Abstract
We have previously demonstrated that HMGA1B and HMGA2 overexpression in mice induces the
development of GH and prolactin (PRL) pituitary adenomas mainly by increasing E2F1
transcriptional activity. Interestingly, these adenomas showed very high expression levels of
PIT1, a transcriptional factor that regulates the gene expression of Gh, Prl, Ghrhr and Pit1 itself,
playing a key role in pituitary gland development and physiology. Therefore, the aim of our study
was to identify the role of Pit1 overexpression in pituitary tumour development induced by
HMGA1B and HMGA2. First, we demonstrated that HMGA1B and HMGA2 directly interact with
both PIT1 and its gene promoter in vivo, and that these proteins positively regulate Pit1 promoter
activity, also co-operating with PIT1 itself. Subsequently, we showed, by colony-forming assays
on two different pituitary adenoma cell lines, GH3 and aT3, that Pit1 overexpression increases
pituitary cell proliferation. Finally, the expression analysis of HMGA1, HMGA2 and PIT1 in human
pituitary adenomas of different histological types revealed a direct correlation between PIT1 and
HMGA expression levels. Taken together, our data indicate a role of Pit1 upregulation by HMGA
proteins in pituitary tumours.
Endocrine-Related Cancer (2012) 19 123–135
Introduction
Pituitary adenomas are one of the most frequent
intracranial tumours with a prevalence of clinically
apparent tumours close to one in 1000 of the general
population and are the third most common intracranial
tumour type after meningiomas and gliomas
(Scheithauer et al. 2006). They are mostly non-
metastatising monoclonal neoplasms arising from
adenohypophyseal cells in the anterior pituitary, and
exhibit a wide range of hormonal and proliferative
activity. The most common types (about 50%) of
pituitary adenomas are prolactinomas, while GH- or
ACTH-secreting adenomas account for 20 and 10%
of pituitary tumours respectively, and TSH-secreting
adenomas are rare (1%) (Llyod et al. 2004). About one-
third of pituitary adenomas are named non-functioning
adenomas because they do not exhibit signs of
hypersecretion or gonadotrophin adenomas related to
FSH–LH immunoreactivity (Trouillas et al. 1986).
They are usually large tumours diagnosed following
local compressive effects on brain structures and
cranial nerves.
Pituitary tumorigenesis is generally considered a
model of the multi-step process of carcinogenesis, in
which molecular genetic alterations represent the
initialising event that transforms cells, and hormones
and/or growth factors promote cell proliferation (Asa
& Ezzat 2002). However, the molecular events leading
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to pituitary tumour development are still unclear, since
somatic mutations identified in other neoplasias, such
as the BRAF and RAS genes, are rare events in pituitary
adenomas (Lania et al. 2003, De Martino et al. 2007a).
Activating mutations of Gsa (the so-called gsp
mutations) are the most important somatic mutation
in pituitary adenomas, being present in up to 40% of
GH-secreting adenomas (Lyons et al. 1990). Mutations
of MEN1A, the gene mutated in the MEN-1 syndrome,
which includes pituitary adenomas, are uncommon in
sporadic tumours (Zhuang et al. 1997, Schmidt et al.
1999). Similarly, other genes involved in familial
pituitary adenomas, such the AIP gene, responsible for
familial isolated pituitary adenomas, or the CDKN1B
gene, mutated in the MEN-1-like syndrome MEN-4,
have been found to be mutated in about 3% of sporadic
GH-secreting adenoma or never in sporadic pituitary
adenomas respectively (Occhi et al. 2010). However,
epigenetic events, such as hypermethylation and/or
microRNA-dependent impairment of protein trans-
lation, are likely to be responsible for the down-
regulation of gene and/or protein expression associated
with pituitary tumorigenesis (Amaral et al. 2009,
Dudley et al. 2009, Tateno et al. 2010). Moreover, a
parental-specific methylation pattern of the Gsa gene,
responsible for a tissue-specific near-exclusive
expression of Gsa from the maternal allele, is relaxed
in the majority of GH-secreting pituitary adenomas
negative for gsp (Hayward et al. 2001). Therefore, both
genetic and epigenetic alterations appear to be
involved in pituitary tumorigenesis. Our recent studies
have identified a crucial role for the high-mobility
group A (HMGA) proteins in pituitary tumour
development (Fedele et al. 2002, 2005).
HMGA protein family includes four members,
HMGA1A,HMGA1BandHMGA1C, splicing isoforms
of the HMGA1 gene, and HMGA2, encoded by the
HMGA2 gene (Fusco & Fedele 2007). They are small
acidic non-histone nuclear factors that bind the minor
groove of AT-richDNA sequences through their amino-
terminal region containing three short basic repeats, the
so-called AT-hooks (Fusco & Fedele 2007). HMGA
proteins do not have transcriptional activity per se, but
regulate gene expression interacting with other tran-
scription factors andmodifying the structure of DNA, in
order to modulate the formation of stereo-specific
complexes on the promoter/enhancer regions of target
genes (Thanos & Maniatis 1992, Falvo et al. 1995).
Both HMGA genes have a critical role during
embryogenesis, when they are widely expressed,
whereas their expression is absent or low in normal
adult tissues (Zhou et al. 1995, Chiappetta et al. 1996).
Conversely, they are frequently overexpressed in several
human cancers including thyroid (Chiappetta et al.
1998, 2008), prostate (Tamimi et al. 1993,Winkler et al.
2007), cervix (Bandiera et al. 1998), colorectum (Fedele
et al. 1996) and pancreas carcinoma (Abe et al. 2000,
2003), and several studies indicate that HMGA proteins
are causally involved in tumour development (Fusco &
Fedele 2007). In fact, overexpression of both HMGA1
and HMGA2 results in the transformation of rat1a
fibroblast and human lymphoblastoid cells (Wood et al.
2000) while inhibition of their expression prevents
thyroid transformation induced by mouse transforming
retroviruses (Vallone et al. 1997) or induces apoptosis in
two different thyroid anaplastic carcinoma cell lines
(Scala et al. 2000).
Several data support a critical role for HMGA2 (and
probably for HMGA1) in the generation of human
pituitary adenomas (Fedele et al. 2010). Indeed,
HMGA2 was found amplified and overexpressed in a
large set of human prolactinomas (Finelli et al. 2002),
and pituitary adenomas secreting prolactin (PRL) and
GH developed in transgenic mice overexpressing
HMGA1B or HMGA2 (Fedele et al. 2002, 2005). Our
previous studies demonstrated that HMGA2 induces
pituitary tumour development by enhancing E2F1
activity (Fedele et al. 2006). Indeed, following the
interaction with the retinoblastoma protein pRB,
HMGA2 displaces histone deacetylase 1 (HDAC1)
from the pRB/E2F1 complex, increasing E2F1 acetyl-
ation and transcriptional activity. Consistently,
functional loss of E2F1 activity (obtained by mating
Hmga2 transgenic and E2f1 knockout mice) strongly
reduced the incidence of pituitary tumours (Fedele et al.
2006). However, Hmga2 mice still develop pituitary
neoplasias also in an E2f1 knockout background,
although with a lower frequency and a less aggressive
phenotype, suggesting that other molecular pathways
may be involved in pituitary tumour development
induced by HMGA overexpression. Recently, using a
genechip microarray approach, we have shown that
HMGA proteins can contribute to pituitary cell
transformation through the transcriptional modulation
of target genes, such asMia (Cd-rap) (De Martino et al.
2007b) and Ccnb2 (De Martino et al. 2009).
Our previous findings also showed a very abundant
expression of Pit1 (whose expression was not
detectable in adult mouse pituitary) in pituitary
adenomas from Hmga1b and Hmga2 transgenic mice
(Fedele et al. 2002, 2005). PIT1, also named GHF1, is
a member of the POU transcription factor family
(Delhase et al. 1996), and plays a key role in the
specification, expansion and survival of three specific
pituitary cell types (somatotropes, lactotropes and a
subset of thyrotropes) during the development of the
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anterior pituitary (Lefevre et al. 1987, Nelson et al.
1988, Li et al. 1990), and its transcriptional activity
on many genes, such as GH, PRL, TSHB, GHRHR
and PIT1 itself, is crucial for pituitary gland
physiology (Lefevre et al. 1987, Nelson et al. 1988,
Chen et al. 1990, Li et al. 1990, McCormick et al.
1990). Moreover, PIT1 is overexpressed in GH, PRL
and TSH pituitary adenomas (Asa et al. 1993,
Delhase et al. 1993, Friend et al. 1993, Pellegrini
et al. 1994, Pellegrini-Bouiller et al. 1997).
The aim of the present study was to investigate the
role of Pit1 overexpression in the generation of pituitary
adenomas in Hmga1b and Hmga2 transgenic mice.
Here, we demonstrate that both HMGA1B and
HMGA2 bind both PIT1 and PIT1-responsive DNA
elements, thus positively modulating Pit1 promoter
activity. Functional studies show that Pit1 overexpres-
sion enhances pituitary adenoma cell proliferation.
Finally, a correlation was found between PIT1 and
HMGA overexpression in human pituitary adenomas,
further supporting a role of HMGA-mediated PIT1
overexpression in pituitary tumours.
Materials and methods
Plasmids, siRNAs, recombinant proteins and
antibodies
Expression vector containing the V5-tagged full-length
cDNA for Pit1 sub-cloned in the pcDNA3.1/GS vector
was purchased from Invitrogen. HA-tagged HMGA1B
and HMGA2 expression plasmids were previously
described (Fedele et al. 2001, 2006). The PIT1
promoter construct, carrying the region K1321 to
C15, related to the transcriptional start site, of the
human PIT1 gene fused to the luciferase cDNA (PIT-1-
Luc), was a generous gift of Dr M Delhase (Brussels,
Belgium). The pBABE-puro vector was previously
described (Monaco et al. 2001). The siRNA anti-
HMGA1 was purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). GST- and His-
HMGA1B and HMGA2 fusion proteins were
expressed in Escherichia coli strain BL21 (DE3) and
purified using glutathione sepharose or nickel beads
as described previously (Baldassarre et al. 2001,
Pierantoni et al. 2001). Full-length PIT1 protein,
anti-HA (sc-805) and anti-PIT1 supershift antibodies
(sc-442X) were purchased from Santa Cruz
Biotechnology, whereas anti-V5 (R960-25) antibody
was purchased from Invitrogen. Anti-HMGA1 and
anti-HMGA2 antibodies were previously described
(Fedele et al. 2006, Pierantoni et al. 2007).
Cell cultures and transfections
Human embryonic kidney (HEK) 293T, rat pituitary
adenoma GH3 and mouse pituitary adenoma aT3 cells
were cultured in DMEM supplemented with 10% FCS
(GIBCO-BRL, Life Technologies). DNA was trans-
fected by the calcium phosphate procedure, as
described previously (Graham & Van der Eb 1973),
in HEK293T, and by Lipofectamine 2000 (Invitrogen),
according to the manufacturer’s instructions, in GH3
and aT3 cells.
GST pull-down assay, protein extraction and
co-immunoprecipitation
For in vitro protein–protein binding, 5 mg PIT1
recombinant protein were incubated with 5 mg resin
conjugated to GST, GST-HMGA1B or GST-HMGA2
recombinant proteins. Reactions and analysis of the
protein–protein interactions were performed as
described previously (Pierantoni et al. 2001). A similar
procedure was also applied to HEK293T cells tran-
siently transfected with the Pit1-V5 expression vector.
Briefly, 500 mg total protein extracts were incubated
with 5 mg resin conjugated to GST, GST-HMGA1B or
GST-HMGA2 recombinant proteins. The protein–
protein complexes formed on the resin were pulled
down by centrifugation. The resinwaswashed five times
at 4 8C with 1 ml cold NETN buffer containing 0.1%
NP-40, 1 mM EDTA, 50 mM Tris–HCl (pH 7.5),
150 mMNaCl, 20 mM pirophosphate, 0.2 mg aprotinin,
4 mMPMSF, 25 mM sodium fluoride, 10 mM activated
sodium orthovanadate (Sigma) and a cocktail of
protease inhibitors (Roche Applied Science).
Protein extracts were obtained by lysing cells
and tissues in NETN buffer and then processed
for co-immunoprecipitation as described previously
(Pierantoni et al. 2001).
Electrophoretic mobility shift assay
Recombinant proteins (5 ng) were incubated for
15 min at RT in binding buffer (10 mM Tris–
HCl, pH 7.5, 50 mM NaCl, 1 mM DTT, 2 mg BSA,
1 mg poly-dCdG) with a 32P-end-labelled double-
strand (DS) oligonucleotides (specific activity,
8000–20 000 c.p.m./fmol), corresponding to the PIT1
consensus (sc-2541; Santa Cruz Biotechnology) or to
the same element mutated in the PIT1 binding site
(sc-2542). Up to 400-fold excess of specific unlabelled
competitor oligonucleotide was added as the control.
Supershift analysis was carried out by incubating the
reaction mix with 1 mg antibody for 30 min in ice.
The DNA–protein complexes were resolved on 6%
Endocrine-Related Cancer (2012) 19 123–135
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non-denaturing acrylamide gels and visualised by
exposure to autoradiographic films.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was carried
out with an acetyl-histone H3 immune precipitation
assay kit (Upstate Biotechnology, Lake Placid, NY,
USA) according to the manufacturer’s instruction, as
described previously (De Martino et al. 2009). Input
and immunoprecipitated chromatin were analysed by
PCR for the presence of the Pit1 promoter sequence.
PCR were performed with AmpliTaq gold DNA
polymerase (Perkin–Elmer, Monza, Italy). Primers
used to amplify the sequence of the Pit1 promoter
were 5 0-GCACCAACCTATCATTAC-3 0 (forward)
and 5 0-TGCTACTAACACAATTGC-3 0 (reverse).
PCR products were resolved on a 2% agarose gel,
stained with ethidium bromide, and scanned using a
Typhoon 9200 scanner. The intensity of the bands was
quantified by densitometric analysis using ImageQuant
software (GE Healthcare, Milan, Italy).
Luciferase and colony assays
For the luciferase assay, a total of 2!105 cells were
seeded into each well of a six-well plate and transiently
transfected with 1 mg PIT-1-Luc and with the indicated
amounts of HA-HMGA1B and HA-HMGA2, together
with 0.5 mg Renilla and various amounts of the
backbone vector to keep the total DNA concentration
constant. Transfection efficiency, normalised for the
Renilla expression, was assayed with the dual
luciferase system (Promega Corporation). All transfec-
tion experiments were repeated at least three times.
For the colony assay, GH3 and aT3 cells were seeded
at a density of 2.5!106 per 10 mmdish. Two days after,
the cells were transfected with 10 mg pcDNA3.1 or
10 mg pcDNA3.1/Pit1-V5 or 5 mg Pit1 shRNA (Santa
Cruz Biotechnology) or 5 mg scrambled shRNA (Santa
Cruz Biotechnology) plus 2 mg pBABE-puro. After
about 15 days of positive selection in puromycin, the
cells were stained with 500 mg/ml crystal violet in 20%
methanol, and the resulting colonies were counted.
Tissue samples
The human pituitary adenoma samples were obtained
from 46 surgical excision biopsies, including 13 GH
and 33 PRL adenomas) from patients of ’Federico II’
University (Naples) and Neurosurgical Department (Pr
Jouanneau E) of Hospices Civils de Lyon (France).
One part of each pituitary adenoma was saved for
routine histopathology evaluation, including
immunohistochemistry with the systematic detection
of GH, PRL, ACTH, TSH, FSH and LH, and the other
one immediately frozen atK80 8C until the extraction
of nucleic acids. Informed consent for the scientific use
of biological material was obtained from all patients.
RNA extraction and real-time RT-PCR
Total RNA was extracted from tissues using TRI
REAGENT (Molecular Research Center, Inc., Cincin-
nati, OH,USA) solution, according to themanufacturer’s
instructions. The RNA integrity was verified by
denaturing agarose gel electrophoresis (virtual presence
of sharp 28S and 18S bands) and spectrophotometry.One
microgram of total RNA of each sample was reverse-
transcribed with the QuantiTect Reverse Transcription
(Qiagen) using an optimised blend of oligo-dT and
random primers according to the manufacturer’s instruc-
tions. To ensure that RNA samples were not contami-
nated with DNA, negative controls were obtained by
performing the PCR on samples that were not reversed-
transcribed but identically processed. Quantitative PCR
was performed with the SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) as follows:
95 8C for 10 min and 40 cycles (95 8C for 15 s and 60 8C
for 1 min). A dissociation curve was run after each PCR
in order to verify amplification specificity. Each reaction
was performed in duplicate. To calculate the relative
expression levels, we used the 2KDDCt method (Livak &
Schmittgen 2001).
Primer sequences are available upon request.
Statistical analyses
For the comparison between two groups of experi-
ments, Student’s t-test was used. Three or more groups
of experiments were compared using the one-way
ANOVA followed by Tukey’s multiple comparison
test. All results are expressed as meanGS.D. The
statistical significant difference was considered when
P value was !0.05. Linear regression analysis was
performed to determine the association of PIT1 with
HMGA1 or HMGA2 expression levels in human
pituitary adenomas. The square of correlation coeffi-
cient (R2) close to 1 was considered to be indicative of
a significant direct correlation.
Results
HMGA proteins interact with PIT1
To investigate the role of HMGA proteins in the
modulation of PIT1 function, we first hypothesised that
HMGA proteins directly bind PIT1 protein. The finding
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that other members of the POU transcription factor
family, such as Oct-6 and Oct-2A, interact with HMGA
proteins through their POU domain supports this
hypothesis (Abdulkadir et al. 1995, Leger et al. 1995,
Zwilling et al. 1995). Therefore, we performed a GST
pull-down assay incubating the PIT1 recombinant
protein with GST-HMGA1B or GST-HMGA2 fusion
proteins. As shown in Fig. 1A, PIT1 was able to directly
interact with both GST-HMGA1b and GST-HMGA2,
but not with GST alone. To confirm this interaction in a
cellular context, we transfected HEK293T cells with
expression vectors containing the full-length cDNAs for
PIT1, HMGA1b or HMGA2, fused to the V5 (Pit-1-V5)
andHA (HA-HMGA1b andHA-HMGA2) tags respect-
ively. Total cell extracts were immunoprecipitated with
anti-V5 antibody and analysed by immunoblot with
anti-HA antibody. As shown in Fig. 1B (left panels),
HA-HMGA1b and HA-HMGA2 were immunoprecipi-
tated by the anti-V5 antibody only when transfected
along with Pit-1-V5. This result was confirmed by
reverse co-immunoprecipitation carried out by immu-
noprecipitating with anti-HA antibody and analysing
with anti-V5 antibody (Fig. 1B, right panels). The
negative result obtained by blotting for the unrelated
and endogenous E2F1 protein confirmed the specificity
of the PIT1/HMGA interactions. Ethidium bromidewas
added to the immunoprecipitation reaction to prevent
DNA-mediated interaction between proteins. Interest-
ingly, cells co-transfected with PIT1 and each of the
HMGA proteins show more abundant levels of HMGA
proteins than those transfected with HMGA1b or
HMGA2 alone (input in Fig. 1B, middle panels),
suggesting that PIT1 can positively influence their
expression. Western blot anti-V5 or anti-HA antibody,
for samples immunoprecipitated with anti-V5 or anti-
HA antibody respectively was performed to control the
successful immunoprecipitation reactions (Fig. 1B).
Finally, to validate the HMGA/PIT1 interaction in the
context of the pituitary tumours,we pulleddownpituitary
adenoma extracts from Hmga1b or Hmga2 transgenic
mice, where PIT1 is abundantly expressed (Fedele et al.
2002, 2005), from GST-HMGA1B or GST-HMGA2
beads. Figure 1C shows that both GST-HMGA1B and
GST-HMGA2, but not GST, interacted with endogenous
PIT1 protein in transgenic mouse tumours. These data
demonstrate that HMGA proteins are direct molecular
partners of PIT1 both in vitro and in vivo.
HMGA proteins bind to and activate the Pit1
promoter
PIT1 is able to directly regulate the expression of
several genes with a key role in pituitary gland
physiology such as PRL, GH, GHRHR and PIT1 itself
(Lefevre et al. 1987, Nelson et al. 1988, Chen et al.
1990, Li et al. 1990, McCormick et al. 1990). Since
HMGA proteins physically interact with PIT1, we
investigated whether this interaction may affect PIT1
activity. HMGA1B or HMGA2 recombinant proteins
were incubated with a 32P-end-labelled DS oligonu-
cleotide corresponding to the consensus site recognised
by PIT1 in an electrophoretic mobility shift assay
(EMSA). As shown in Fig. 2A, both HMGA1B and
HMGA2 were able to bind the PIT1 responsive
element (Pit-1-RE) in vitro. The specificity of the
binding was assessed using a 100- and 400-fold molar
excess of the specific unlabelled DS oligonucleotide or
a 100-fold molar excess of the same unlabelled, but
single-strand (SS) oligonucleotide as specific and non-
specific competitors respectively. Moreover, the
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Figure 1 In vitro and in vivo interaction between PIT1 and
HMGA proteins. (A) Recombinant PIT1 protein was incubated
with immobilised GST-HMGA1B, GST-HMGA2 or GST alone in
a GST pull-down assay. (B) HEK293T cells were transiently
transfected with the Pit-1-V5, HA-HMGA1B and HA-HMGA2
expression plasmids where indicated. Protein extracts were
immunoprecipitated (IP) with the anti-V5 or anti-HA, and probed
with either anti-HA, anti-V5 or anti-E2F1 antibodies, as
indicated on the right. Proteins detected are indicated on the
left. Ethidium bromide was added to the IP reaction to make
sure that the interaction was not mediated by any contaminating
DNA. Western blot anti-V5 (lower panel) was done as a positive
control of the IP reaction. Fifty micrograms of total cell extracts
before IP were loaded as the control (input). (C) Protein extracts
from pituitary adenoma tissues developed by Hmga1b (blot on
the left) and Hmga2 transgenic mice (blot on the right) were
incubated with immobilised GST-HMGA1B, GST-HMGA2 or
GST alone in a GST pull-down assay, and then probed with
anti-PIT1 antibody.
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binding was also abolished pre-incubating the reaction
mix with anti-HMGA1 and anti-HMGA2 antibodies,
which, as reported previously (Martinez Hoyos et al.
2009), specifically displace HMGA proteins from their
target DNA (data not shown). As shown in Fig. 2B, the
binding of HMGA proteins to the Pit-1-RE does not
interfere with the binding of PIT1 to the same
oligonucleotide. Moreover, as shown by the absence
of a slower migrating spot when both HMGA and PIT1
proteins are incubated with the probe, it appears that
they do not form a unique complex, but independently
bind the same DNA response element. We also used, as
a control of specificity of the PIT1 binding, an
oligonucleotide mutated in a key residue within the
PIT1 consensus site, which was incapable of binding
PIT1 (Fig. 2C, lane 1). Interestingly, this mutant
oligonucleotide still binds HMGA1B with the same
efficiency of the wild-type Pit-1-RE, whereas the
binding to HMGA2 was highly compromised
(Fig. 2C, lanes 2 and 3). Therefore, it is likely that
HMGA1B and HMGA2 do not bind exactly to the
same residues nearby the PIT1 consensus site.
Next, since one of the PIT1 targets is Pit1 gene itself,
we focused on the potential role of HMGA in PIT1-
dependent Pit1 gene regulation in pituitary adenomas.
For this purpose, we first performed a ChIP assay in
pituitary adenomas from Hmga1b or Hmga2 transgenic
mice. Chromatin was immunoprecipitated using
specific anti-HMGA1 or anti-HMGA2 antibody, or
IgG as the negative control, and analysed by PCR using
primers specific for the mousePit1 promoter. Figure 3A
shows the in vivo binding of bothHmga1 andHmga2 to
the Pit1 promoter, while no amplification was obtained
in the negative control. Then, we investigated the
functional effect of the physical interaction between
HMGAproteins and PIT1 on thePIT1 promoter activity
by luciferase assays. HEK293T cells were transiently
transfected with a reporter vector (PIT1-1-Luc),
containing the luciferase gene under the control of
the PIT1 promoter, along with vectors coding for
HA-HMGA1B, HA-HMGA2 or Pit-1-V5 proteins.
As shown in Fig. 3B, only HA-HMGA2, but not
HA-HMGA1B, was able to positively regulate the
activity of the PIT1 promoter. Moreover, a strong and
significant cooperation between HMGA2 and PIT1 was
observed (P!0.001), while HMGA1 only slightly but
significantly increased the positive transcriptional effect
of PIT1 on its promoter (P!0.05). To confirm these
data in a pituitary context, we transiently transfected
GH3 cells, derived from a rat pituitary PRL- and
GH-secreting adenoma expressing high levels of
endogenous PIT1 (Fig. 3D), with HMGA1B or
HMGA2 expression vectors, along with the Pit-1-Luc
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To assess the specificity of the binding, a 100- and 400-fold
excess of unlabelled double-strand (DS) oligonucleotide was
added as a specific competitor, and a 100-fold excess of
unlabelled single-strand (SS) oligonucleotide was added as a
non-specific competitor. (B) EMSA performed with the same
oligonucleotide as in (A), incubated with recombinant PIT1,
His-HMGA1B and His-HMGA2 as indicated. Supershift assay
was performed with anti-PIT1 antibody where indicated. Two
different autoradiographic exposure timeswere needed to allow a
good view of both the binding of HMGA proteins and that of PIT1:
upper panel, 18 h; lower panel, 1 h. (C) The sameEMSAas in (B),
but with an oligonucleotide mutated in the PIT1 consensus site.
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vector. As shown in Fig. 3C, HA-HMGA2 expression
led to a significant increase in Pit1 promoter
activity, while only a slight but not significant increase
was observed after the transfection of the HA-
HMGA1B construct. These data clearly demonstrate
that HMGA2 is able to positively regulate PIT1
promoter activity in co-operation with PIT1, whereas
they suggest thatHMGA1 shows only a veryweak effect
on the regulation ofPIT1 gene expression. The abundant
expression of HMGA1 in GH3 cells, in contrast to the
total absence of HMGA2 expression (Fig. 3D), could
probably account for the lack of a significant effect
of HMGA1 transfection on PIT1 promoter activity.
To further evaluate the role of endogenous HMGA1 on
Pit1 expression in pituitary cells, Pit1 expression was
analysed in GH3 cells interfered for HMGA1, through
an anti-HMGA1 siRNA, in comparison with GH3 cells
treated with a scrambled siRNA. As shown in Fig. 3E,
Pit1 mRNA levels were significantly decreased in cells
knocked down for HMGA1 compared with their
scrambled-treated controls. Therefore, both HMGA1
and HMGA2 play a crucial role in the regulation of Pit1
expression in GH3 cells.
Overexpression of Pit1 increases the
proliferation rate of pituitary adenoma cells
To evaluate the role of Pit1 overexpression in cell
proliferation in a pituitary context, we performed a
colony-forming assay in GH3 cells. As shown in
Fig. 4A, the number of colonies obtained, after
puromycin selection, by transfection of a Pit1
expression vector, was significantly higher (a fourfold
increase) compared with that obtained by transfecting
the empty vector. Consistently, the knock-down of the
endogenous PIT1 in GH3 cells caused a significant
decrease in their growth in a colony-forming assay
(data not shown). Similar results were obtained using a
different pituitary cell type, such as the mouse
gonadotroph cell line aT3. Indeed, as shown in
Fig. 4B, Pit1 overexpression caused a twofold increase
in the number of colonies with respect to the backbone
vector. Since aT3 cells do not express Pit1 normally,
we asked whether the exogenous expression of Pit1
upregulates the classical PIT1 targets, such as Gh and
Ghrhr. To answer this question, we performed
RT-PCR analysis in aT3 cell clones stably expressing
Pit1, with the result that Gh was not expressed in these
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Figure 3 In vivo binding and activation by HMGA of the PIT1 promoter. (A) Chromatin immunoprecipitation (ChIP) assay performed
on pituitary adenomas from Hmga1b and Hmga2 transgenic mice to detect the endogenous in vivo binding of HMGA proteins to the
Pit1 promoter gene, as indicated. As an immunoprecipitation control, IgG was used. Input, PCR products with genomic DNA without
immunoprecipitation. All the PCR products were quantified with ImageQuant software and reported in the histograms below each
band. (B and C) Luciferase activity (fold of activation vs promoter basic activity) of the PIT1 promoter in HEK293T (B) and GH3
(C) cells. Where indicated, PIT1 and/or either Hmga1b or Hmga2, or both, expression vectors were co-transfected with the
PIT1-1-Luc plasmid. Data express meanGS.D. of three independent experiments. Asterisks indicate the statistical results of a
multiple comparison test vs promoter basic activity. *P!0.05; ***P!0.001. (D)Western blot analysis to detect HMGA1, HMGA2 and
PIT1 expression in GH3 and HEK293T cells. (E) qRT-PCR analysis of Pit1 and Hmga1 expression in GH3 cells interfered for
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cells (data not shown), and Ghrhr expression did not
change significantly between parental and Pit1-
transfected cells (Fig. 4C). Similarly, the expression
of Pit1 in these cell clones does not lead to a different
expression, compared with the parental cells, of genes,
such as Ccnb2 and Mia (Cd-rap) (Fig. 4C), that are
directly regulated by HMGA proteins in pituitary
adenomas (De Martino et al. 2007a,b, 2009). Con-
versely, as reported for other cell systems (Gaiddon
et al. 1999), the expression of Pit1 in aT3 cells, but not
in GH3 cells, leads to the upregulation of c-Fos
(Fig. 4C and D). Surprisingly, overexpression of Pit1
in GH3 cells inhibits the expression of Mia (Cd-rap)
(Fig. 4D). These findings indicate that Pit1 over-
expression positively regulates pituitary cell prolifer-
ation through different mechanisms depending on the
specific pituitary cellular context.
Positive correlation between HMGA and PIT1
expression in human pituitary adenomas
Overexpression of PIT1 is a common feature of GH-,
PRL- and TSH-, but not of ACTH-, FSH-, LH- or non-
functioning human pituitary adenomas (Pellegrini-
Bouiller et al. 1997). Moreover, we have previously
demonstrated that HMGA1 and HMGA2 expression
levels are significantly increased in human pituitary
adenomas compared with normal gland (De Martino
et al. 2009). To evaluate whether there is a direct
correlation betweenHMGA1/2 and PIT1mRNA levels,
we analysed a panel of 46 human pituitary adenomas
(including 13 GH and 33 PRL adenomas) for the
expression of PIT1, HMGA1 and HMGA2 mRNAs by
quantitative RT-PCR. As shown in Fig. 5, a direct
correlation between PIT1 and HMGA1 or HMGA2
mRNA levels was observed. In fact, the correlation
coefficients for the fold changes between adenomas and
normal gland, calculated in both PIT1 and HMGA1, as
well as PIT1 and HMGA2 expression levels, were R
2
Z
0.82 (P!0.001) andR2Z0.61 (P!0.001) respectively.
Discussion
Various studies support a critical role of HMGA
proteins in the development of human pituitary
adenomas (Finelli et al. 2002, De Martino et al.
2009, Qian et al. 2009, Wang et al. 2010). However,
the mechanism by which they act in pituitary tumour
development is still not completely known. We have
previously demonstrated, using mouse models over-
expressing HMGA2 and knockout for E2F1, that
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expression changes upon transfection of Pit1 in aT3 (C) and GH3 (D) cells. The resulting meanGS.D. of three independent
experiments are reported. The genes analysed are indicated below the x-axis. *P!0.05.
D Palmieri et al.: HMGA proteins upregulate Pit1
www.endocrinology-journals.org130
induction of pituitary adenomas in Hmga2 transgenic
mice is mainly due to E2F1 activation (Fedele et al.
2006). Nevertheless, alternative pathways that may
co-operate in the achievement of the full pituitary
phenotype have been envisaged because of the
incomplete rescue of the pituitary tumour phenotype
in double HMGA2/E2F1 mutants (Fedele et al.
2006). Analysing the gene expression profile of
pituitary adenomas from Hmga2 transgenic mice in
comparison with normal pituitary glands from control
mice (De Martino et al. 2007b), we identified Mia
(Cd-rap) and Ccnb2 genes as directly downregulated
or upregulated respectively by both HMGA1 and
HMGA2 proteins, and able to affect pituitary cell
proliferation (De Martino et al. 2007b, 2009).
Here we report another mechanism, based on Pit1
induction, by which HMGA overexpression may
induce the development of pituitary adenomas. Indeed,
we previously demonstrated that Pit1 is expressed at
high levels in pituitary adenomas developed by Hmga
transgenic mice (Fedele et al. 2002, 2005), and here we
show that HMGA proteins bind both PIT1 and PIT1-
responsive DNA elements, thus positively modulating
the PIT1 promoter activity, also synergistically
co-operating with Pit1. Moreover, we demonstrated
that Pit1 overexpression drastically enhances (up to
fourfold) pituitary cell proliferation by inducing the
expression of c-Fos in gonadotroph cells or by
inhibiting the expression of Mia (Cd-rap) in GH/
PRL-secreting cells. Therefore, these results indicate a
potential causal role of the aberrant Pit1 expression in
the cell biology of pituitary tumour.
We can envisage two different, but not mutually
excluding, mechanisms by which HMGA-mediated
Pit1 upregulation may contribute to pituitary cell
transformation:
a) HMGA overexpression may upregulate Pit1 levels
in pituitary adenoma cells of the Pit1 lineage,
enhancing their proliferation.
b) The enhancement of Pit1 expression by HMGA
during development might lead to abnormal
growth of the embryonic cells secreting GH and
PRL, which results in pituitary adenoma during
adult life.
Interestingly, high expression levels of PIT1
represent a constant feature of human pituitary GH,
PRL and TSH adenomas (Asa et al. 1993, Delhase
et al. 1993, Friend et al. 1993, Pellegrini et al. 1994,
Pellegrini-Bouiller et al. 1997), and several previous
studies suggested a potential role for PIT1 in cell
proliferation, the prevention of apoptotic death and the
pathogenesis of pituitary tumours (Castrillo et al. 1991,
Gaiddon et al. 1999, Salvatori et al. 2002, Pellegrini
et al. 2006). In fact, microinjection of Pit1 antisense
sequences blocks cell growth in the GC somatotroph
cell line (Castrillo et al. 1991) and dominant-negative
mutants of Pit1 reduce cell viability by decreasing the
growth rate and inducing apoptosis via a caspase-
independent pathway (Pellegrini et al. 2006). More-
over, PIT1 can also upregulate the expression of genes,
such as c-Fos (Gaiddon et al. 1999) and Ghrhr
(Salvatori et al. 2002), involved in cell proliferation.
Interestingly, recent studies have identified an
increased expression of PIT1 also in breast tumours
(Ben-Batalla et al. 2010), suggesting a potential role of
PIT1 in the proliferation of different cell types.
In conclusion, our data demonstrate that the high
expression of Pit1 in the pituitary adenomas of Hmga
transgenic mice is induced by a positive regulation by
HMGA proteins of Pit1 transcription and support a role
for Pit1 overexpression in pituitary tumour.
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Figure 5 qRT-PCR analysis of PIT1 mRNA in correlation with
HMGA1 and HMGA2 expression in human pituitary adenomas.
(A and B) Statistical analysis of the correlation between
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